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Abstract 
Schizophrenia (OMIM: 181500) is a common, debilitating and life-altering 
disorder. It affects 1% of the population worldwide and most often presents in 
early adulthood leading to devastating effects for patients, their families and 
society. Despite thousands of studies performed on the underlying mechanisms 
of schizophrenia, the causes of the disease remain unknown. However, what is 
known is that environmental, genetic and epigenetic factors contribute to the 
development of this complex disorder. Although a genetic role in schizophrenia is 
well established, the search for schizophrenia genes using traditional approaches 
has remained challenging. Interestingly, monozygotic twins show concordance 
for schizophrenia only 50% of the time and therefore provide a unique scenario 
for genomic analysis. 
This Doctoral thesis examines the genetic and epigenetic contributions to 
schizophrenia discordance in monozygotic twins. In this thesis, I have identified 
and characterized genome-wide changes through the use of the Affymetrix SNP 
6.0 Microarray, Complete Genomics whole genome sequencing and the 
Nimblegen Methylation 720k Microarray. Specifically, I have identified genetic 
and epigenetic differences between monozygotic twins discordant for 
schizophrenia. 
The results show multiple genetic and epigenetic changes between 
monozygotic twins with discordance for schizophrenia. Some of these differences 
are patient-specific and others are shared between affected twins in the study. In 
addition, some of these differences affected genes and others did not. Many of 
the genes and genomic regions have been previously implicated in schizophrenia 
and neurodevelopmental disorders. The findings reinforce the concept that 
individual genomes harbor extensive variability, some inherited and some 
acquired. Even monozygotic twins are not identical and each individual may be a 
mosaic; carrying different sequence variations in different cells. The results also 
suggest that discordance for schizophrenia in monozygotic twins may result from 
the accumulation of genetic and epigenetic mutations that lead to the disease 
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threshold being met in one twin only. The results argue for the involvement of de 
novo mutations in genetic individuality and complex disease. Improved 
understanding of the genomic contributions to schizophrenia is critical for 
movement towards earlier and more accurate diagnosis, better treatment and 
further understanding of this complex mental health disorder. 
 
Keywords: Monozygotic Twins, Discordance, Schizophrenia, Genomics, DNA 
Microarray, Complex Disease, Psychosis, Epigenomics, Complete Genomics 
Sequencing, meDIP, de novo change, DNA Variation, Copy Number Variation, 
Structural Variation, DNA Methylation, Differentially Methylated Regions, CNV 
Calling Methods 
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Chapter 1!– Introduction 
1.0 Overview 
In 1865, Francis Galton wrote that twins offer a ‘‘means of distinguishing 
between the effects of tendencies received at birth, and of those that were 
imposed by the circumstances of their after lives; in other words, between the 
effects of nature and nurture’’. Monozygotic twins arise from a single fertilized 
egg and thus begin life as identical entities. Interestingly, monozygotic twins can 
be discordant for a number of traits, including disease. Monozygotic twins thus 
offer the ideal condition to study genomic change and specifically the level of 
dynamic processes occurring in our genomes during ontogeny and the effect of 
this dynamic nature on individual physiology. The next decade will see increasing 
efforts to understand two related issues in genetics: the basis of human 
individuality and the genetic underpinnings of complex diseases. Identical twins 
have the potential to assist in unraveling the answer to both of these challenging 
questions.  
Few studies have looked at multiple types of de novo genetic changes 
with single base pair resolution in the same twins. To better understand genome 
changes within and across generations as well as the implications of these 
mutations to disease, this thesis investigates multiple types of de novo genomic 
changes in families with monozygotic (MZ) twins discordant for schizophrenia. 
Indeed, a number of de novo, patient-specific variations may play a large role in 
the development of schizophrenia and an experimental design that includes 
families with MZ twins discordant for the disorder allows a unique approach to 
the identification of these variants.  
 
1.1 Schizophrenia 
Schizophrenia (OMIM 181500) is a damaging disease with 1% prevalence 
worldwide (Huxley et al., 1964; Regier et al., 1993). It has a devastating effect on 
patients, their families and society (Jablensky et al., 1992). Schizophrenia is a 
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highly polygenic disorder with a complex array of risk loci (Ripke et al., 2014). 
Attempts to identify a set of genes that are definitively contributing to 
schizophrenia etiology have been unsuccessful. At present, the single greatest 
risk-factor for developing schizophrenia is a family history of the disease 
(Mortensen et al., 2010; Perala et al., 2007). Schizophrenia patients have long 
been known to have reduced fecundity which should cause negative selection 
pressure for schizophrenia-causing genes (Bassett et al., 1996; Laursen and 
Munk-Olsen, 2010). However, the rate of schizophrenia in society remains 
constant at around 1%, which strongly suggests that there is likely to be a 
genetic mechanism working to balance the negative selection. This supports the 
notion that de novo insults may be playing a significant role in the etiology of 
schizophrenia. Further supporting the hypothesis that de novo mutation may be 
responsible is the observation that paternal age, and an associated increase in 
germ cell mutations, is associated with an increased risk of schizophrenia (Byrne 
et al., 2003). 
Schizophrenia onset is typically seen just prior to, or during, early adult life 
(Delisi, 2009). Schizophrenia has a high heritability (~80%) and is classified by 
both positive and negative symptoms including pronounced impairment in 
cognitive functioning (Sullivan et al., 2003). The hallmark of this disorder is a 
distortion in the perception of reality (Regier et al., 1993). Diagnosis of 
schizophrenia usually follows the Diagnostic and Statistical Manual of Mental 
Disorders (First et al., 1996, 1997). The disease presents with significant 
heterogeneity across patients and variability in both presentation and 
classification of the disease is common. Monozygotic twins show a high 
discordance rate (~50%) and dizygotic twins are concordant for the disease only 
17% of the time (McGuffin et al., 1994). The symptoms of schizophrenia are 
generally divided into four main subtypes: positive, negative, cognitive and mood 
disturbances. Positive symptoms include delusions and hallucinations; negative 
symptoms include a flat affect and social/emotional withdrawal; cognitive 
symptoms include attention, memory, decision-making and executive functioning 
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deficits; and mood disturbances include dysphoria and depression (Cañas et al., 
2005).  
There is no cure for schizophrenia and treatment often includes a 
combination of antipsychotic medications, cognitive therapy, daily support and 
social skills training. Current treatments seek to target the positive symptoms of 
schizophrenia and have very little effect on the other categories of symptoms 
(Wright, 2014). In addition, the current drugs available for schizophrenia 
treatment are not without negative side effects. Due to the lack of effective 
treatment of schizophrenia, more than two-thirds of patients live their lives with 
detrimental symptoms and 5-13% eventually die by suicide (Pompili et al., 2007; 
Saha et al., 2005). Schizophrenia is therefore a large social, financial and health 
burden to patients, families and society (Knapp et al., 2004). In fact, 
schizophrenia has been estimated to cost $2.02 billion per year in direct health 
care costs in Canada (Goeree et al., 2005).  
A summary of current findings regarding the genetics and epigenetics of 
schizophrenia is discussed below, it should be noted that a number of 
environmental factors (too many to list here) have been associated with this 
disease. Increased incidence in migrants, increased incidence in those living in 
urban settings, increased incidence in those exposed to maternal infection during 
pregnancy or suffering from childhood infection as well as substance abuse and 
stressful/traumatic events, have all been linked to the disease (Betts et al., 2014; 
Khandaker et al., 2013; Nielsen et al., 2013; Selten et al., 2013). However, the 
effect of each individual environmental factor appears to be quite small. 
Physiologically, studies have shown that there is a significant increase in 
ventricle size in the brains of affected individuals and that whole brain volume 
appears to be reduced up to 3% (Keshavan et al., 2007).  
 
1.2 Genetics of Schizophrenia 
The genetic basis of schizophrenia is very complex and almost certainly 
polygenic in nature (Consortium et al., 2009; Sullivan et al., 2012). Twin and 
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family studies point to a heritability estimate in schizophrenia that is 
approximately 80% and 60%, respectively (Lichtenstein et al., 2009; Sullivan et 
al., 2003; Wray and Gottesman, 2012). A heritability estimate of less than 100% 
suggests that factors other than simple inheritance are playing a role. These 
additional factors could arise from environmental, epigenetic or de novo genetic 
insults. To date, a number of common variants with small effects have been 
identified by GWAS (Genome-Wide Association Studies) with increasing 
numbers of patients and controls. In addition, although the relative contributions 
of common and rare variants to this disease are not known, rare variants 
(mutations found at a low population frequency) have been estimated to account 
for about 20% of risk (Wright, 2014) and would be expected to have a relatively 
larger effect than a common variant. The morbid risk in families rises with 
increasing genetic relatedness to the index case, and different families, as well 
as different patients from the same family, may carry different susceptibility 
genes (Perala et al., 2007). However, to date, no one specific locus, rare or 
common, can be considered to be causal towards this heterogeneous and 
complex disease (McClellan and King, 2010).  
Copy Number Variants (CNVs) are differences in the number of expected 
copies of a section of DNA and it has been suggested that de novo CNVs are up 
to eight times more frequent in schizophrenia cases versus controls (Xu et al., 
2008). In fact, in general, schizophrenia patients appear to exhibit an increased 
burden of rare (<0.5%) variants when compared to controls (Kavanagh et al., 
2014), and affected offspring seem to have increased levels of de novo genome-
wide mutations as compared to their unaffected siblings (Xu et al., 2011). An 
elevation in de novo mutation rate in schizophrenia may explain the development 
of schizophrenia despite strong negative selection and significantly reduced 
fecundity of patients with schizophrenia (Nimgaonkar, 1998). Given this 
complexity, it is not surprising that a causal association or linkage to 
schizophrenia has been difficult to establish (Arribas-Ayllon et al., 2010).  
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In recent years, GWAS have shown the important contribution of genetic 
variants to complex human traits and disease susceptibility at the population 
level (Ripke et al., 2014; Rudan, 2010; Stranger et al., 2011). By comparing 
thousands of variants between cases and controls at a population level, GWAS 
identifies disease-associated Single Nucleotide Variants (SNVs) and regions of 
the genome that may elevate disease risk (Ott and Wang, 2011; Stranger et al., 
2011). However, the heterogeneity of genomic differences at the population level, 
often between entirely unrelated individuals, may be limiting (Ott and Wang, 
2011; Rudan, 2010). In contrast, family studies reduce the heterogeneity and 
narrow the pool of genomic differences that may account for the phenotypic 
difference under study. The new wave of GWAS data has far exceeded the 
search for schizophrenia candidate genes by linkage and candidate gene 
studies, which produced results that were inconsistent and difficult to reproduce. 
However, most of the variants identified by GWAS have been common variants, 
that is, variants with allele frequencies greater than or equal to 1%. Some of the 
most interesting and consistent GWAS findings have highlighted genes involved 
in immunity including the major histocompatibility complex (MHC) on 
Chromosome 6 and the genes TCF4, NRGN and DPYD/MIR317 (Chen et al., 
2015). These findings are not surprising given that the immune system has long 
been thought to be involved in schizophrenia pathology (Chen et al., 2015). In 
addition to these loci, the Psychiatric Genomics Consortium (PGC) recently 
published the largest schizophrenia GWAS to date of 150,000 individuals 
including over 35,000 affected with schizophrenia, which also represents the 
largest genetic study on the disease that has currently been performed (Ripke et 
al., 2014). This collaboration of over 80 research groups identified 108 common 
genetic loci overrepresented in schizophrenia patients, covering 348 genes, 83 of 
which had not been previously identified (Ripke et al., 2014). These loci included 
a large list of potential genes, most notably DRD2, a common anti-psychotic 
target, as well as a number of glutamate receptors (GRIA1, GRIN2A, GRM3) 
(Ripke et al., 2014). In addition, many CNVs have been associated with 
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schizophrenia risk, the most notable being deletions at 2p16.3 (overlapping the 
NRXN1 gene) and duplications at 7p36.3 (overlapping the VIPR2 gene) 
(Levinson et al., 2011; Rujescu et al., 2009). Other regions identified to harbour 
structural variations (SVs) contributing to risk include deletions and duplications 
at 1q21.1 and 3q29, as well as deletions at 15q13.3 and 22q11.2 and 
duplications at 16p13.1 (Chen et al., 2015; Levinson et al., 2011; Sullivan et al., 
2012). However, it has been shown that a polygenic burden exists in 
schizophrenia patients arising from rare disruptive mutations primarily comprising 
ultra-rare nonsense mutations distributed across many genes (Purcell et al., 
2014) and increased studies on rare variants are likely to uncover the missing 
heritability not yet identified. 
It is noteworthy that the earliest definitive report of rare variation 
contributing to schizophrenia includes copy number variability at 22q11.2 which 
confers close to a 25-fold increase in risk for schizophrenia (Karayiorgou et al., 
1995; Malhotra and Sebat, 2012). This suggest that structural variability may play 
a large role in the cause of this disease. To date, at least 11 rare risk alleles have 
been identified to be associated with this disorder (Rees et al., 2014).  
Evidence is now emerging for the effect of de novo mutations in 
schizophrenia. Identification of genetic variants in schizophrenia patients has 
also given some insight into the biological processes that might be affected in 
schizophrenia. Neurodevelopmental genes appear to be preferentially 
represented in the gene sets identified by multiple groups; specifically, synaptic 
strength modulation at glutamatergic synapses appears to have been strongly 
implicated in schizophrenia (Kirov et al., 2012; Walsh et al., 2008). Together, 
these recent advances represent a new era in the study of schizophrenia 
genetics and there is no doubt that the advances in genetic technology such as 
high throughput sequencing are in part responsible for these successes 
(Kavanagh et al., 2014). 
These associations of regions of interest with this complex disease are 
helping the field to inch closer to a clearer understanding of the genetics 
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underlying predisposition and/or causation in schizophrenia. In addition, these 
studies reinforce the highly polygenetic nature of schizophrenia. It has been 
estimated that the variants that have been previously identified account for >50% 
of the heritability of schizophrenia (Lee et al., 2012). However, there are still 
unidentified risk genes for schizophrenia and continuing to increase sample size 
may not uncover them. Alternative approaches should be considered, including 
the use of families with monozygotic twins discordant for schizophrenia. In 
addition, the accumulation of results on schizophrenia genetics suggests that the 
insults responsible for schizophrenia in individual patients may not overlap, which 
implies the need for patient specific inquiry and treatment. 
 
1.3 Epigenetics of Schizophrenia 
It is now apparent that the manifestation of the genetic code into 
psychiatric phenotypes including mental disorders is not determined solely by 
DNA sequence (Bell and Saffery, 2012; McCarthy and Hirschhorn, 2008). The 
causation of psychiatric disorders likely involves complex interactions involving 
chromatin, where epigenetic signals superimpose a regulatory role. In fact, it has 
been suggested that the missing heritability seen in some neuropsychiatric 
disorders could be due in part to the effect of epigenetic patterning (Bell and 
Saffery, 2012; McCarthy and Hirschhorn, 2008). The epigenome is in a dynamic 
state influenced by both deterministic as well as stochastic processes. This 
complexity also makes it difficult to tease apart the underlying factors that 
contribute to its state at any given time (Mill et al., 2008). It represents a major 
challenge for future studies. DNA methylation in mammals involves the 
modification of cytosine to methylated cytosine (or its equivalent) in the genome 
and is the most widely studied of epigenetic marks. This form of gene regulation 
is sequence-specific and is needed for the proper functioning of the genome. In 
addition, DNA methylation provides regulatory roles in cellular functioning via 
regulation of gene transcription (Razin and Riggs, 1980), genomic imprinting (Li 
et al., 1993), gene splicing (Shukla et al., 2011) and chromatin structure and 
!! 8!
stability (Xu et al., 1999). Indeed, any alteration from normal patterns of 
methylation may cause abnormal cellular functioning including disease 
phenotypes (Zhao et al., 2014). DNA methylation profiles can potentially be 
altered by various factors including seasonal, social and additional environmental 
factors such as chemicals and prescription drugs (Alvarado et al., 2014; Singh et 
al., 2003). This property may help to further the understanding of disease 
processes including mechanisms of actions of drugs which are often used to 
treat this disease.  
Studies on brains from patients with schizophrenia and matched controls 
have identified differences in DNA methylation (Wockner et al., 2014). The 
results on brain samples are comparable to similar studies on blood samples 
from schizophrenia patients (Wockner et al., 2014). The questions of both tissue 
specificity and the effect of antipsychotic drugs on epigenetics are critical, and 
present concerns in studies on methylation involving human brain disorders. 
Some non-brain tissues may serve as markers for abnormalities in the brain 
(Singh et al., 2002a). Further, the genes affected by enriched methylation 
changes in patients are related to a number of pathways particularly the 
glutamatergic and GABAergic neurotransmission pathways, which have been 
previously implicated in psychosis (Bonsch et al., 2012; Shimabukuro et al., 
2006). These findings suggest that a common epigenetic regulation mechanism 
may be applicable both in the brain and in peripheral tissues of schizophrenia 
patients (Auta et al., 2013). However, it is not entirely clear if the observed 
changes in methylation in these studies represent epigenetic changes that 
promote the disorder or are reflective of changes induced by the drugs 
administered to treat the patients (Melka et al., 2014). The results of studies 
involving medication-free schizophrenia patients show that some of the altered 
DNA methylation seen in schizophrenia is likely to be directly involved in the 
pathophysiology of the disease. For example, a recent study on medication-free 
patients suggests that methylation is indeed a part of the complexity of 
manifestation of schizophrenia (Kinoshita et al., 2013). 
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Conclusions drawn from genome-wide association studies are compatible 
with methylation studies that have reported hypermethylation of the serotonin 
transporter gene promoter particularly in schizophrenia patients (Abdolmaleky et 
al., 2014). Some pathways are shared by a number of neurological disorders. As 
an example, CDK5 and CREB signaling is often reported in schizophrenia (Allen 
et al., 2008), in excessive anxiety induced by stress (Bignante et al., 2008), as 
well as in depressive-like behavior (Zhu et al., 2012). Interestingly, altered DNA 
methylation of genes involved in the CREB pathway has been reported in a 
recent study of DNA methylation in schizophrenia (Yu et al., 2014). Further, 
DRD2, DRD4 and DRD5 promoters were significantly methylated in 
schizophrenia patients as compared with healthy controls (Kordi-Tamandani et 
al., 2013), suggesting that the dopamine network is actively involved in an 
increased risk for psychosis. Thus, although only a small number of studies have 
been performed on the epigenetics of schizophrenia, alterations in DNA 
methylation appear to be important to the etiology of psychosis.  
 
1.4 Genetic Differences Between Monozygotic Twins 
Monozygotic twins result from the division of the morula during 
development. In some cases, the morula divides before day 5 post-fertilization, in 
other cases, twinning occurs after the separation of the morula (between day 5 
and 9), the latter being more common. In rare exceptions, twins are formed after 
day 9 and will end up sharing only one placenta. Genetic mutations that are seen 
in one twin but not in the other identical twin are presumed to have occurred after 
the separation of the morula (Weber-Lehmann et al., 2014). 
Although MZ twins originate from a single zygote, many reports have now 
identified genetic differences between them (Bruder et al., 2008; Ehli et al., 2012; 
Maiti et al., 2011). For example, Bruder et al (2008) reported that all of 19 MZ 
twins studied differed in CNVs (Bruder et al., 2008). Similarly, de novo CNVs can 
be identified by comparison of the genomes of MZ twins with their parents (Maiti 
et al., 2011). Further, a duplication found only in the affected monozygotic twin in 
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a tissue specific manner has been implicated in the causation of Mayer-
Rokitansky-Kuster-Hauser syndrome (Rall et al., 2015). In addition, a recent 
report identified somatic mutations at the base pair level in monozygotic twins 
and found two de novo somatic mutations that occurred early in embryonic 
development (Li et al., 2014). In fact, many post-twinning single nucleotide 
mutations have been reported (Kondo et al., 2002; Reumers et al., 2012; 
Sakuntabhai et al., 1999; Vadlamudi et al., 2010; Ye et al., 2013), however these 
are expected to be rarer than post-twinning CNVs.  
Many studies have looked at identifying CNV differences between 
monozygotic twins. The largest study of this kind looked at CNVs in 159 
monozygotic pairs and confirmed 10 post-twinning mutations (Forsberg et al., 
2012). It is likely that older twin pairs have an increase in somatic mutations 
based solely on de novo mutation rates and accumulation of mutations over the 
lifespan (Ye et al., 2013). The rate is also likely to be tissue specific (Piotrowski 
et al., 2008). Lending further support, Dal et al found that early post-zygotic 
mutations exist in humans and arise from early mitotic events occurring during 
embryogenesis leading to genome mosaicism (multiple genotypes arising from a 
single fertilized egg) (Dal et al., 2014). This genomic mosaicism could be an 
important contributor to the development of disease.  
 
1.5 Epigenetic Differences Between Monozygotic Twins 
Differences in methylation between identical twins have been identified as 
early as in newborn twin pairs (Ollikainen et al., 2010). DNA methylation profiles 
are more similar within pairs of dichorionic twins than between monochorionic 
twins and this suggests that sharing a placenta may cause imbalanced in utero 
conditions leading to epigenetic differences (Castillo-Fernandez et al., 2014). 
Also, these differences change over time, supporting the potential for 
neurodevelopmental programming and reprogramming in the causation of 
disease (Dempster et al., 2011). It has been suggested that contributions to the 
discordance of monozygotic twins may involve epigenetic change (Kim et al., 
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2014), strengthening the case for dynamic processes including DNA methylation 
in psychosis. These processes are likely directed by genetic as well as random 
and environmental contributors over the lifetime (Wong et al., 2010). 
Results on DNA methylation analysis of blood DNA from monozygotic 
twins discordant for schizophrenia support the involvement of DNA methylation in 
psychosis (Dempster et al., 2011). Methylation of genomic DNA and promoter 
methylation of specific genes in blood samples of twins discordant for 
schizophrenia showed hypermethylation and hypomethylation of several genes 
(Bonsch et al., 2012). The results on twins to-date argue for the potential 
involvement of regulatory mechanisms, particularly DNA methylation, in the 
development of disease (Singh et al., 2002b). These mechanisms may underlie 
aberrations in neurodevelopment known to exist in a number of mental disorders 
(Rapoport et al., 2012; Singh et al., 2004; Weinberger, 1996).  
 
1.6 Evidence for Somatic Mutation 
 Evidence has emerged in the literature to support the existence of somatic 
mutations in individual genomes. Generally, without involving identical twins, the 
estimated number of SNV substitution mutations per generation ranges from 
1x10-8 -3x10-8 per human single base pair which is equal to approximately 10–40 
expected SNVs per generation (Krawczak et al., 2012; Xue et al., 2009). 
Although little is known about the exact mechanism by which somatic mutations 
may arise, it is suspected that they occur randomly and as a by-product of 
replication. This would make the occurrence of the same somatic mutation, in the 
same tissue, in different individuals, a rare occurrence. If post-zygotic mutations 
occur late in development, they would be expected to result in mosaics. Given 
the trillions of cell divisions occurring, post-zygotic replication errors are likely to 
be present in all individuals. The impact of these errors will most often be benign, 
however, the likelihood for contribution to pathology will depend on the tissue 
affected. Somatic mutations may reshape the genetic circuitry that underpins 
normal and abnormal neurobiological processes (Baillie et al., 2011). As we 
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know that not all mutations are deleterious, some may represent normal aspects 
of genetic diversity and development in some organs (Muotri and Gage, 2006) 
and cell types (Muotri et al., 2010). It follows then, that rare and unique somatic 
mutations should exist between the genomes of identical twins. 
 Accordingly, somatic point mutations have been shown to occur during 
early development with a frequency of 1.2 × 10−7 per base pair per twin pair (Li et 
al., 2014). This somatic point mutation frequency does not take into account the 
frequency of lesions (deletions, insertions, indels) which are expected to occur at 
a ratio of approximately one in three relative to SNVs (Krawczak et al., 2012). 
The earlier in the development of an embryo a rare somatic mutation arises, the 
more tissues it will be seen in (Weber-Lehmann et al., 2014). There is also 
potential for these somatic mutations to exist in the germline. Krawczak et al 
have proposed that SNVs, though rare, will exist and discriminate the genetic 
landscape of any pair of monozygotic twins (Krawczak et al., 2012).  However, 
many have also failed to find any confirmable differences between MZ twins at 
the SNV level, presumably because of low Next Generation Sequencing (NGS) 
coverage (Baranzini et al., 2010; Handunnetthi et al., 2010; Miyake et al., 2013). 
Results also show that where DNA sequence differences exist between identical 
twins, genotypes usually show unexpected ratios, that is, instead of identifying 
expected heterozygote ratios between twins (e.g., 50/50 ratio of original and 
mutation genotype in one twin), more often a ratio that resembles for example an 
80/20 split between the original and new mutation genotype, respectively 
(Weber-Lehmann et al., 2014) is ascertained by Sanger Sequencing. The best 
possible explanation for the identification of a newly arisen allele in only a small 
fraction of cells assayed (ie. 20%) is somatic mosaicism. 
 
1.7 Advancing Technology in the Era of Genomics 
 As geneticists, our understanding of genomic change is driven by 
technology. Technological advances have been growing exponentially in recent 
years. As such, the resolution with which we can ascertain understanding of 
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genomic architecture is constantly increasing. Never before has the field had the 
ability to fine-map individual genomes as we currently can. The resolution has 
increased substantially and the methods available to analyze the datasets are 
becoming increasingly sophisticated.   
 This thesis utilizes three major technologies: the first, a comprehensive 
DNA Microarray; the second, Complete Genome Sequencing; and the third, a 
MeDIP Promoter Microarray. In addition, Real-Time PCR and Sanger 
Sequencing were used to confirm selected findings.  
 Although the specific technologies utilized will be discussed in further 
chapters, I briefly present here the rationale for the choice of each platform. 
 
1.7.1 Affymetrix® Human SNP 6.0 Microarray 
The Affymetrix SNP 6.0 microarray is one of the most comprehensive 
arrays available for hybridization with human DNA. At the time of purchase, this 
array had the highest resolution on the market with over 1.8 million genetic 
markers on each array. In addition, the average inter-marker distance of less 
than 700 base pairs makes it an excellent array for breakpoint estimation. In 
addition, this microarray is compatible with many third-party software packages 
and algorithms.   
 
1.7.2 Complete Genomics Inc. Whole Genome Sequencing 
Complete Genomics has significant experience in sequencing high-quality 
human genomes (Drmanac et al., 2010). The platform utilizes efficient imaging 
with a combinatorial probe anchor ligation chemistry to independently assay each 
base from patterned nanoarrays of self-assembling DNA nanoballs. The high-fold 
coverage (~50 fold) that it achieves alongside high accuracy calls (99.999% 
accuracy) at single base pair resolution made this platform the ideal choice for 
this study.  
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1.7.3 NimbleGen Human DNA Methylation 3x720k CpG Island Plus RefSeq 
Promoter Microarray  
This array utilizes a MeDIP (Methylated DNA immunoprecipitation) format 
and is a highly comprehensive assessment of CpG islands and promoter regions 
of RefSeq genes in humans. The array also includes a number of positive, 
negative and non-CpG control regions for quality control. In addition, the ability to 
ascertain over 700,000 regions of interest for methylation status allows for ideal 
comparison between samples in a study.  
 
1.8 Hypothesis and Thesis Objectives 
The collective research experiments presented in this thesis seek to 
assess the following hypothesis through the listed objectives: 
 
Genome-wide de novo mutations and epimutations contribute to genomic 
individuality and may explain the discordance of monozygotic twins for 
schizophrenia. 
 
1.8.1 Objectives 
1.! To use new and emerging technologies to identify Single Nucleotide 
Variants, Small Indels, Block Substitutions, Structural Variants (Insertions, 
Deletions, Tandem Duplications, Distal Duplications, Inversions, 
Interchromosomal Events and Copy Number Variants), and Methylation 
Changes in blood samples. Specifically through the use of the:  
a.! Affymetrix® Human SNP 6.0 Microarray 
b.! Complete Genomics Inc. Whole Genome Sequencing platform 
c.! NimbleGen Human DNA Methylation 3x720k CpG Island Plus 
RefSeq Promoter Microarray  
2.! To analyze data obtained from the three platforms using multiple methods. 
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3.! To identify differences between participants, specifically between 
monozygotic twins and their respective parents (where available) and 
annotate differences as de novo or inherited (where parental samples are 
available). 
4.! To characterize de novo differences between twins based on their 
potential involvement in schizophrenia discordance or predisposition. 
5.! To confirm a subset of novel results. 
6.! To test a model that may explain the results identified by the collective 
studies. 
 
1.9 Overview of Participants in Thesis Experiments 
This thesis focuses on the use of rare monozygotic twins who show 
discordance for schizophrenia. The research outlined in this thesis took place 
after ethics approval from The University of Western Ontario’s Committee on 
research involving human subjects (Appendix B). All subjects provided written 
informed consent to participate in the study. Our close collaboration with Dr. 
Richard O’Reilly, Psychiatrist, has allowed for the acquisition of DNA from these 
rare twins and selected parental samples. Dr. O’Reilly has assured accurate 
diagnosis and has kept in contact with the families since sample collection (>5 
years ago) to ensure that throughout the study the twins have remained 
discordant. However, it should be noted that previous studies have established 
that the vast majority of twin pairs that become concordant for schizophrenia will 
do so within five years of initial onset of the illness by the first affected twin 
(Belmaker et al., 1974). 
 These thesis experiments include six pairs of monozygotic twins 
discordant for schizophrenia and two sets of parents. The following table 
describes which participants were used in each chapter of this thesis (Table 1.1).!
!! 16!
Table 1.1. Summary of participants included in the thesis experiments. 
Twin Pair 
Affymetrix 6.0 
DNA Microarray 
(N=16) 
[Chapters 2,5] 
Complete 
Genomics 
Sequencing (N=6) 
[Chapters 3,5] 
Roche Nimblegen 
MeDIP Promoter 
Array (N=8) 
[Chapters 4,5] 
Other Identifier 
[Chapters 3, 4, 5] 
Twin Pair 1 YES    
Twin Pair 2 YES YES YES 
Family 2 Parents of 
Twin Pair 2 
YES  YES 
Twin Pair 3 YES YES YES 
Family 1 Parents of 
Twin Pair 3 
YES YES YES 
Twin Pair 4 YES    
Twin Pair 5 YES    
Twin Pair 6 YES    
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Twin Pair 1 
Members of twin pair 1 were assessed at age 20. These twins are male 
and self-declare their background to be Asian/Indian. The affected male patient 
of twin pair 1 was diagnosed with a psychotic disorder (not otherwise specified) 
and mild obsessive-compulsive disorder, at age 19. The unaffected co-twin has 
never been diagnosed with any mental health disorder. The twins remain 
discordant for psychosis >5 years after assessment.   
 
Twin Pair 2 (Family 2) 
 Members of twin pair 2 were assessed at age 43. These twins are female 
and self-declare their background to be Caucasian. The affected female patient 
of twin pair 2 was diagnosed with schizoaffective disorder at age 27. The 
unaffected co-twin had a single episode of major depression at age 18. The twins 
remain discordant for psychosis >5 years after assessment.   
Parents, Twin Pair 2 
Father, Twin Pair 2: Caucasian male who was 80 when the samples for 
DNA testing were obtained. He has never been treated for any emotional or 
psychiatric disorders. 
Mother, Twin Pair 2: Caucasian female who was 76 when the samples 
for DNA testing were obtained. She has never been treated for any emotional or 
psychiatric disorders. 
 
Twin Pair 3 (Family 1) 
Members of twin pair 3 were assessed at age 53. These twins are female 
and self-declare their background to be African American. The affected female 
patient of twin pair 3 was diagnosed with paranoid schizophrenia at age 22. The 
unaffected co-twin was diagnosed with bipolar I disorder at age 52. The twins 
remain discordant for psychosis >5 years after assessment.   
 
 
!! 18!
Parents, Twin Pair 3 
Father, Twin Pair 3: Afro-American male who was 82 when the samples 
for DNA testing were obtained. He had never been treated for any emotional or 
psychiatric disorders though he did exhibit a mild obsessive-compulsive 
personality upon assessment. He was diagnosed with Chronic Leukemia (CLL) 
at age 69. 
Mother, Twin Pair 3: Afro-American female who was 74 when the 
samples for DNA testing were obtained. She has never been treated for any 
emotional or psychiatric disorders. 
 
Twin Pair 4  
Members of twin pair 4 were assessed at age 22. These twins are female 
and self-declare their background to be Caucasian. The affected female patient 
of twin pair 4 was diagnosed with paranoid schizophrenia at age 18. The 
unaffected co-twin had a single episode of major depression at age 20. The twins 
remain discordant for psychosis >5 years after assessment.   
 
Twin Pair 5 
Members of twin pair 5 were assessed at age 36. These twins are male 
and self-declare their background to be Caucasian. The affected male patient of 
twin pair 5 was diagnosed with undifferentiated schizophrenia at age 20. The 
unaffected co-twin has never been diagnosed with any mental health disorder. 
The twins remain discordant for psychosis >5 years after assessment.   
 
Twin Pair 6 
 Members of twin pair 6 were assessed at age 42. These twins are male 
and self-declare their background to be Caucasian. The affected male patient of 
twin pair 6 was diagnosed with paranoid schizophrenia at age 16. The unaffected 
co-twin had a single episode of major depression at age 17. The twins remain 
discordant for psychosis >5 years after assessment.   
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Chapter 2!- Assessing Copy Number Variation (CNV) in Monozygotic Twins 
Discordant for Schizophrenia Using the Affymetrix Human SNP 6.0 
Microarray 
2.0 Overview of Chapter 2 
Studies involving the analysis of structural variation including Copy 
Number Variation (CNV) have recently exploded in the literature. Furthermore, 
CNVs have been associated with a number of complex diseases and 
neurodevelopmental disorders (Firth et al., 2009; Jacquemont et al., 2011; Zhang 
et al., 2011). Copy number variants have the potential to alter dosage of gene(s) 
in regions they overlap, thereby having the potential to modify the expression of 
genes (Henrichsen et al., 2009). The discovery of CNVs from DNA microarrays 
works on the assumption that the majority of the diploid genome exists in two 
copies and therefore the signal intensity of markers along the chromosome 
should remain approximately the same. When the signal intensity changes over 
multiple markers, it can be inferred that a copy number change may be present 
(Chen et al., 2015). This chapter uses Affymetrix Human SNP 6.0 Arrays on 16 
individuals to assess the copy number variation calls between identical twins and 
their parents (where available). 
 
This chapter is divided into two main sections: 
2A: Explores the use of four software programs for the analysis of Affymetrix 
Human SNP Array 6.0 data and leverages the unique nature of monozygotic 
twins to assess the calls made by each software program. 
 
2B: Reports the results of the use of three of the four software programs to find 
de novo variants that may be associated with the disease in monozygotic twins 
discordant for schizophrenia. 
 
 ! !
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A version of this chapter has been published in Castellani et al., BMC Bioinformatics (2014a)  
2A Biological relevance of CNV calling methods using familial 
relatedness including monozygotic twins 
2A.0 Overview of Chapter 2A 
Common methods for CNV detection use microarrays, where the signal 
intensities of consecutive probes are used to define the number of copies 
associated with a given genomic region. These practices pose a number of 
challenges that interfere with the ability of available methods to accurately call 
CNVs. It has, therefore, become necessary to develop experimental protocols to 
assess the reliability of CNV calling methods from microarray data so that 
researchers can properly discriminate biologically relevant data from noise.  
I have developed a workflow for the integration of data from multiple CNV 
calling algorithms using the same array results. It uses four CNV calling 
programs: PennCNV (PC), Affymetrix® Genotyping Console (AGC), Partek® 
Genomics Suite (PGS) and Golden HelixTM SVS (GH) to analyze CEL files from 
the Affymetrix® Human SNP 6.0 Array. To assess the relative suitability of each 
program, I used individuals of known genetic relationships, including 
monozygotic twins. I found significant differences in CNV calls obtained by 
different CNV calling programs. 
Although the programs showed variable patterns of CNVs in the same 
individuals, their distribution in individuals of different degrees of genetic 
relatedness has allowed me to offer two recommendations. The first involves the 
use of multiple algorithms (PC, AGC and PGS) for the detection of the largest 
possible number of CNVs, and the second suggests the use of PennCNV over 
other methods in this study, when the use of only one software program is 
desirable.  
 !  
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2A.1 Introduction 
Copy number variants (CNVs) are defined as DNA segments (often 
outlined as 1 kb or larger) that are present in variable numbers in a genome 
(Feuk et al., 2006a; Iafrate et al., 2004; Sebat et al., 2004). Although common in 
the human genome, some CNVs have no apparent phenotypic effect (Freeman 
et al., 2006; Iafrate et al., 2004; Redon et al., 2006), while others are implicated 
in a variety of phenotypic effects including disease phenotypes (Firth et al., 2009; 
Jacquemont et al., 2011; Zhang et al., 2011). As such, the search for CNVs 
associated with disease phenotypes has emerged as a productive approach to 
identify genetic factors underlying a number of common and complex 
neurodevelopmental disorders (Conrad and Hurles, 2007; Glessner and 
Hakonarson, 2009; Kirov, 2010; Maiti et al., 2011; Sebat et al., 2004). There are 
two reasons for this productivity. Firstly, CNVs are a major contributor to genomic 
variation, with approximately 13% of the human genome affected by CNVs 
(Redon et al., 2006), and over 350,000 CNVs have been mapped to specific 
genomic locations that are documented in the Database of Genomic Variants 
(DGV) (Macdonald et al., 2013). Secondly, advances in technology, including 
microarrays, permit high-throughput methods to identify CNVs. Such 
technologies are now relatively common and are economically feasible 
alternatives to methods like whole genome sequencing. With a number of array 
platforms and bioinformatic algorithms available, it is necessary to identify 
optimal analytical pipelines to make inferences regarding specific genomic 
regions, their copy number identity, and their biological relevance.  
On genome-wide microarrays, such as the Affymetrix Genome-Wide 
Human SNP Array 6.0, sets of probes are designed to determine which allele is 
present at genomic sites of known single nucleotide polymorphism (SNP probes). 
The arrays may also include additional probes designed for genomic sites where 
there is no known variance (known as copy number probes). Normally, CNVs are 
identified by fluorescent signals generated by SNP probes on the microarray. 
The fluorescent signals emitted by both SNP probes and copy number probes (if 
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present on the array) are summarized and analyzed for variance in signal 
intensity using bioinformatic tools, typically in comparison to a set of reference 
samples. Consecutive markers that exhibit altered signal intensity from the 
reference are interpreted as CNVs. There are a number of algorithms that have 
been developed to identify putative CNVs. Unfortunately, not all putative CNVs 
called by any existing algorithm can be viewed as biologically relevant. The 
application of multiple software programs that are designed to call CNVs from the 
same microarray data often yield differing results (Baross et al., 2007; Kim et al., 
2012; Pinto et al., 2007; Winchester et al., 2009; Zhang et al., 2011). The use of 
multiple algorithms has been shown to increase the reliability of observations 
with different degrees of confidence. For example, Kim et al. used three calling 
algorithms (PennCNV, QuantiSNP, and Birdsuite) on a set of results from 
Affymetrix arrays. They found that only 1.5% of total CNV calls could be identified 
by all three distinct algorithms (Kim et al., 2012). Furthermore, their attempt to 
confirm putative CNV calls using qPCR produced differing results; 38.3% of 
CNVs called by a single algorithm, 57.6% of CNVs called by two algorithms and 
71.4% of CNVs called by three algorithms could be confirmed by qPCR (Kim et 
al., 2012).  
Although SNP arrays have become popular for ascertaining copy number 
data in addition to SNP genotypes, there are many issues intrinsic to the use of 
SNP arrays for the identification of CNVs. Theoretically, it is possible to resolve 
some of these issues through the use of sensitive analytical methods. In fact, the 
past ten years have seen a boom in the development of algorithms and technical 
resolution that have been applied across platforms and programs (Valsesia et al., 
2012). Quality control measures such as batch effect correction, normalization 
methods, and reference group choice seem like simple considerations when 
compared to the choices available in both algorithms and CNV identification 
software, as well as in post-analysis filters like marker density and minimum 
marker thresholds. The reality of limited biological validity in the use of 
microarrays to call copy number variable regions is concerning for this area of 
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research that may hold exceptional promise in clinical applications (Duclos et al., 
2011). The need for best practices in the workflow for CNV calling protocols has 
never been more essential.  
This study is aimed at assessing putative CNV calls made using the 
Affymetrix Human SNP 6.0 Array using four CNV calling programs: PennCNV 
(Wang et al., 2007), Affymetrix Genotyping Console (Korn et al., 2008), Partek 
Genomics Suite (Partek Inc., St. Louis, MO, USA), and Golden Helix SNP and 
Variation Suite (Golden Helix, Bonzeman, MT, USA). Using individuals of known 
relatedness, I have identified overlapping copy number variants across the four 
algorithms. Using the dataset generated, I have assessed the relative sensitivity 
of each of the four methods from the following comparisons: between unrelated 
individuals, between parents and offspring, and between monozygotic twins, that 
are thought to share 0%, 50%, and 100% genetic relatedness, respectively. The 
most biologically relevant CNVs will be expected to follow this relationship, with 
the exception of de novo events. The results showed that overall, Affymetrix 
Genotyping Console identified the most differences between unrelated 
individuals, while Partek yielded the most similarity between identical twins. On 
average, PennCNV called CNVs that were comparable to Affymetrix Genotyping 
Console across unrelated individuals and CNVs that were similar to the Partek 
results. Assessments using Golden Helix did not follow the trends expected from 
the known genetic relatedness of individuals. I propose that a combination of 
three programs (Affymetrix Genotyping Console, Partek, and PennCNV) may be 
optimal to identify biologically relevant CNV calls due to their ability to resolve 
copy number variations across different biological relatedness.  
 
2A.2 Methods 
2A.2.1 Subjects 
This study received ethics approval by the University of Western Ontario’s 
Committee on Research Involving Human Subjects (Appendix B). Written 
informed consent was obtained from all participants. Sixteen genomic DNA 
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samples were isolated from whole blood representing the study participants that 
included six pairs of MZ twins (three female pairs and three male pairs) and two 
sets of parents for two of the twin pairs (N = 16). The six twin pairs ranged in age 
from 20 to 53 years at the time of sample collection. Genomic DNA was 
extracted from whole blood using the PerfectPure DNA Blood Kit following the 
manufacturer’s protocol (Invitrogen, Carlsbad, CA).  
 
2A.2.2 Microarray Hybridization and Analysis 
Whole genome microarray analysis was performed using the Affymetrix 
Genome-Wide Human SNP Array 6.0 at the London Regional Genomics Centre 
(London, ON) following the manufacturer’s protocol. Sixteen arrays (one array 
per sample) were processed and analyzed as a single batch and scanned to 
produce CEL files. The CEL files were used to generate CNV calls on all 16 
individuals using four programs: Affymetrix Genotyping Console 4.1.1 (AGC), 
Partek Genomics Suite (PGS) PennCNV (PC), and Golden Helix SVS Suite 7.0 
(GH). In Affymetrix Genotyping Console, I used both the Birdsuite package 
(version 2) and the Canary algorithm for CNV detection. Birdseye, which is found 
in Birdsuite, was used for the detection of rare CNVs via a Hidden Markov Model 
(HMM) and Canary was used to call copy number state in genomic regions with 
known copy number polymorphism. In Partek, HMM Region Detection using 
default parameters was selected. In PennCNV, the default HMM algorithm was 
selected. In Golden Helix I used the Copy Number Analysis Method (CNAM) 
optimal segmenting algorithm. HMM- based algorithms use prior probabilities of 
copy number states in conjunction with array-derived normalized fluorescent 
intensity values to call the most likely copy number state in a given genomic 
region. The copy number states determined by HMM are discrete and they 
include 0, 1, 2, 3, and 4+. On the other hand, genomic segmentation scans two 
adjacent regions of the genome to find differences in copy number using two 
specific t-tests. CNAM optimal segmenting uses genetic marker map information 
alongside log2 ratios to discover regions in which log2 ratios vary significantly 
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between adjacent segments. I used the univariate method of optimal segmenting 
which segments each sample in the study separately. Canary, which was used in 
Affymetrix Genotyping Console, calculates Copy Number Polymorphism (CNP) 
copy number state for over 1,100 regions of known copy number polymorphism 
(frequency in the population greater than one percent).  
The user-defined analytical parameters were kept consistent across the 
analysis. Specifically, the HapMap 270 6.0 Array reference was used as a 
reference file and variants were identified as DNA regions, which were called as 
copy number state of 0, 1, 3, or 4+ covering a minimum of 10 consecutive 
markers on the array. Only variants greater than or equal to 1 kb in size were 
included in subsequent analysis.  
 
2A.2.3 CNV Call Merging 
The CNV calls made by each of the four software programs were merged 
with adjacent CNV calls that may represent the same CNV event. The criteria 
used to merge were 1) CNVs had to be adjacent on the same chromosome (no 
other CNV call between them); 2) CNVs had to share the same gain/loss status; 
and 3) adjacent calls were ≤ 20% of the total length, that is, if there were three 
consecutive genomic segments A, B and C, where A and C are both losses and 
B is unchanged, I divided the length of the gap B by the length of A + B + C. If 
this fraction was ≤20%, then I merged A + B + C as a single CNV call. If there 
were multiple consecutive CNVs, each with 20% or less length between one and 
all of the others, then I extended the formula to the next CNV and merged all of 
the CNVs into one event. When multiple smaller CNVs were merged into one 
large CNV event, I identified the event as a merged CNV. I then labeled the 
newly merged CNVs and any CNVs that remained unmerged as either “CNV-
Gain” or “CNV-Loss” within the calls from all four software programs in all 
individuals.  
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2A.2.4 Comparison of CNV Calls Between Software Programs 
To compare CNV calls made by different software programs, I used a 50% 
reciprocal overlap (RO) criterion to compare the calls made within an individual 
from the four software programs. The use of 50% RO for comparing calls is 
consistent with other reports (Pang et al., 2010; Wain et al., 2009; Yavas et al., 
2009). Two CNV events were considered to pass the 50% RO criterion if at least 
half of the length of the first CNV overlapped with the second CNV and vice 
versa. If the 50% RO criterion was met, the two events were then considered to 
be the same event (called by different algorithms but identified in the same 
individual) as long as their call states also matched. I calculated the reciprocal 
overlap (O) (≥50% criteria) as follows:  
Where x and y are both CNVs, L is length in base pairs that the two CNVs 
(x and y) overlap, end indicates the end base pair position of the given CNV, and 
start indicates the start base pair position of the given CNV.  
 
CNVs met the ≥50% RO criteria if O(A) and O(B) were both ≥50%. CNVs that did 
not meet this criterion were considered to be different events.  
 
2A.2.5 Comparison of CNV Calls Between Subjects 
The same RO definition (≥50%) was used to compare shared and 
unshared calls in a pairwise comparison between individuals in the following 
categories of genetic relatedness: between MZ twins in a twin pair, between 
parent and child, and between unrelated individuals. Following RO comparisons, 
I calculated the average difference (d) within each group (where d is the total 
number of unshared CNVs across the two compared individuals, divided by the 
total number of CNVs called across the two compared individuals). Specifically, I 
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looked at three comparisons within each group, that is, three MZ twin 
comparisons, three parent–child comparisons and three unrelated pair 
comparisons. This calculation was used to test the relationship within each group 
in relation to their expected genetic relatedness. To perform the reciprocal 
overlap formula, HD-CNV (Hotspot Detector for Copy Number Variants) was 
used with 50 as the identified RO merge criteria (Butler et al., 2013). The d value 
was averaged for each type of relatedness in each individual software program. 
The results were assessed to compare the effectiveness of each individual 
algorithm in the identification of biologically relevant CNVs.  
 
2A.3 Results 
Table 2.1 shows the total number of unmerged CNVs representing gains 
and losses identified by each of the four software programs for 16 individuals 
using the same CEL files from Affymetrix Human SNP 6.0 Arrays. The 16 
individuals included in this analysis represent six pairs of MZ twins and the two 
parents for twin pairs 2 and 3. The results show that the number of raw CNVs 
identified in each individual varies depending on the program used. This 
variability is apparent in the numbers of gains and losses as well as the total 
numbers. Although AGC, PGS, and PC identified similar numbers of CNVs for 
most individuals (average of ~78 CNVs per individual), GH yielded more CNVs in 
each individual (average of ~317 CNVs per individual). While PGS yielded 
relatively more gains than losses, the other programs (AGC, PC and GH) yielded 
relatively more losses than gains. The differences in the number of gains and 
losses called between programs have suggested that each method may highlight 
some aspects of CNV calling but not others. I attempted to gain an insight into 
this variability by assessing the distribution of CNV calls in different contexts.  
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Table 2.1. Raw (pre-merge) Copy Number Variant Calls by Program. 
Note: A=Affected Twin, B=Unaffected Twin 
 
ID 
Affymetrix Genotyping 
Console 
PennCNV Partek Genomics Suite Golden Helix SVS 
Gain Loss Total Gain Loss Total Gain Loss Total Gain Loss Total 
1A 12 29 41 12 24 36 22 31 53 47 121 168 
1B 19 31 50 20 21 41 44 28 72 107 102 209 
2A 19 29 48 17 24 41 49 17 66 79 121 200 
2B 17 29 46 17 25 42 41 24 65 77 114 191 
3A 19 28 47 9 16 25 34 20 54 72 120 192 
3B 18 26 44 6 15 21 29 14 43 73 127 200 
4A 13 31 44 7 18 25 36 13 49 78 122 200 
4B 17 35 52 6 16 22 25 12 37 63 107 170 
5A 15 41 56 8 37 45 15 39 54 82 122 204 
5B 12 42 54 7 34 41 13 45 58 73 99 172 
6A 30 31 61 25 25 50 20 27 47 82 104 186 
6B 26 27 53 26 27 53 21 27 48 73 108 181 
Father 2A/2B 1065 101 1166 49 42 91 105 32 137 1009 297 1306 
Mother 2A/2B 175 34 209 13 35 48 19 96 115 496 301 797 
Father 3A/3B 24 41 65 14 13 27 16 11 27 113 263 376 
Mother3A/3B 21 48 69 10 25 35 9 89 98 62 262 324 
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First, I assessed the size distribution of CNVs called by the four programs. 
I found that the four programs vary in the number of CNVs called and that CNVs 
fall into different size categories (Figure 2.1). CNVs in the range of 1-100 kb were 
most frequent in AGC calls (>80% of total calls) and least frequent in PGS calls 
(<60% of total calls). Similarly, the largest CNVs (1-10 Mb) were observed at 
higher frequency in PGS calls (>10%) as compared to the other three programs 
(range 1-5%).  
The chromosomal distribution of CNVs identified by the four programs 
showed that GH calls more CNVs on all chromosomes as would be expected 
with the higher number of calls overall (Figure 2.2). Also, this number is closely 
followed by PGS calls particularly on chromosome 2, 9, 14 and 15. Otherwise, 
the distribution of CNVs across chromosomes is proportional to chromosome 
size, as expected.  
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Figure 2.1. Distribution of raw copy number variant calls (3957) by size 
generated by each software package. 
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Figure 2.2. Chromosomal distribution of raw copy number variants in autosomes (3957) generated by each 
software package.
!! 42!
Next, I assessed the overlaps in CNV calls made by each of the four 
programs in the twelve MZ twins (Figure 2.3). Most CNVs called by GH were not 
shared by calls made by any other program. The low degree of overlap suggests 
that the underlying assumptions of CNV calling by GH are different from the other 
three methods. Also, a significant number of CNV calls called by the other three 
methods (AGC, PGS and PC) showed overlaps. The CNV calls by PGS and 
AGC showed the most overlap (59%), closely followed by the overlap between 
PC and PGS (54%), and between AGC and PC (46%). CNV calls that 
overlapped between AGC, PGS, and PC represented 27% of the total number of 
CNV calls made by the three programs. When calls made by GH were included, 
all four programs shared only 0.32% (12/3713) of total CNV calls made. These 
results are similar to other reports involving comparison of different CNV calling 
programs (Kim et al., 2012; Pinto et al., 2007).  
I expected that differences and similarities in CNV calls would follow the 
genetic relatedness of individuals. For example, monozygotic twins would be 
expected to share the most CNV calls, while CNV calls for two unrelated 
individuals will show the highest amount of divergence. Similarly, pairs of 
individuals (parent and child) with presumed genetic relatedness would be 
expected to fall between 100% (MZ twins) and 0% (unrelated individuals).  
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Figure 2.3. Overlap of copy number calls across programs. 
Venn diagram showing CNV (post merging of adjacent calls into one event) calls 
made by each software program across six pairs of monozygotic twins (numbers 
in parenthesis), as well as the number of CNVs shared in common between three 
software programs and between four software programs (3 CNVs overlapping 
KGFLP1, CACNB2, ST8SIA6). The total number of non-unique CNVs identified 
post-merge across four software programs was 3713.  
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Figure 2.4 shows the degree of CNV difference (d) involving randomly 
selected pairs of unrelated individuals (N = 3), parent–child pairs (N = 3), and MZ 
twins (N = 3) for each of the four software programs. The estimate of difference 
(d) for CNVs called by GH has no relationship to the genetic relatedness 
between individuals. Conversely, CNV calls made by the other three programs 
(AGC, PGS, and PC) follow the expected genetic relatedness. The largest 
difference between unrelated individuals was identified by AGC (82%) and 
followed closely by PC (80%). The smallest difference found between MZ twins is 
reflected by PGS (18%) followed by PC (21%). Interestingly, the parent–child 
differences for the three methods PGS, PC, and AGC were estimated to be 
~56%, ~61%, and ~72%, respectively. Even though the standard error 
associated with these means (based on only 3 comparisons) are relatively large, 
the overall trends for the pairwise comparisons made by PGS, PC, and AGC 
follow the expected pattern based on the known genetic relatedness. 
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Figure 2.4. Copy number call differences made by each program and categorized by relatedness.  
Mean difference (d) ± SEM, of three pairwise comparisons between two unrelated individuals, parent and child, and 
monozygotic twins as determined by each software program (PennCNV, Affymetrix: Affymetrix Genotyping 
Console, Partek: Partek Genomics Suite, GH: Golden Helix SNP and Variation Suite). 
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2A.4 Discussion 
The results support the likelihood that PGS, PC, and AGC are identifying 
biologically relevant CNV calls. Calls made by multiple programs provide a 
greater likelihood that the underlying CNV may be real. At the same time, if one 
is forced to choose only one method, my analysis based on the ability to resolve 
varying degrees of genetic relatedness favours the use of PC. The reason for this 
choice is based on the fact that it has a relatively high d value for unrelated 
individuals, a low d value between MZ twins, and an intermediate degree of 
difference involving parent and child, as would be expected. On average, the 
number of CNVs found in parental samples was higher than the number found in 
twin samples; this finding may reflect the age of sample collection. Environmental 
effects may also be contributing to the increased number, particularly in Twin 
Pair 2 where the Father has undergone chemotherapy treatment. 
I compared four programs to call CNVs (AGC, PGS, PC, and GH) from the 
same microarray data for 16 individuals using the Affymetrix Human SNP 6.0 
Array. The CNV calls are different across the four methods, but some overlap 
was observed. It follows a number of other reports in the literature that have also 
reported similar discrepancies (Eckel-Passow et al., 2011). It is therefore not 
surprising that the results are different across the four methods and particularly 
between the three methods that use a HMM (AGC, PGS, and PC) based 
approach versus the method that uses a segmentation approach (GH). Unlike 
the HMM that assume the means of different copy number states to be 
consistent, optimal segmenting delineates CNV boundaries with increased 
sensitivity.  
Overall, I conclude that some CNV calling methods can appropriately 
distinguish known levels of genetic relatedness and others have more difficulty 
doing so. I also note that some differences between related individuals, including 
monozygotic twins would be expected due to somatic mosaicism; however, these 
differences would be expected to be relatively small in number.  
The results presented in this report suggest that microarray experiments 
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are prone to errors in CNV calls. Further, my results are likely to include false 
positive as well as false negative calls found in the arrays. Most CNV databases 
are populated with entries from the past half-decade that include results that 
have not been confirmed and may represent error (Eckel-Passow et al., 2011; 
Lin et al., 2011; Pawitan et al., 2005; Zhang et al., 2011). In fact, research 
involving CNV calling from microarray results would benefit from better 
microarray technologies, better algorithms for CNV calling and better standards 
for independent confirmation. 
All steps in a microarray experiment, from the isolation of DNA from tissue 
samples to the calling of CNVs from CEL files, are points at which error can be 
introduced. These and other confounding factors could affect the accuracy of 
biologically-significant CNV detection. Inferring copy number from array data is 
notoriously plagued with false-positive rates that may vary depending on the 
algorithm used (Eckel-Passow et al., 2011). Given the scientific and clinical 
implications for accurate CNV detection (Valsesia et al., 2012) as well as the 
introduction of ascertainment bias into future studies via microarray design, 
algorithm parameters, and database entries (Teo et al., 2012; Wineinger and 
Tiwari, 2012), it is necessary to identify the most reliable CNV calling programs.  
 
2A.5 Conclusion 
The results presented here offer a number of insights with respect to the 
total number of CNVs across individuals including gains and losses, program-
specific distributions of CNV size, and CNV distribution across chromosomes. As 
expected, the number of CNVs was related to the size of the chromosome. The 
major observation from the collective results is that the number of CNVs 
identified by Golden Helix (GH) software was much higher than the number 
called by the other three programs (AGC, PC, PGC). Also, Golden Helix 
identified vastly different CNVs when compared to those identified by Affymetrix 
Genotyping Console (AGC), Partek Genomic Suite (PGS), and PennCNV (PC). 
Excluding GH as an outlier, AGC yielded more CNV calls than PGS and PC. As 
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expected, AGC, PGS, and PC yielded a relatively large number of overlapping 
CNVs. These results are consistent with previous reports (Pang et al., 2010).  
Further assessment of the four CNV calling methods was considered in 
the context of similarities and differences involving individuals of differing genetic 
relatedness. As it stands, three of the four methods met such expectations to 
different degrees. The results offer two conclusions. First, overlapping CNV calls 
by three of the programs (AGC, PGS, and PC) will offer the highest likelihood of 
discovering biologically relevant calls. The combination of AGC and PC identified 
the most differences among unrelated individuals whereas PGS and PC showed 
the least differences between MZ twins. The results from GH showed a higher 
number of CNVs than would be expected and also did not follow the expected 
pattern when groups of known relatedness were compared. For this reason, I do 
not recommend GH and suggest that further research should explore the 
unexpected profile generated from the software. Secondly, the PC calls best 
reflect the expectations at all three levels involving unrelated individuals, parent–
child, and MZ twins. My results and conclusions are in agreement with other 
groups, which have found that without independent validation using bench 
confirmation techniques such as qPCR, CNVs calls should not be assumed to be 
truly valid variants (Kim et al., 2012; Pinto et al., 2011). Finally, I suggest that 
incorporation of family data will help in improving the quality of CNV calls 
alongside the use of multiple CNV calling methods.  
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A version of this chapter has been published in Castellani et al., Twin Res. Hum. Genet. (2014b)  
2B Assessment of Copy Number Variation in Monozygotic Twins 
Discordant for Schizophrenia 
2B.0 Overview of 2B 
As mentioned above, when the Affymetrix Human SNP 6.0 arrays were 
analyzed using Affymetrix Genotyping Console™, Partek Genomics Suite, 
PennCNV, and Golden Helix SVS the results yielded both program-specific and 
overlapping variants. In the further assessment of CNVs that may contribute to 
disease discordance, only CNVs called by Affymetrix Genotyping Console, 
Partek Genomics Suite, and PennCNV were used in further analysis. This 
analysis included an assessment of calls in each of the six twin pairs towards 
identification of unique CNVs in affected and unaffected co-twins. Real time 
polymerase chain reaction (PCR) experiments confirmed two CNVs that were 
found in the affected patient but not in the unaffected twin. The results identified 
CNVs and genes that were previously implicated in mental abnormalities in four 
of the six twin pairs. Specifically the genes PYY (twin pairs 1 and 5), EPHA3 
(twin pair 3), KIAA1211L (twin pair 4), and GPR139 (twin pair 5) were identified 
as patient specific. They represent potential candidate genes and CNV regions 
that may contribute to the discordance of these monozygotic twin pairs for this 
heterogeneous neurodevelopmental disorder. These findings suggest that 
phenotypic differences between monozygotic twins may arise from ontogenetic 
de novo events arising after the splitting of the zygote. 
 
2B.1 Introduction 
Schizophrenia clusters in some families and has a high heritability 
estimate (80%) (Sullivan et al., 2003). In fact, the best predictor of the occurrence 
of this disease is family history. The inheritance pattern of schizophrenia is 
complex. This complexity is reflected in the observation that monozygotic twins, 
who are said to share 100%, and dizygotic twins who are said to share 50%, of 
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their genetic makeup are concordant in only 48% and 17% of cases, respectively 
(McGuffin et al., 1994). These observations suggest a role for non-genetic and 
random genetic factors (O’Reilly and Singh, 1996; Singh and O’Reilly, 2009), 
including random developmental events (Singh et al., 2004), epigenetic 
mechanisms (Singh et al., 2002), and environmental factors (Torrey et al., 1997). 
Over 30 years of genetic research using linkage and association analysis have 
identified a number of promising linkages (Sullivan, 2005) and candidate genes 
(Hamilton, 2008; Karayiorgou and Gogos, 2006). Most of these results have 
been difficult to reliably replicate except in the case of a few variants, which have 
been associated across multiple studies, typically when large sample sizes are 
employed (Ripke et al., 2013; Torkamani et al., 2010). This difficulty in identifying 
causal genes for schizophrenia has been attributed to extensive heterogeneity, 
including genetic differences among patients from the same family (Beckmann 
and Franzek, 2000). Application of genome-wide expression arrays in 
schizophrenia has identified a long list of genes with altered expression in the 
brain (McInnes and Lauriat, 2006; Verveer et al., 2007) and blood (Gladkevich et 
al., 2004; Tsuang et al., 2005). However, altered expression of these genes 
cannot always be replicated. 
Recent advances have helped in the identification of CNVs and opened a 
new direction in schizophrenia genetics research (Kirov, 2010). By virtue of their 
variable size, they may directly disrupt multiple genes that are co-located (Feuk 
et al., 2006b). In addition to having a direct effect on the expression of the 
amplified or deleted genes (Stranger et al., 2007), they may have indirect effects 
on gene expression extending upstream and downstream of the CNV region 
(Henrichsen et al., 2009). While most CNVs are polymorphic, some are 
generated de novo (Zogopoulos et al., 2007). Common CNVs in humans are 
believed to play a role in evolution (Lee and Scherer, 2010). They also underlie a 
significant proportion of variation in humans, including differences in cognitive, 
behavioral, and psychological features (Lee and Lupski, 2006). Further, they 
have been implicated across a wide variety of common disorders (Buchanan and 
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Scherer, 2008; Consortium et al., 2010; Stankiewicz and Lupski, 2010), including 
mental disorders (Feuk et al., 2006a; Lee and Lupski, 2006; McCarroll and 
Altshuler, 2007), particularly autism (OMIM: 209850) (Consortium et al., 2007; 
Glessner et al., 2009; Moessner et al., 2007; Sebat et al., 2007; Wang et al., 
2009) and schizophrenia (Glessner et al., 2010; Kirov et al., 2008; Need et al., 
2009; Stefansson et al., 2008; Walsh et al., 2008; Xu et al., 2008). The results, 
generated with increasing genomic coverage and numbers of patients, have 
identified a set of candidate CNVs. These include rare deletions at 1q21.1, 
15q13.3, 15q11.2, and 22q11.2, as well as duplications at 16p11.2, 16p13.1, and 
7q36.3 (Kirov et al., 2008). In addition, various gene regions have been 
associated with copy number variation in schizophrenia, namely deletions of 
NRXN1, APBA2, and CNTNAP2 (Friedman et al., 2008; Liu et al., 2002). 
The findings in the field also suggest that, with few exceptions, 
schizophrenia is caused by aberrations in a relatively large number of genes, 
most with relatively small effects, that cumulatively produce a genetic 
predisposition. Some of these aberrations may be inherited while others may 
represent de novo events (Singh et al., 2009). The field is starting to recognize 
that rare variants likely play a role in the causation of schizophrenia. This model 
is not compatible with traditional experiments in which a group of patients are 
compared with an equally large group of unaffected controls. In such an 
approach, adding more patients will add additional genetic heterogeneity across 
cases. This complexity is likely better approached by the precise genetic 
matching of patients with unaffected controls that can be achieved using 
monozygotic twins. Even if rare variants identified using this approach are limited 
to a given set of twins or a given family, they are likely to help in identifying the 
underlying pathways and genes involved in this disorder. 
In this research, I used six pairs of monozygotic twins discordant (MZD) 
for schizophrenia and assessed the CNV differences between twin pairs. The 
resulting CNV differences are of interest in identifying patient-specific differences, 
including gene dosage changes that may differ in a MZD pair. Previous studies 
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utilizing monozygotic twins have associated CNV differences between twins with 
various diseases. Using MZ twins, three somatic CNV events were found to be 
associated with discordance for congenital heart defects (Breckpot et al., 2012). 
Similarly, two de novo CNVs — a pre-twinning duplication and a post-twinning 
deletion were found to be associated with attention problems (Ehli et al., 2012). 
The results are twin-specific and trends are not always consistent (Bloom et al., 
2013; Halder et al., 2012; Maiti et al., 2011). Some studies call CNV differences 
(Maiti et al., 2011) while others call no difference in CNVs between MZ twins 
discordant for schizophrenia (Bloom et al., 2013). In either case, the MZD 
strategy is effective in the identification of previously undiscovered genes in 
schizophrenia, particularly when combined with the use of multiple software 
programs for CNV analysis. Given the high heterogeneity of this disorder, I would 
a priori expect many aberrations to be patient-specific. These patient-specific 
genetic changes can be best identified using nature’s best match for each patient 
- their monozygotic twin. I have hypothesized that the discordance of 
monozygotic twins for schizophrenia may involve de novo mutations (DNM) 
(Singh et al., 2009) contributing to a disease liability threshold. If that is so, I 
should be able to identify differences between MZD twins for schizophrenia that 
are de novo in nature and do not apply to all twin pairs, but instead show twin-
pair specificity. In this report, I have employed a stringent CNV detection protocol 
using multiple CNV calling methods, and identified CNV differences between 
MZD for schizophrenia. The results support the potential presence of de novo 
CNVs that are compatible with the development of schizophrenia. 
 !  
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2B.2 Methods 
2B.2.1 Ethics Statement and Clinical Background  
As mentioned in the methods for section 2A, this study received ethics 
approval by the University of Western Ontario’s Committee on research involving 
human subjects (Appendix B). All subjects provided written informed consent to 
participate in this study and were interviewed by a psychiatrist (ROR) using the 
SCID-I (First et al., 1996) and the SCID-II (First et al., 1997). All of the patients 
were adults at the time of consent. Past clinical notes were obtained to aid 
diagnosis. Whole blood samples were obtained from each individual. The twin 
pairs studied ranged in the age from 20 to 53 years at the time of sample 
collection. Three of the pairs were female and three of the pairs were male.  
The overall strategy used to generate and interpret the results is outlined 
in a flowchart in Figure 2.5. 
 
2B.2.2 DNA Preparation, Hybridization and CEL File Analysis  
Deoxyribonucleic acid was extracted from whole blood using the 
PerfectPure DNA Blood Kit (http:// www.5prime.com) following the 
manufacturer’s protocol. Whole genome microarray analysis using the Affymetrix 
Genome-Wide Human SNP Array 6.0 was performed at the London Regional 
Genomics Centre (LRGC) following the manufacturer’s protocol. For downstream 
analysis of CEL files, Affymetrix Genotyping Console 4.1.1 (A), Partek Genomics 
Suite (P), PennCNV (p), and Golden Helix SVS Suite 7.0 (G) were used. 
 
 
 
 
 
!! 54!
!
Figure 2.5. Flowchart of Chapter 2B experimental design
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2B.2.3 Calling and Merging of CNVs for Individual Genomes 
The Hap Map 270 6.0 Array reference was utilized as a model reference 
file. Variants were identified as those DNA regions, which were called as copy 
number state 0, 1, 3, or 4+ by 10 or more consecutive markers on the chip. 
Recent literature suggests that a baseline of at least seven consecutive probes is 
necessary for reliable CNV detection (Wineinger and Tiwari, 2012). In addition, 
only variants that were greater than 1 kb in size were classified as CNVs for the 
purposes of this study and only those identified by at least three software 
programs in the same individual were included in subsequent analysis. I used 
quantile normalization across all four software programs. Overlapping genes 
were identified using the UCSC (University of California, Santa Cruz) genome 
browser table view (NCBI36/hg18). Identification of CNVs was followed by 
merging of CNV calls within software programs and comparison of calls between 
software programs to identify CNVs called by the three software programs. I 
identified CNVs within each of the four software programs that were likely to be 
the same event using the following criteria: (1) CNVs had to be adjacent on the 
same chromosome (no other CNV call between them); (2) had to share the same 
gain/loss status; (3) adjacent calls were merged together into one single call, 
using gap ≤20% of total length. That is, if there are three genomic segments, A, 
B, and C, where A and C are both losses, I divided the length of gap B by the 
length of A+B+C, and if this fraction is ≤20%, then I merged A + B + C as a single 
CNV call. 
 
2B.2.4 Identification of Overlapping CNV Calls for Individual Genomes  
I used the 50% reciprocal overlap (RO) formula as discussed in Chapter 
2A. Copy number variants that shared 50% or more similarity with one another 
were classified as overlapping. This is consistent with the definition of an 
overlapping CNV identified by other groups (Pang et al., 2010; Wain et al., 2009; 
Yavas et al., 2009). In other words, if at least half of the first CNV overlapped 
with the second CNV and vice versa they were considered to be the same event. 
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2B.2.5 Comparison of CNV Calls Within Monozygotic Twin Pairs  
The same RO definition was used to compare calls between monozygotic 
twin pairs. CNVs were compared between affected and unaffected twin pairs to 
determine which CNVs were shared and unshared between twins. Unshared 
CNVs between twins were then annotated with gene information and compared 
to CNVs in the Database of Genomic Variants (DGV). The genes overlapping 
CNVs that were different between twin pairs and called by at least three software 
programs were further characterized using Ingenuity Pathway Analysis (IPA; 
Ingenuity Systems, California) and GeneMania (Toronto, ON) to identify gene 
networks and canonical pathways. Finally, I compared the genes identified in this 
study to those genes listed in the Schizophrenia Gene Database (http:// 
www.schizophreniaforum.org/res/sczgene/default.asp) to determine the genes 
that appear to be most likely to play a role in schizophrenia discordance. 
Additional searches from PubMed covering the most recent results helped 
update any connection between genes of interest and disease pathology. 
 
2B.2.6 Confirmation of Unique CNVs  
A subset (10) of the CNV differences identified between monozygotic 
twins were confirmed using TaqMan Quantitative PCR (qPCR) Copy Number 
Assays from Life Technologies, Inc (Grand Island, NY). In particular, CNVs which 
were unique to co-twin and overlapped regions of interest to disease were 
chosen. The control used for comparison of copy number in the TaqMan 
experiments was RNAseP and the calibrator used was the individual’s unaffected 
co-twin. Each Real Time experiment was repeated four times. The delta-delta Ct 
method was used and significance was defined as a Z-Score <1.75 and 95% 
confidence level. The Ct value is the Cycle Threshold, and is defined as the 
number of cycles required for the fluorescent signal to cross the threshold value. 
CNV calls were determined using Copy Caller (Life Technologies). 
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2B.3 Results 
First, the number of unfiltered CNVs identified by each software program 
in each of the six twin pairs varied by program (Table 2.1). Golden Helix’s SVS 
identified the highest number of CNVs in each individual, with a range of 168 to 
209 variants. Affymetrix Genotyping Console and Partek Genomics Suite called 
similar numbers of CNVs in each individual, with ranges of 41 to 61 and 37 to 72 
variants, respectively. PennCNV called the smallest number of CNVs in each 
individual, with a range of 21 to 53 variants. The smallest number of unfiltered 
variants called in any one individual was 21 (PennCNV) and the largest number 
was 209 (Golden Helix SVS). The majority of CNV calls across all four software 
programs were between 1 kb and 100 kb in size, with at least 56% of the total 
CNVs in each analysis falling into this range. Partek Genomics Suite yielded the 
highest number of large calls (1-10 Mb) and Affymetrix Genotyping Console 
yielded the greatest number of small CNV calls (1–100 kb). 
Second, the percentage of Affymetrix Genotyping Console CNV calls 
detected by three or more algorithms was 23.04%, the percentage of Partek CNV 
calls detected by three or more algorithms was 30.30%, the percentage of 
PennCNV calls detected by three or more algorithms was 33.02% and the 
percentage of SVS CNV calls detected by three or more algorithms was only 
0.36%. This summary of overlapping CNVs across four programs strongly 
suggests that the most reliable calls may represent overlapping CNVs involving 
Affymetrix (A), Partek (P), and PennCNV (p), termed as A/P/p. A combination 
that includes Golden Helix along with any other two methods yielded rare CNVs 
only and was considered too restrictive. More importantly, the overlap generated 
by A/P/p calls was less restrictive across the twin pairs. Consequently, the CNVs 
identified by this combination were further assessed in the follow-up analysis 
involving shared and unshared CNVs between members of the six twin pairs 
studied (Table 2.2). 
Third, I found a total of 38 CNV events called by the three (A/P/p) software 
programs that were not shared with their co-twin across the six pairs. 
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Specifically, 14 unique CNV events were observed in co-twins affected with 
schizophrenia (Table 2.3), while 22 were unique to the six unaffected co-twins of 
the six MZD pairs (Table 2.4). Some of the CNVs in both categories contained 
genes, while others were located in non-coding regions of the genome. In fact, 
there was a total of 12 unique genes overlapping the 14 CNVs that were found in 
affected members only. Similarly, there was a total of 28 unique genes 
overlapping the 22 CNVs that were found in unaffected twins only. The results 
confirm that monozygotic twins do differ for rare CNVs. I have undertaken a pair-
specific analysis in an effort to explain the discordance of the monozygotic twin 
pairs for schizophrenia which is described below. 
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Table 2.2. Shared and unshared status of CNVs called by 3+ software programs in identical twins. 
Twin 
Called by Affymetrix GC, 
Partek and Golden Helix 
SVS 
Called by Partek, Golden 
Helix SVS and PennCNV 
Called by Affymetrix GC, 
Golden Helix SVS and 
PennCNV 
Called by Affymetrix GC, 
Partek and PennCNV 
(A/P/p) 
Shared Unique Total Shared Unique Total Shared Unique Total Shared Unique Total 
1A 
0 
0 0 
0 
0 0 
0 
0 0 
10 
4 14 
1B 3 3 4 4 3 3 2 12 
2A 
0 
0 0 
1 
2 3 
0 
0 0 
11 
1 12 
2B 0 0 0 1 0 0 4 15 
3A 
0 
0 0 
0 
1 1 
0 
0 0 
6 
4 10 
3B 0 0 0 0 0 0 1 7 
4A 
0 
0 0 
0 
0 0 
0 
0 0 
7 
3 10 
4B 0 0 0 0 0 0 0 7 
5A 
0 
0 0 
0 
0 0 
0 
0 0 
8 
2 10 
5B 1 1 0 0 1 1 10 18 
6A 
0 
0 0 
0 
0 0 
0 
0 0 
8 
0 8 
6B 0 0 0 0 0 0 5 13 
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Table 2.3. CNVs identified by Affymetrix Genotyping Console, Partek Genomics Suite and PennCNV (A/P/p) and 
only present in the affected co-twin. (NCBI36/hg18) 
Note: Chr= Chromosome, DGV= Database of Genomic Variants. 
ID Chr Region Start Position 
End 
Position 
Length 
(kb) State 
# of 
Probes Genes DGV
 
1A 6 6q14.1 77016905 77027694 11 Loss 33 None No 
 7 7q31.1 109441200 109453946 13 Loss 13 None No 
 14 14q21.2 41628351 41657337 29 Loss 11 None No 
 17 17q21.31 39423041 39430053 7 Loss 17 PYY No 
2A 11 11p15.1 18949072 18961778 13 Gain 55 None Yes 
3A 3 3p11.2-3p11.1 89394600 89419369 25 Loss 51 EPHA3 No 
 7 7q11.21 64594329 64955220 361 Loss 174 
LOC441242, 
INTS4L2, 
CCT6P1, 
SNORA22 
Yes 
 11 11p15.4 5789589 5809449 20 Loss 30 OR52N2 Yes 
 16 16p11.1 34459037 34624994 166 Gain 128 
LOC283914, 
LOC146481, 
LOC100130700 
Yes 
4A 2 2q11.2 98858308 98879625 21 Loss 52 KIAA1211L No 
 3 3q25.1 151511085 151547185 36 Loss 30 None No 
 16 16q23.2 78372440 78377393 5 Loss 11 None No 
5A 16 16p12.3 19945650 19965863 20 Loss 30 GPR139 No 
 17 17q21.31 39423041 39430053 7 Loss 17 PYY No 
6A NONE 
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Table 2.4. CNVs identified by Affymetrix Genotyping Console, Partek Genomics Suite and PennCNV (A/P/p) and 
only present in the unaffected co-twin. (NCBI36/hg18) 
ID Chr Region Start Position End Position Length (kb) State 
# of 
Probes Genes DGV
 
1B 2 2q22.1 138045294 138065759 20 Loss 24 THSD7B No 
 7 7q35 143917601 144051219 134 Gain 31 TPK1 Yes 
2B 1 1q21.2 149086185 149202838 117 Loss 76 ARNT,SETDB1 Yes 
 7 7q21.2 91031620 91040715 9 Loss 29 None Yes 
 17 17q21.32 44535027 44739523 204 Gain 30 
B4GALNT2,GNGT2, 
ABI3,PHOSPHO1, 
FLJ40194,ZNF652 
No 
 19 
19q13.13-
19q13.2 
43294390 43538078 244 Loss 117 
SIPA1L3,DPF1,PPP1R14,
SPINT2,YIF1B,C19orf33, 
KCNK6, CATSPERG 
Yes 
3B 3 3q26.1 165046890 165083684 37 Loss 65 None No 
4B NONE 
5B 1 1p36.33 61735 86161 24 Loss 14 None Yes 
 1 1p21.1 104155790 104248433 93 Loss 31 None Yes 
 1 1q25.2 174796556 174801847 5 Loss 17 PAPPA2 No 
 2 2p22.3 34709689 34727855 18 Loss 21 None Yes 
 3 3p14.1 68746577 68747401 1 Loss 11 None No 
 3 3q11.2 98944458 98949409 5 Loss 38 EPHA6 No 
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Note: Chr=Chromosome, DGV=Database of Genomic Variants. 
 4 4p15.1 34779042 34822761 44 Loss 40 None No 
 4 4q24 104742390 104761153 19 Loss 37 TACR3 No 
 8 8p11.23 39301780 39384688 83 Loss 28 ADAM5 Yes 
 9 9p11.2 44247866 44705656 458 Loss 16 LOC643648 Yes 
6B 2 2p22.3 34709689 34727867 18 Loss 21 None Yes 
 2 2q14.3 129638490 129640285 2 Loss 11 None Yes 
 3 3q26.1 162551776 162619878 68 Gain 39 SPTSSB No 
 12 12p11.1 33301406 33306843 5 Loss 10 None Yes 
 17 17q21.32 44214888 44362186 147 Gain 89 
TTLL6,CALCOCO2, 
ATP5G1, UBE2Z 
Yes 
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2B.3.1 Twin Pair 1 
The affected male patient in twin pair 1 was diagnosed with a psychotic 
disorder at age 19. He had 41, 53, and 36 raw CNV calls by each of the three (A, 
P, or p) programs, respectively. In comparison, his unaffected co-twin had 50, 72, 
and 41 raw CNV calls by the three methods. After CNV merging and discarding 
of CNVs that were not called by the combination of A/P/p, the affected and 
unaffected members of this twin pair yielded 14 and 12 CNVs, respectively. 
These CNVs fell into three categories; shared between the twin pair (10), unique 
to unaffected (2), and unique to the affected member of twin pair 1 (4). The two 
CNVs that were found to be unique to the unaffected twin were a loss at 2q22.1 
and a gain at 7q35. These CNVs overlapped the genes THSD7B and TPK1, 
respectively (Table 2.4). Of the four CNVs that were found to be unique to the 
affected member, none are reported in the DGV. Three of these CNVs (6q14.1, 
7q31.1, 14q21.2) cover no gene overlaps while one (17q21.31) covers the PYY 
gene (Table 2.3). Interestingly, the 14q21 region has been previously implicated 
in bipolar disorder (Liu et al., 2003).  
 
2B.3.2 Twin Pair 2 
The affected female patient in twin pair 2 was diagnosed with 
schizoaffective disorder at age 27. She had 48, 66, and 41 raw CNV calls by 
each of the three (A, P, or p) programs, respectively. In comparison, her 
unaffected co-twin had 46, 65, and 42 raw CNV calls. After CNV merging and 
discarding of CNVs that were not called by the combination of A/P/p, 12 and 15 
CNVs remained in the affected and unaffected twins, respectively. Of these, 11 
were shared between the twin pair, 4 were unique to unaffected, and 1 was 
unique to the affected member of this twin pair. The four CNVs that were found to 
be unique to the unaffected member were a loss at 1q21.1 that overlapped two 
genes, a loss at 7q21.2 that overlapped no genes, a gain at 17q21.32 that 
overlapped six genes, and a loss at 19q13.13-19q13.2 that overlapped eight 
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genes (Table 2.4). The CNV that was found to be unique to the affected member 
was a gain found in the region 11p15.1 that does not overlap with any known 
genes and has been previously reported in the DGV (Table 2.3). No CNVs 
identified in twin pair 2 have been reported for any neurodevelopmental disorder 
and the observations do not seem to be likely candidates to explain the 
discordance for schizophrenia seen in this twin pair. 
 
2B.3.3 Twin Pair 3 
The affected female in twin pair 3 was diagnosed with paranoid 
schizophrenia at age 22. She had 47, 54, and 25 raw CNV calls by each of the 
three (A, P, or p) programs, respectively. In comparison, her twin sister had 44, 
43, and 21 raw CNV calls. The merging and discarding of non-overlapping CNVs 
yielded 10 and 7 CNVs in the affected and unaffected twins, respectively. Of 
these, six of the CNVs were shared between twin pair 3, one was unique to 
unaffected, and four were unique to the affected member. The CNV that was 
found to be unique to the unaffected member was a loss at 3q26.1 that did not 
overlap any gene (Table 2.4). The four CNVs that were found to be unique to the 
affected twin overlapped four regions: 3p11.2-3p11.1, 7q11.21, 11p15.4, and 
16p11.1 (Table 2.3). Of these, the loss at 3p11.2-3p11.1 is the only one that was 
not previously reported in the DGV. This CNV overlapped the EPHA3 gene. The 
other genes unique to the affected twin were LOC441242, INTS4L2, CCT6P1, 
SNORA22, OR52N2, LOC283914, LOC146481, and LOC100130700. Yet 
another identified gene, SNORA22, encodes a small nucleolar ribonucleic acid 
(RNA), which may guide chemical modifications of other RNAs (Kiss, 2001). 
Interestingly, CCT6P1 is highly expressed in brain (Velculescu et al., 1995). 
Further, the 16p11 region has been implicated in mental disorders, including 
psychosis (Steinberg et al., 2012).  
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2B.3.4 Twin Pair 4 
The female patient in twin pair 4 was diagnosed with paranoid 
schizophrenia at age 18. She had 44, 49, and 25 raw CNV calls identified by 
each of the A, P, or p programs, respectively. In comparison, her unaffected co-
twin had 52, 37, and 22 raw CNV calls. After CNV merging and discarding of 
CNVs that were not called by A/P/p, 10 and 7 CNVs remained in the affected and 
unaffected members of this twin pair, respectively; seven were shared between 
the twin pair and three were unique to the affected member. Interestingly, there 
was no CNV that was unique to the unaffected twin (Table 2.4). Of the three 
CNVs that were found to be unique to the patient, none are reported in the DGV. 
Two of the CNVs (3q25.1, 16q23.2) cover no genes while one (2q11.2) covers 
the KIAA1211L gene (Table 2.3). Interestingly, the 3q25 region has been 
previously implicated in autism-spectrum disorders (Auranen et al., 2002). Also, 
KIAA1211L is expressed in the brain and has been reported in bipolar disorder 
(Scott et al., 2009). Also of interest, this CNV has not been previously identified 
in the DGV, making this CNV loss a potential candidate for the discordance for 
schizophrenia of this twin pair. 
 
2B.3.5 Twin Pair 5 
The affected male in twin pair 5 was diagnosed with undifferentiated 
schizophrenia at age 20. He had 56, 54, and 45 raw CNV calls and his 
unaffected co-twin had 54, 58, and 41 calls identified by the A, P, or p software 
programs, respectively. After CNV merging and discarding of CNVs that were not 
called by all three programs, 10 and 18 CNVs remained in the affected and 
unaffected twins, respectively. These CNVs fell into three categories: shared 
between the twin pair (8), unique to unaffected (10), and unique to the affected 
member of twin pair 5 (2). The 10 CNVs that were found to be unique to the 
unaffected member were found in the regions 1p36.33, 1p21.1, 1q25.2, 2p22.3, 
3p14.1, 3q11.2, 4p15.1, 4q24, 8p11.23, and 9p11.2, and overlapped the 
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PAPPA2, EPHA6, TACR3, ADAM5, LOC643648, LOC283914, LOC146481, and 
LOC100130700 genes (Table 2.4). Of the two CNVs that were found to be 
unique to the patient (16p12.3 and 17q21.31), the first, a loss at 16p12.3, 
overlaps the GPR139 gene and the second, a loss at 17q21.31, overlaps the 
PYY gene (Table 2.3). PYY, as also discussed in the pair-specific results shown 
for twin pair 1 above, is a potential candidate for the discordance for 
schizophrenia identified in this twin pair as well. GPR139 is a gene that is an 
important mediator of signal transduction. G-protein receptors are predominantly 
expressed in the brain and are known to play important roles in the central 
nervous system. GPR139 has been previously reported to be associated with 
attention deficit hyperactivity disorder (ADHD; OMIM: 143465) (Ebejer et al., 
2013). Both the CNV loss overlapping the GPR139 gene and the CNV loss 
overlapping the PYY gene have not been listed in the DGV. They may represent 
de novo events and candidates for the disease discordance of this twin pair. 
 
2B.3.6 Twin Pair 6 
The male patient in twin pair 6 was diagnosed with paranoid schizophrenia 
at age 16. He had 61, 47, and 50 raw CNV calls as identified by the A, P, or p 
software programs, respectively. In comparison, his unaffected co-twin had 53, 
48, and 53 raw CNV calls. After CNV merging and discarding of CNVs that were 
not called by all three (A/P/p) programs, 8 and 13 CNVs remained in the affected 
and unaffected members, respectively. These CNVs fell into three categories: 
shared between the twin pair (8), unique to unaffected (5), and unique to the 
affected member of twin pair 6 (0). The five CNVs that were found to be unique 
to the unaffected member were found at 2p22.3, 2q21.1, 3q26.1, 12p11.1, and 
17q21.32. Only the CNV gains at 3q26.1 and 17q21.32 overlapped genes. The 
CNV at 3q26.1 overlapped the SPTSSB gene and the CNV at 17q21.32 
overlapped TTLL6, CALCOCO2, ATP5G1, and UBE2Z (Table 2.3). No CNVs 
were found to be unique to the affected member of this twin pair. Consequently, 
!! 67!
no CNVs identified in twin pair 6 seem to represent candidates to explain their 
discordance for schizophrenia. 
The results outlined above have identified rare and pair-specific CNV 
differences between monozygotic twins in each of the six twin pairs discordant 
for schizophrenia. Some CNVs involve single or multiple genes and others 
represent non-coding genomic regions. Also, a number of the CNVs are not 
reported in DGV, specifically 10 of 14 events found to be unique to affected twins 
and 9 of 22 events found to be unique to unaffected twins. 
 
2B.4 Discussion 
It has become apparent that CNVs are common in human populations and 
play a significant role in the etiology of complex diseases, including 
schizophrenia (Ahn et al., 2013; St Clair, 2013). However, it is not easy to identify 
disease-specific CNVs and establish their mode of action in the causation of the 
disease. Of special concern is the use of arrays with different degrees of genome 
coverage and the large number of algorithms available to call CNVs. Although 
the Affymetrix Human Array 6.0 appears to meet most of the platform criteria, 
including coverage for CNV calling in humans, a gold standard algorithm for the 
analysis of data has not been established (Zhang et al., 2011). There is a 
likelihood of false positive results. Despite this, such experiments have generated 
and continue to generate valuable insights. Reports assessing the use of 
different software algorithms to analyze the same microarrays have identified a 
low concordance rate between software programs (Kim et al., 2012; Pinto et al., 
2011). This is likely due to the substantial background noise, which contributes to 
a false discovery rate of variants (Grayson and Aune, 2011). To avoid this, often 
two programs are used to call the CNVs and the resulting shared CNVs are 
considered to be reliable. Although logical, this approach is not totally satisfactory 
as it may ignore and miss out on some critical results. In this analysis I have 
focused on shared results and specifically I have used four different software 
programs to call CNVs. I found a relatively low percentage of concordance 
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between the calls. This is consistent with findings in the literature (Kim et al., 
2012; Pinto et al., 2011) and highlights the necessity for more stringent 
guidelines for CNV calling from microarrays. A study conducted by Kim et al. 
(2012) suggested that at least three calling algorithms should be used to ensure 
the reliability of results (Kim et al., 2012). 
 
2B.4.1 Selected Regions/Genes  
As stated, I used four CNV calling programs (Golden Helix’s SVS, 
Affymetrix Genotyping Console, Partek Genomics Suite, and PennCNV) and 
selected CNVs that were called by three methods (Affymetrix Genotyping 
Console, Partek Genomics Suite, and PennCNV) referred to as A/P/p. I chose 10 
CNVs to confirm the results by Real Time PCR. The qPCR results established 
that one CNV, a CNV loss at 7q11.21 in twin pair 3 was significantly different 
between twins and matched the expected result from the microarray (Figure 2.6). 
Further, three CNVs (CNV loss at PYY in twin pair 5, CNV loss at OR52N2 in 
twin pair 3 and CNV gain at 5q11.2 in twin pair 6) showed the expected trend 
when analyzed by qPCR but were not statistically significant (Table 2.5).  
 Taken together, the genes/regions that were either confirmed as different 
between twins or not confirmed but showed the expected direction were 7q11.21, 
EPHA3, OR52N2, 5q11.2, and PYY. These genes/regions have been previously 
identified in the literature, as discussed below: 
The 7q11.21 region had a 361 kb loss in twin pair 3 that was confirmed by 
real time PCR. What is of particular interest is the proximity of this region to the 
deletion on 7q11.23 responsible for Williams-Beuren syndrome and previously 
associated with schizophrenia (Mulle et al., 2014). 
The EPHA3 gene showed a significant difference between the members 
of twin pair 3, however the direction of the difference in the Real Time PCR result 
was a gain when a loss was expected from the microarray result (Table 2.5). 
EPHA3 belongs to the ephrin receptor subfamily of protein-tyrosine kinases that 
have been implicated in mediating developmental events, particularly in the 
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nervous system, and have been previously associated with neurodegenerative 
diseases (Martinez and Soriano, 2005). Also, the EPHA3 gene is the only CNV 
identified in twin pair 3 that has not been previously reported in the DGV and 
therefore has the potential to explain discordance for schizophrenia in this twin 
pair. 
Results on OR52N2, an olfactory receptor, suggested a loss in the patient 
of twin pair 3. Olfactory receptors share a seven-transmembrane domain 
structure with many neurotransmitter and hormone receptors and are responsible 
for the recognition and G protein-mediated transduction of odorant signals 
(Malnic et al., 2004). Recent reports suggest robust olfactory deficits in 
schizophrenia patients (Moberg et al., 2013). 
Similarly, a loss in the PYY gene was identified by the microarray in twin 
pairs 1 and 5. However, only in twin pair 5 was a loss suggested by real time 
PCR. PYY encodes a protein that releases a peptide that inhibits pancreatic 
secretion and mobility in the gut and has been previously identified to be a 
cerebrospinal fluid marker for mental illness (Widerlov et al., 1988) and autism 
spectrum disorders (de Krom et al., 2009). This CNV loss at the PYY gene has 
not been previously reported in the DGV and therefore may be a potential 
candidate for the observed discordance. 
These results highlight that genes identified by this DNA Microarray and 
also found to show expected trends in qPCR, are compatible with candidate 
genes implicated in mental disorders, including schizophrenia.
!! 70!
Table 2.5. TaqMan Real Time PCR Results.  
The asterisk refers to a significant difference relative to unaffected co-twin. Significance was defined as a Z-Score 
<1.75 and 95% confidence level. ^=Right direction, not significant. CNV call refers to Copy Caller Result. 
(NCBI36/hg18) 
Gene/Region 
Life 
Technologies 
Product 
Number 
Chr Start End Size (kb) Twin  
Expected 
Based on 
Microarray 
CNV 
Call in 
Affected 
Twin 
(qPCR) 
Result 
EPHA3 Hs06670176 3 89394600 89419369 25 3A Loss 2.3* Significant, Wrong direction 
GPR139 Hs01989810 16 19945650 19965863 20 5A Loss 2.0 Not significant 
OR52N2 Hs01320916 11 5789589 5809449 20 3A Loss 1.9^ Not significant, Same direction 
CACNB2 Hs05191328 10 18444576 18790807 346 1A Gain 1.9 Not significant, Wrong direction 
ST8SIA6 Hs05146368 10 17428699 17652707 224 1A Gain 2.0 Not significant 
PYY Hs05489586 
17 39423041 39430053 7 1A Loss 2.0 Not significant 
17 39423041 39430053 7 5A Loss 1.9^ Not significant, Same direction 
KIAA1211L Hs04657032 2 98858308 98879625 21 4A Loss 2.1 Not significant, Wrong direction 
5q11.2 Hs06079478 5 57326027 57333521 7 6A Gain 2.2^ Not significant, Same direction 
7q11.21 Hs07521783 7 64594329 64955220 361 3A Loss 1.5* Significant, Same direction 
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Figure 2.6. Copy Number Variation Loss at 7q11.21 in Twin 3A. 
A variant in this location was independently identified using all three programs (Partek, PennCNV and Affymetrix 
Genotyping Console) (NCBI36/hg18). 
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2B.4.2 De novo Mutation and Discordance 
Another challenge with genetic studies in schizophrenia is the extensive 
heterogeneity that may include multiple genetic, and environmental factors (van 
Dongen and Boomsma, 2013; Singh and O’Reilly, 2009). Two observations are 
of particular relevance to this discussion. First, a number of genomic regions and 
genes including CNVs, both inherited (relatively common) and de novo 
(extremely rare), have been implicated in this complex neurodevelopmental 
disease (Van Den Bossche et al., 2013; Kirov, 2010; Maiti et al., 2011). Also, 
there is less than 100% concordance (48%) between monozygotic twins 
(McGuffin et al., 1994). Consequently, it is not always possible to genetically 
match controls with patients. This research is exceptional in that it uses 
monozygotic twins discordant for schizophrenia where the unaffected member 
represents nature’s best-matched genetic control. Further, in some cases the 
discordance of monozygotic twins for schizophrenia could be attributed to 
differences in their CNVs potentially caused by de novo mutations (DNM) (Maiti 
et al., 2011; Singh et al., 2009). The results suggest that DNM are not limited to 
the germlines alone. Rather they are ongoing throughout life, including stages of 
differentiation, development, and aging (Lupski, 2010). The occurrence of DNMs 
has now been demonstrated using a variety of strategies including MZ twins 
(Bruder et al., 2008; Singh et al., 2009), trios (Vissers et al., 2010), and MZ twins 
compared with both parents (Maiti et al., 2011). Quantitatively, Maiti et al. 
identified one and two DNMs in two pairs of MZ twins respectively, based on 
parental genotypes, while Vissers et al. identified one to two DNMs per trio in 
eight trios with a mentally retarded proband using family-based exome 
sequencing (Maiti et al., 2011; Vissers et al., 2010). The results suggest that 
DNMs can account for phenotypic discordance between MZ twin pairs. Also, the 
degree of difference may vary from pair to pair. Their phenotypic impact will 
depend not only on the genomic region involved but also on the background 
genotype, and the timing of DNMs during ontogeny. In addition, the mechanism 
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that is responsible for genomic discordance of MZ twins may generate mosaics, 
with or without significant phenotypic manifestation (Ruderfer et al., 2013). 
My results on six MZD pairs show that each MZD pair differs in rare 
CNVs. Also, the discordance of some of the pairs could be attributed to CNVs 
identified in this analysis. For this, I have used the following criteria. First, the 
CNV should be present in the affected member(s) of the twin pair only. Second, 
the gene must be expressed in the brain and/or the gene must have relevance to 
the neurodevelopment and physiological outcomes associated with 
schizophrenia. Finally, the CNV of interest must not have been identified 
previously in normal healthy individuals (DGV). The use of these criteria has 
allowed me to identify potential genes implicated in schizophrenia in four of the 
six pairs studied. The four pairs that do meet this criterion have their own twin-
pair-specific CNVs. Given extensive heterogeneity and the rare nature of de novo 
events; these patterns are expected to be variable. Not surprisingly, the observed 
differences are pair-specific with respect to the genomic region(s) and gene(s) 
involved. For example, the region 16p11 was identified as uniquely disrupted in 
the affected member of twin pair 3 only - this is particularly interesting as this 
region has been previously associated with psychosis (Steinberg et al., 2012). 
Although the results are patient and pair-specific, I did find some genomic 
regions and genes that were common across unrelated patients. An example of a 
region identified in more than one sample was 2p22.3, the same CNV was 
uniquely identified in this region in the unaffected member of twin pair 5 and twin 
pair 6 only — this may suggest a possible protective or mediating effect on the 
disease from a copy number variation loss in this region. 
 
2B.5 Conclusion 
In conclusion, the MZD twin-based genomic (CNV) strategy to identify 
candidate genes and regions that may be involved in schizophrenia is logical. It 
has the potential to serve as an effective strategy in identification of genes and 
genetic mechanisms that may cause complex disorders. Specifically, individuals 
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with schizophrenia have CNV gains and losses that are likely to contribute to the 
disease. Here, the inherited mutations may provide predisposition that may not 
be sufficient for disease manifestation. Occurrence of any/some additional de 
novo events (CNV or mutation) may add to the disease liability threshold and 
manifest the disease. This model (Maynard et al., 2001; Singh et al., 2004) of 
disease development may explain a number of observations on schizophrenia. 
First, in most cases of discordance in monozygotic twins, even the normal twin 
may have some or delayed manifestation of some or all symptoms. Second, in 
most cases of familial schizophrenia, the additional hits may or may not be 
needed depending on the nature of familial predisposition. Also, in some cases, 
environmental components may add to the predisposition or be enough by itself 
to affect neurodevelopment and result in the disease. What is needed to 
accurately assess this hypothesis are precise and reliable results that 
unfortunately are not always available. This challenge is apparent from my 
results where only one of the 10 CNVs identified by the microarray could be 
statistically confirmed, while three CNVs showed the expected trend but failed to 
reach the level of significance in qPCR. This follows a number of recent reports 
(Ehli et al., 2012). Despite these limitations, the MZD strategy outlined appears 
realistic. Specifically, the use of strict criteria for the assessment of CNVs in 
monozygotic twin genomes discordant for schizophrenia has identified a novel 
CNV (7q11.21) that is surrounded by low copy repeats with the potential to 
undergo mechanisms that generate CNVs de novo. This confirmed CNV was 
seen exclusively in the affected patient of twin pair 3 and deserves further 
investigation as a candidate region for schizophrenia and related disorders in this 
twin pair and beyond. 
 !  
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A version of this chapter has been submitted for publication in Nature Scientific Reports  
Chapter 3!- Whole Genome Sequencing of Monozygotic Twins Discordant 
for Schizophrenia Defines de novo Features of Twin Differences 
3.0 Overview 
I analyzed the complete genomes of two pairs of monozygotic twins 
discordant for schizophrenia, including one representing a family tetrad (Family 1 
- Mother, Father and their discordant monozygotic twins). I found multiple 
sequence differences between co-twins. They were caused by a variety of 
genetic mechanisms and included 4,275 (Family 1) and 10,725 (Family 2) small 
sequence changes (single nucleotide variants, small indels and block 
substitutions of 2+ bps), 5 (Family 1), and 5 (Family 2) copy number variations 
(CNVs) as well as 41 (Family 1), and 141 (Family 2) structural variants (SVs), 
that were not shared between co-twins. Based on their absence in the two 
parents of family 1, I was also able to assign some of the events as de novo. 
Interestingly, the genes affected by these changes belonged to a number of 
canonical pathways that have the potential to provide genetic predisposition 
(liability) for the development of schizophrenia in the two families. The results 
may account for the extensive heterogeneity observed in schizophrenia. Two 
specific pathway defects, Glutamate Receptor Signaling and Dopamine 
Feedback in cAMP Signaling Pathways, were uniquely found in the two patients. 
The results show that errors in multiple genes via multiple mutational 
mechanisms affecting different biochemical pathways may contribute to the 
threshold of liability in the manifestation of this complex disease. While requiring 
further independent confirmation, the results support the proposition that de novo 
events are important contributors to the development of schizophrenia including 
its discordance in monozygotic twins.  
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3.1 Introduction 
Monozygotic (MZ) twins that originate from a single fertilized zygote have 
been used to study the relative contribution of nature and nurture on a variety of 
phenotypes and disorders for well over a century. Schizophrenia, which is among 
the most devastating of the major mental health disorders, is thought to have 
both genetic and environmental causes (Gottesman and Shields, 1967). Results 
show that although the frequency of schizophrenia is only 1% in the general 
population, its concordance in MZ twins approximates only ~50% and not 100%, 
as might be expected (Cardno and Gottesman, 2000). Further, recent and rare 
genomic results have shown that MZ twins may differ for de novo CNVs (Bruder 
and Piotrowski, 2008; Maiti et al., 2011), as well as epigenetic features 
(Dempster et al., 2011, 2014; Ehli et al., 2012; Fraga et al., 2005). However, the 
timing, rate, extent and impact of such de novo events have been difficult to 
confirm. It is assumed that post-zygotic (somatic) de novo mutations may occur 
anytime during development. Thus, de novo mutations appear to be a normal 
aspect of development of some organs (Muotri and Gage, 2006) and cell types 
(Muotri et al., 2010). Depending on the developmental stage at which they arise, 
these changes may be present in all or almost all cells of an individual or 
represent mosaicism. The random nature of these de novo events is expected to 
differ between MZ twins that started independent life from a single zygote and 
thus may contribute to twin discordance. Although logical and attractive as a 
potential hypothesis for the cause of discordance in MZ twins, an experimental 
approach based on this hypothesis faces two challenges. The first is the 
complete identification of all or almost all changes that exist between the 
genomes of discordant MZ twins and the second is establishing the role of the 
observed differences in disease discordance. Although the former is gradually 
becoming possible through increased resolution of genomic technologies, the 
latter remains challenging and will demand diligent efforts (Li et al., 2014; Rall et 
al., 2015).  
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The challenge of analysis and interpretation of complete genome 
sequences is attributed to a variety of factors (Baranzini et al., 2010).  First, the 
sequence coverage is not always 100% (due to difficult to sequence regions and 
assembly errors) and second, the conclusions are not always easy to confirm 
due in part to expected mosaicism (Petersen et al., 2014). This research 
identifies differences between two pairs of MZ twins discordant for schizophrenia. 
Also, it includes the parental sequences of one twin pair. Such direct 
observations not only identify the differences between twins, they also offer direct 
evidence for their pre-zygotic (germline) or post-zygotic (somatic) origin. The next 
question is the involvement of these differences in the development of 
schizophrenia; this of course is a much more complicated question. 
Schizophrenia is a highly heterogeneous and severe psychiatric disorder that 
affects ~1% of the world’s population, and has a heritability estimate of ~80% 
(Gottesman, 1991; Gottesman and Shields, 1967). Extensive research on the 
genetics of this disorder has generated a large number of candidate genes, but 
no causal genes. This includes a recent report involving 150,000 individuals with 
over 35,000 schizophrenic patients that has implicated over 108 genetic loci 
(Ripke et al., 2014). The results allow for assessment of previously identified loci 
in genome-wide studies of de novo changes between MZ twins that are 
discordant for schizophrenia. I note that some previously identified loci include 
DRD2, a common anti-psychotic target, as well as a number of glutamate 
receptors (GRIA1, GRIN2A, GRM3), members of the voltage gated calcium 
channels (CACNA1C, CACNA1l and CACNB2) and genes involved in synaptic 
plasticity (Ripke et al., 2014). As it stands, there are no common variants that 
account for a substantial portion of the liability to develop this disease (Kavanagh 
et al., 2014). These findings demonstrate that the disease is highly 
heterogeneous and that most patients are genetically distinct. 
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3.2 Methods 
3.2.1 Subjects 
This research started following ethics approval from the Committee on 
Research Involving Human Subjects at The University of Western Ontario, 
London, Ontario, Canada (Appendix B). The families were recruited and 
assessed in-person by Richard O’Reilly (Psychiatrist), using the Structured 
Clinical Interview for DSM-IV (SCID I and SCID II) and a review of available 
medical records (First et al., 1996, 1997).  All participants provided written 
informed consent. A second senior psychiatrist independently reviewed 
videotapes of the structured interviews of the twins and confirmed the diagnoses. 
All 6 subjects (Figure 3.1) provided blood and cheek swab samples that were 
used to isolate genomic DNA using the PerfectPure DNA blood kit (Blood 
samples), and the QIAGEN DNA Micro Kit (Buccal samples), following the 
manufacturer’s protocols. The experimental workflow of the analysis is 
summarized in Figure 3.2. 
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!
Figure 3.1. Members of the two discordant monozygotic twin pairs and one set of 
parents included in the study. 
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 Figure 3.2. Flowchart of Methods Employed. 
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The twins from Family 1 are Afro-American females and contributed DNA 
samples at age 53. The affected twin (I-2-1) was diagnosed with schizophrenia at 
age 22. She was admitted to a psychiatric unit on at least 12 occasions and 
experienced paranoid delusions, auditory hallucinations and occasionally 
euphoria during her acute episodes of illness. This twin had significant functional 
decline and lived with her parents throughout her adult life. The diagnosis of 
schizophrenia was confirmed by the study psychiatrist. I-2-2 did not experience 
any significant symptoms of mental illness until she developed a brief episode of 
depression at age 48, which was treated with an antidepressant. Four years later 
this twin developed an acute episode of mania which required hospitalization and 
she was placed on the mood stabilizer divalproex sodium. She was diagnosed as 
having a bipolar disorder by the study psychiatrist. This twin pair has been 
previously described in detail (O’Reilly et al., 2013). At the time of sample 
collection, the twins were discordant for schizophrenia for 31 years. The father (I-
1-1) of the twins was aged 82 at assessment and had a mild obsessive-
compulsive personality disorder but no other psychiatric problems, while the 
mother (I-1-2) was aged 74 and has never had any psychiatric problems.  
At the time of sample collection, the twins from Family 2 were 43 years of 
age. The twins are Caucasian females. Twin II-2-1 became ill at age 27. She 
experienced paranoid delusions and hallucinations, which usually occurred in the 
context of a euphoric or depressed mood. She lived with her twin sister and had 
worked intermittently. She was diagnosed with a schizoaffective disorder. The 
twin sister (II-2-2) sustained skeletal injuries in a motor vehicle accident at age 
18. A boyfriend died close to the time of this accident and II-2-2 became 
depressed for a short period around this time.  She has had no further episodes 
of depression or other emotional or psychiatric problems. The twins were 
considered discordant for 16 years at the time of sample collection.  
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3.2.2 Complete Genomics Sequencing and Calling of Variants 
The genome sequence of the six subjects (Figure 3.1) was generated at 
Complete Genomics Inc. (Mountain View, CA) in the form of ~2 billion 
overlapping 70-base nucleotide sequences. They allowed reconstruction of six 
individual genomes. The sequences met the criteria of high accuracy (99.999%) 
and were considered suitable for identification of rare variants including somatic 
mutations as described by Drmanac et al (Drmanac et al., 2010). These variants 
included single nucleotide variants (SNVs), indels and block substitutions (2+ 
bp), as well as larger variants classified as CNVs and SVs that were called in 
comparison to reference sequence (NCBI Build 37/hg19).  
The Complete Genomics (CG) sequencing approach has been fully 
described in Drmanac et al (2010) and Carnevali et al. (2012). Briefly, Complete 
Genomics sequencing generates reads on self-assembling DNA nanoballs 
resulting in short mate-pair reads. The Complete Genomics sequencing workflow 
uses Combinatorial Probe Anchor Ligation (cPAL) chemistry to independently 
assay each base. Reads are initially mapped using a fast algorithm to find the 
most likely location of each read in the reference genome. Next, these initial 
mappings are refined by Complete Genomics local de novo assembly at any 
region of the genome that appears to differ from reference. It should be noted 
that the coverage at segmental duplication regions is known to be limited when 
using this platform for sequencing. 
In the analysis of family 1, variants that were present in the affected twin 
and not present in the unaffected twin or their mother or father, were assessed 
as de novo. Also, in the twin analyses of family 2, without parents, variants that 
were present in the affected twin and not present in the unaffected twin were 
labeled as provisional de novo.  
CNVs were called based on a read depth or depth-of-coverage algorithm 
provided by Complete Genomics (Drmanac et al., 2010). Sequence coverage 
was averaged and then GC bias was corrected for over a fixed window (2 kb) 
and normalized relative to a set of standard (CG 45 genome reference) genomes 
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sequenced by Complete Genomics. A Hidden Markov Model (HMM) was used to 
determine the integer copy number state (0-10).  
SVs were detected by identifying discordant mate pair mappings found 
during the assembly process and were considered their own category apart from 
CNVs due to the different procedure used to call them.  Although, it is recognized 
that CNVs are a type of structural variant and that some redundancy would be 
expected from the CNV read depth and SV discordant mate pair analyses. Mate 
pair mappings where each arm maps to the reference genome but with either an 
unexpected length between them or an anomalous orientation are subjected to 
local de novo assembly to refine junction breakpoints at single base pair 
resolution. Complete genomics then generated a HighConfidenceJunctions file 
that reports junctions that are most likely to be accurate. CGAtools 
junctions2events was then used to convert high confidence junctions to possible 
SV events using repeat masker 37 data, NCBI Build 37/hg19 reference file and a 
refseq gene information file. The junctions2events command in CGAtools 
identifies likely deletion, inversion and translocation events that are at least 500 
bp in size, from the list of high confidence junctions delivered by Complete 
Genomics. SVs were further refined into 5 categories: deletions, tandem 
duplications, distal duplications, inter-chromosomal events and inversions. To 
call small variants (small sequence changes) in the dataset, Master Variation 
Files (MasterVar) were generated using CGAtools and NCBI Build 37/hg19 as 
reference. VCF files were then generated from each MasterVar file using 
CGAtools command mkvcf.  VCF files generated this way were directly inputted 
into Ingenuity Variant Analysis (Ingenuity Systems, Redwood City, CA). Given 
the potential for false positives identified in genome sequencing, a stringent read 
depth of 50 and a call quality of 100 (calculated by complete genomics and 
based on a phred scale) were chosen as parameters for variant filtering. Variants 
were annotated with overlapping genes, cytoband, gene region (Exonic, Intronic, 
Promoter, 5’UTR, 3’UTR, Splice Site), translational impact (if applicable), SIFT 
function prediction (if applicable), SIFT score (if applicable), dbSNP ID (if 
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applicable) and frequency in the 1000 Genomes as well as frequency in the 
Complete Genomics Public Genome dataset. The biological context filter in 
Ingenuity Variant Analysis was applied to downstream data with “Schizophrenia, 
Neurological Disease and diseases consistent with those two phenotypes” as the 
filtering criteria. Genes had to have a direct connection to these phenotypes (no 
hops allowed).  
In the case of CNVs and SVs a 50% reciprocal overlap rule (Pang et al., 
2010; Wain et al., 2009; Yavas et al., 2009) was applied to determine if two 
variants were the same or different between twins/parents. All CNVs/SVs had to 
meet the ≥ 50% rule when compared to the other CNV/SV, otherwise, the two 
were considered unique. Pairwise comparisons were performed for all CNVs and 
SVs. To increase the efficiency of this, HD-CNV (Hotspot Detector for Copy 
Number Variants) was used (Butler et al., 2013). Files were prepared using a 
custom python script and the 50% reciprocal overlap rule was applied to 
determine the CNVs and SVs that were unique to an individual. 
Interchromosomal and inversion comparisons were analyzed manually due to the 
limitations of HD-CNV. Inter-chromosomal events were considered the same if 
the origin and the destination chromosome numbers matched and the junction 
positions were less than 500 bp apart. Inversions had to share the same direction 
and 50% or more identity to be classified as shared. 
Circos (Krzywinski et al., 2009) was used for visualization of post-filtering 
variation data.  Unique variants were separated into files to generate relevant 
tracks in the genome diagram. Structural variants that involved more than one 
chromosome were visualized using “links” in Circos.  
 
3.2.3 Confirmation of Findings 
Quantitative PCR using TaqMan® Assays in an Applied Biosystem 
StepOne were performed on selected CNVs and SVs on blood samples. CNVs 
and SVs that were confirmed via Real Time PCR in blood were then assessed in 
the Buccal DNA from the same individuals to identify if the variant arose before 
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or after the differentiation of the germ layers. RNAseP was used as the reference 
gene for normalization as it is known to be present in two copies in every human 
diploid genome. RNAseP is a type of ribonuclease that cleaves RNA. 
Predesigned TaqMan assays were ordered from Life Technologies for regions of 
interest. CopyCaller 2.0 was used to generate the predicted copy numbers. Each 
Real Time experiment was repeated four times. 
Sanger Sequencing was used to assess small variants of interest in the 
dataset that were unique to the affected twin. Variants were chosen based on 
three criteria, 1) They were exonic; 2) They had high call qualities and, 3) They 
had high read depths. Regions were sequenced at the London Regional 
Genomics Centre (LRGC). The selected variants (24) were sent for Sanger 
Sequencing using traditional forward and reverse primers. Variants that 
appeared mosaic in nature were further assessed using PASA (PCR 
Amplification of Specific Alleles). PASA uses an allele specific primer to 
preferentially amplify DNA with a specific allele of interest.  
 
3.2.4 Pathway Analysis 
Any unique variant that overlapped a gene was identified and these gene 
lists were used in Core Pathway Analysis (Ingenuity Systems, Redwood City, 
CA) to identify pathways and networks that were overrepresented in the filtered 
dataset. Only the genes that were identified to overlap high confidence de novo 
(Family 1) or provisional de novo (Family 2) variations were included in the 
pathway analysis. Variants that were found to be unique to unaffected twins were 
also assessed in a separate pathway analysis. The top 20 canonical pathways 
found to be overrepresented in each individual were then compared between all 
members in the study; pathways that were found in affected and unaffected twins 
were labeled as gp (genetic predisposition). Pathways that were unique to 
affected twins only were labeled as gpd (genetic predisposition leading to 
disease). 
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3.3 Results 
3.3.1 Defining genetic variation including de novo events 
3.3.1.1 Sequence characteristics of six complete genomes 
The complete genome sequences on two MZD twin pairs and one set of 
parents (Figure 3.1) were generated with a high average call quality above 100 
(Figure 3.3) and an average read depth of 47-50 fold coverage (Figure 3.4) 
following my workflow (Figure 3.2).  
They represented over 99% of the reference sequence for each genome 
(Table 3.1).  I compared individual genome sequences with the Genome 
Reference Consortium Human Genome Build 37 (hg19) using Complete 
Genomics Analysis Tools (CGATools) for identification of individual variation 
events and their genomic location at single base pair resolution. The results 
show that each genome harbors 3.3 to 3.9 million single nucleotide variants 
(SNVs), 370-430 thousand indels (small insertions and deletions), 71-80 
thousand block substitutions (variation in 2+ adjacent nucleotides), 1 thousand 
structural variations, and 150 copy number variations as well as a 
transition/transversion ratio of 2.1:1 (Table 3.1). The exception to this pattern was 
the father in Family 1 who carried 592 copy number variations and 1110 
structural variations, that may be associated with a diagnosis of chronic leukemia 
unrelated to this study (Kumar et al., 2013). I further grouped individual variations 
as Small Sequence Changes, (SSCs - SNVs, Indels, Block Substitutions), CNVs 
or SVs (Table 3.1).
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Table 3.1. Identity of Sequenced Genomes. 
ID Family Gender Age*  Age of Onset 
Disease 
Status 
% of 
Genome 
Called 
Normalized 
Average 
Coverage 
Small 
sequence 
Variations 
(SNVs, Indels, 
Block Subs) 
Copy 
Number 
Variants 
Structural 
Variants Ti:Tv  
I-1-1 Family 1 Male 80 N/A Unaffected 99.037 49.55 4,392,314 592 1110 2.1:1 
I-1-2 Family 1 Female 76 N/A Unaffected 99.042 47.27 4,093,396 163 904 2.1:1 
I-2-1 Family 1 Female 43 27 Affected 99.042 48.07 4,295,920 152 919 2.1:1 
I-2-2 Family 1 Female 43 N/A Unaffected 99.042 47.41 4,265,089 154 893 2.1:1 
II-2-1 Family 2 Female 53 22 Affected 99.039 49.71 3,780,127 156 996 2.1:1 
II-2-2 Family 2 Female 53 N/A Unaffected 99.037 50.25 3,789,298 157 977 2.1:1 
Note: Ti/Tv = Transition/Transversion Ratio (of variants), Age* = Age at assessment
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Figure 3.3. Call Quality of raw variant calls in each sample.  
Each line represents the plotted call quality of each called variant in that 
individual sample. Call qualities were first ordered by number and then plotted in 
order. The Call Quality is provided by Complete Genomics and based on a Phred 
scale. I am thankful to Marjorie E Locke (PhD Candidate) who created this figure 
for use in this thesis. 
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Figure 3.4. Read Depth Density of raw variant calls in each sample. 
Each line represents the plotted read depth of each variant called in that 
individual sample. A density for each read depth was first assigned and then 
plotted. The read depth represents the number of times that base pair location 
was sequenced. Outliers (above 250) were not included. I am thankful to Marjorie 
E Locke (PhD Candidate) who created this figure for use in this thesis. 
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For each type of mutational event, the highest number of differences was 
found between unrelated individuals, the least number between MZ twins and an 
intermediate number between a parent and child. For example, two unrelated 
individuals differed for approximately 1.5-1.8 million SNVs, a parent and child 
differed for 0.9-1.0 million SNVs and a pair of MZ twins differed for approximately 
100,000 SNVs. These estimates represent raw calls by the algorithm used by the 
Complete Genomics software (Carnevali et al., 2012) that has been suggested to 
reliably detect a substantial portion of genetic variation distributed across the 
genome (Pang et al., 2014). A comparison of raw sequence variations between 
twins in Family 1, and 2 generated approximately 250,000 and 200,000 
differences respectively. Further application of strict confidence filters (see 
methods) resulted in approximately 11,500 (1.21%) unique variations in the 
affected twin of Family 1 and approximately 10,500 (1.17%) unique variations in 
the affected twin of Family 2 (Figure 3.5a and 3.5b). Given that these differences 
occurred between monozygotic twins, they were interpreted as post zygotic de 
novo mutations in the affected twin as compared to their own unaffected co-twin.  
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Figure 3.5. Circos plots of high confidence variant calls. 
 
 
 
Figure 3.5a. Circos plot of high confidence mutations in the affected member of 
Family 1 that were not found in the co-twin or either parent. Blue represents a 
gain and red represents a loss. The outside track displays SSCs, the middle 
track displays CNVs and the inside track displays SVs. The arrow displays an 
inter-chromosomal event.  
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Figure 3.5b. Circos plot of high confidence mutations in the affected member of 
Family 2 that were not found in the co-twin. Blue represents a gain and red 
represents a loss. The outside track displays SSCs, the middle track displays 
CNVs and the inside track displays SVs. 
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The results presented in the preceding section show that every genome is 
unique and the difference between any two individuals include both familial as 
well as de novo events. Further, the majority of differences among unrelated 
individuals appear to be due to population and family history, while the rare 
differences (0.05%) between monozygotic twins are attributed to novel 
ontogenetic de novo events.  In Family 1, 63% of unique small sequence 
changes were identified as inherited and 37% were identified as de novo (Table 
3.2).  
The de novo variants could further be characterized by their presence in 
exons in each family (Table 3.3a and 3.3b). Conversely, in family 1 where the 
complete sequences of both parents were available, 2 unique CNVs were 
identified as inherited and 5 were identified as de novo (Table 3.4). The CNVs 
unique to the affected member of two twin pairs can be seen in Tables 3.5a and 
3.5b. SVs followed a pattern similar to small sequence variations with 70% of 
SVs identified as inherited and 30% identified as de novo (Table 3.6). There are 
a small number of unique CNVs in the affected member of family 1 (unique 
CNVs=7), 5 of which are not found in either parent (de novo) (Table 3.4). In the 
absence of parental data in Family 2, variations that were unique to the affected 
twin were classified as “provisional de novo”. I conclude that most human 
variations are historical and transmitted across generations, yet a proportion are 
acquired through de novo events during genetic transmission via gametogenesis 
as well as during mitosis throughout development and aging. 
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Table 3.2. Shared and de novo Small Sequence Changes identified in blood (SNVs, Substitutions, Indels) as 
compared to NCBI Build 37/hg19. 
Sample 
Total Sequence 
Variations Before 
Confidence Filters 
Applied 
Sequence 
Variations After 
Confidence Filters 
Applied 
High 
Confidence 
Variants 
Unshared with 
Co-twin 
Unshared with Co-twin 
Inherited 
(Present in 
parent) 
de novo 
(Not present 
in parent) 
Family 1 
Affected  
(I-2-1) 
4,295,920 956,470 11,577 (1.2%) 
7,302 
(63.1%) 
4,275 
(36.9%) 
Family 1 
Unaffected 
(I-2-2) 
4,265,089 833,254 9,345 (1.1%) 
5,776 
(61.8%) 
3,569 
(38.2%) 
Family 2 
Affected 
(II-2-1) 
3,780,127 917,899 10,725 (1.2%) N/A N/A 
Family 2 
Unaffected 
(II-2-2) 
3,789,298 926,691 10,351 (1.1%) N/A N/A 
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Table 3.3. Exonic de novo variants in Affected Twins. 
Table 3.3a. Exonic de novo variants in the Affected Twin of Family 1 (I-2-1). Gene variants in blue are not known to 
be polymorphic and considered novel and those with potential pathogenic impact are marked in red. !
Chr Position Ref Sample Type Cytoband Gene 
Translation 
Impact dbSNP ID 1000G 
CG 
Public 
1 117142868 CA TG Sub 1p13.1 IGSF3 In-frame    
4 85996  C Ins 4p16.3 ZNF595 Frameshift    
4 86004 A G SNV 4p16.3 ZNF595 Missense 112290390   
4 86022 CAG GAC Sub 4p16.3 ZNF595 In-frame 386670355   
4 86043 T C SNV 4p16.3 ZNF595 Synonymous 377364445   
7 100549935 T G SNV 7q22.1 MUC3A Missense 73714229   
7 100549942 T C SNV 7q22.1 MUC3A Missense 73714230   
7 100552452 T C SNV 7q22.1 MUC3A Synonymous 112050489   
11 48367133 C A SNV 11p11.2 OR4C45 Missense 79453749   
12 40875389 
CCATCAGCTGGAGTGAC
AGTGACATCCGGA Del 12q12 MUC19 In-frame    
12 40880542 C T SNV 12q12 MUC19 Missense 370502411  14.81 
12 40880545 C G SNV 12q12 MUC19 Missense 199768257  16.66 
12 122359397  
GAGGAGGA
GGAGAAA Ins 12q24.31 WDR66 In-frame 142042908  67.59 
13 25671607 GA AG Sub 13q12.13 PABPC3 In-frame 386769143   
13 46170723 GATACTCTTCCTCCTCCA Del 13q14.13 ERICH6B In-frame    
17 74288565 TGA  Del 17q25.1 QRICH2 In-frame 35035566 46.96 20.37 
22 29885594 A T SNV 22q12.2 NEFH Synonymous 79235463   
22 29885599 AGGAAG  Del 22q12.2 NEFH In-frame 149571560   
Note:&1000G=1000&Genomes,&Sub:&Substitution,&Ins:&Insertion,&Del:&Deletion,&SNV:&Single&Nucleotide&Variation.&
!
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Table 3.3b. Exonic de novo variants in the Affected Twin of Family 2 (II-2-1). Gene variants in blue are not known 
to be polymorphic and considered de novo and those with potential pathogenic impact are marked in red. 
 
Chr Position Ref Sample Type Cytoband Gene Translation Impact dbSNP ID 1000G 
CG 
Public 
1 1650787 T C SNV 1p36.33 CDK11B; CDK11A Missense 1137003  28.7 
1 1650797 A G SNV 1p36.33 CDK11B; CDK11A Missense 1059830  31.48 
1 1650801 T C SNV 1p36.33 CDK11B; CDK11A Synonymous 1137004  31.48 
1 13183225 T C SNV 1p36.21 HNRNPCL1/ HNRNPCL2 Synonymous 28634306   
1 13183228 C T SNV 1p36.21 HNRNPCL1/ HNRNPCL2 Synonymous 144054379   
1 13183237 CT TC Sub 1p36.21 HNRNPCL1/ HNRNPCL2 In-frame    
1 13183243 T C SNV 1p36.21 HNRNPCL1/ HNRNPCL2 Synonymous 138897759   
1 13183248 TC AA Sub 1p36.21 HNRNPCL1/ HNRNPCL2 In-frame    
1 17266536 G C SNV 1p36.13 CROCC Missense 9435714  10.18 
1 62675619 C T SNV 1p31.3 L1TD1 Synonymous 4625314 29.85 33.33 
1 109007867 G A SNV 1p13.3 NBPF4/ NBPF6 Missense   26.85 
1 109007877 T G SNV 1p13.3 NBPF4/ NBPF6 Synonymous   26.85 
1 109737063 C T SNV 1p13.3 KIAA1324 Synonymous 386565601 71.37 68.51 
1 109737090 G A SNV 1p13.3 KIAA1324 Synonymous 386565600 71.53 67.59 
1 111957583 A G SNV 1p13.2 OVGP1 Missense 1126656  3.7 
1 111957592 A G SNV 1p13.2 OVGP1 Missense 56294468 22.32 3.7 
1 120539742 G A SNV 1p12 NOTCH2 Missense 2258139   
1 120548025 G A SNV 1p12 NOTCH2 Synonymous 140551270   
1 120548055 T C SNV 1p12 NOTCH2 Synonymous 199592384   
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1 144873963 T  Del 1q21.1 PDE4DIP Frameshift  28.91 32.4 
1 144922523 C T SNV 1q21.1 PDE4DIP Missense 2455994  28.7 
1 145103928 G A SNV 1q21.1 SEC22B Synonymous 2596251 34.01 35.18 
1 201178819 G A SNV 1q32.1 IGFN1 Missense 72468019  11.11 
1 206566904 T C SNV 1q32.1 
SRGAP2B; 
SRGAP2D; 
SRGAP2; 
SRGAP2C 
Synonymous 2919105 49.44  
1 248813827 T C SNV 1q44 OR2T27 Missense 1782241   
2 132238043 A C SNV 2q21.1 TUBA3C/ TUBA3D Synonymous 74625243  14.81 
3 75786499 CA TG Sub 3p12.3 ZNF717 In-frame   0.92 
3 75786515 GG AT Sub 3p12.3 ZNF717 In-frame  0.92  
3 75787265 C G SNV 3p12.3 ZNF717 Synonymous 144538707   
3 75787269 G T SNV 3p12.3 ZNF717 Missense    
3 75788023 C T SNV 3p12.3 ZNF717 Missense 76889571  50 
3 100170634 T C SNV 3q12.2 LNP1 Synonymous 9848109  24.07 
3 195510827 C T SNV 3q29 MUC4 Missense 413807 3.53 24.07 
3 195511780 G A SNV 3q29 MUC4 Missense 391928   
5 140725160  A Ins 5q31.3 
PCDHGA3; 
PCDHGA2; 
PCDHGA1 
Frameshift 372306793   
6 26406255 G A SNV 6p22.2 BTN3A1 Synonymous 3857550  41.66 
6 33037579 AT TG Sub 6p21.32 HLA-DPA1 In-frame 386699858  37.96 
6 33052986 T C SNV 6p21.32 HLA-DPB1 Synonymous  46.37 37.03 
7 100550039  CTC Ins 7q22.1 MUC3A In-frame    
7 142460313 T C SNV 7q34 PRSS1 Synonymous 6666 39.66 24.07 
7 142460335 A G SNV 7q34 PRSS1 Missense 201550522 0.16  
8 10467652 GC CT Sub 8p23.1 RP1L1 In-frame 386722180   
8 103573011 
TGCAACCCCTGC
AGCCCCTGCAAC
CCG 
Del 8q22.3 ODF1 In-frame  31.29 23.14 
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11 1016776 C T SNV 11p15.5 MUC6 Missense 33988517  38.88 
11 1017110 CGGT TGCC Sub 11p15.5 MUC6 In-frame   32.4 
11 1018069 G A SNV 11p15.5 MUC6 Missense 10736904   
11 1018090 G  Del 11p15.5 MUC6 Frameshift    
11 1018095 G TA Sub 11p15.5 MUC6 Frameshift    
11 1092684 C T SNV 11p15.5 MUC2 Synonymous 201269049   
11 5270686 G A SNV 11p15.4 HBG1 Missense 1061234  75.92 
11 18290866 T C SNV 11p15.1 SAA1 Synonymous 1136745   
11 48346916 G C SNV 11p11.2 OR4C3 Missense 77069283   
11 48346924 T C SNV 11p11.2 OR4C3 Synonymous 72911454   
11 48346932 G A SNV 11p11.2 OR4C3 Missense 80285195 0.28  
11 48347306 G T SNV 11p11.2 OR4C3 Missense 73465911  33.33 
11 48367052  AG Ins 11p11.2 OR4C45 Frameshift    
11 48367073 A C SNV 11p11.2 OR4C45 Missense 7941588 79.55 75 
11 56143357 G A SNV 11q12.1 OR8U1; OR8U8 Synonymous 76949582  36.11 
11 56143963 AATCTATAGC 
GATTT
ACAGT Sub 11q12.1 
OR8U1; 
OR8U8 Synonymous    
11 56468020 T C SNV 11q12.1 OR9G1; OR9G9 Missense 532637 41.21 56.48 
11 57982726 G T SNV 11q12.1 OR1S1 Synonymous 1993089 52.32 52.77 
11 57982763 A G SNV 11q12.1 OR1S1 Missense 61763008  50.92 
11 89703619 G A SNV 11q14.3 TRIM64/ TRIM64B Missense 79824618  77.77 
11 89819403 G T SNV 11q14.3 UBTFL1 Missense    
12 11214857 T C SNV 12p13.2 TAS2R46; PRH1 Missense 201891491   
12 11214870 A T SNV 12p13.2 TAS2R46; PRH1 Synonymous 200226376   
12 11244721 GAA CAC Sub 12p13.2 TAS2R43; PRH1 In-frame   19.44 
12 11244730 AA GG Sub 12p13.2 TAS2R43; PRH1 In-frame   18.51 
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12 49522578 T C SNV 12q13.12 TUBA1B Synonymous 1057725 54.49  
12 49522605 C T SNV 12q13.12 TUBA1B Synonymous 1057548 45.33  
12 52843610 C A SNV 12q13.13 KRT6B Missense    
13 46170724 ATACTCTTCCTCCTCCAG Del 13q14.13 ERICH6B In-frame    
13 53216666 G A SNV 13q14.3 HNRNPA1L2 Synonymous 113869751 1.08 1.85 
13 103399222 G T SNV 13q33.1 CCDC168 Stop gain   25 
18 9887394 C T SNV 18p11.22 TXNDC2 Synonymous 2240910 51.84  
19 4511197 G A SNV 19p13.3 PLIN4 Synonymous 199625614   
19 4511200 C T SNV 19p13.3 PLIN4 Synonymous 200718202 0.14  
19 55286854 A G SNV 19q13.42 KIR2DL1/ KIR2DL3 Missense 666590 0.08  
19 55286864 A C SNV 19q13.42 KIR2DL1/ KIR2DL3 Synonymous 77397437 16.63  
21 10942923 G A SNV 21p11.1 TPTE Missense 76723236  7.4 
22 38120180 CTC  Del 22q13.1 TRIOBP In-frame    
22 39387558 C T SNV 22q13.1 APOBEC3AB/APOBEC3B Synonymous 1065184   
Note:&1000G=1000&Genomes,&Sub:&Substitution,&Ins:&Insertion,&Del:&Deletion,&SNV:&Single&Nucleotide&Variation.&
&
!
!
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Table 3.4. Shared and unshared Copy Number Variants (CNVs) identified in blood as compared to NCBI Build 
37/hg19. 
Sample Total CNVs 
Shared with Co-
twin 
Unshared with 
Co-twin 
Shared with Co-twin Unshared with Co-twin 
Inherited De novo Inherited De novo 
Family 1 
Affected  
(I-2-1) 
152 145  (95.4%) 
7 
(4.6%) 
131/145 
(90.3%) 
14/145 
(9.7%) 
2/7 
(28.6%) 
5/7 
(71.4%) 
Family 1 
Unaffected 
(I-2-2) 
154 145  (94.2%) 
9  
(5.8%) 
131/145 
(90.3%) 
14/145 
(9.7%) 
5/9  
(55.6%) 
4/9 
(44.4%) 
Family 2 
Affected 
(II-2-1) 
156 151 (96.8%) 
5 
(3.2%) N/A N/A N/A N/A 
Family 2 
Unaffected 
(II-2-2) 
157 151 (96.2%) 
6 
(3.8%) N/A N/A N/A N/A 
&
!
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3.3.1.2 Mutational characteristics in twins affected with Schizophrenia 
(i) Small Sequence Changes (SSCs) 
I classified SNVs, small indels and block substitutions as small sequence 
changes (SSCs). The chromosomal distribution of such variants can be seen in 
Figure 3.6. The only exception to the expected chromosomal size pattern was 
chromosome 9, which had on average, less small sequence variations from 
reference. The identity of de novo (family 1) and provisional de novo (family 2) 
high confidence variations in affected twins shows that majority of variants are 
intergenic SNVs and that each individual harbors approximately the same 
number of block substitutions, insertions and deletions (Figure 3.7). 
Overall, the proportions of variants in each category are similar in the 
affected twin in family 1 as well as family 2; however, the actual de novo variants 
in the twins of family 2 that represent twin differences and lack parental data are 
family specific. As expected, the exonic variants comprised a very small number. 
The exonic de novo variations identified were annotated with gene information 
and a summary of these variations can be seen in Table 3.3a and 3.3b for the 
two patients. Of the exonic variants, 13 exonic variants in Family 1 and 22 exonic 
variants in Family 2 were related to brain function or previously implicated in 
schizophrenia. Specifically, a number of de novo exonic variants in Family 1 are 
noteworthy (Table 3.3a). They include two chromosome 22 variants in NEFH that 
are not present in either parent or the unaffected co-twin. These changes 
however represent synonymous and in-frame changes and may not be 
pathogenic. In addition, this patient carries four exonic de novo variants in 
ZNF595, a zinc finger protein, one of which is a frameshift and the other which is 
a missense mutation at 4p16.3. Further, two missense mutations in MUC3A (that 
encode for a transmembrane mucin) and a missense in OR4C45 (that encodes 
for olfactory receptors) may contribute to pathology. Interestingly, these 
variations have not been reported in 1000 genomes as well as CG public 
genomes and may not be polymorphic. In comparison, the patient from Family 2 
appears to carry a much larger number of variants. However, in the absence of 
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parental sequences this only represents the differences between the discordant 
twins. Not surprisingly, most (51/82) of these variants in this patient have been 
reported in 1000 genomes and/or CG public genomes and are considered 
polymorphic. It leaves 31 variants that may be viewed as de novo. Further 
assessment of the impact of these changes has revealed that three of these 
represent frameshifts (140725160 on 5q31.3; 1018090 and 1018095 on 11q15.5) 
and nine represent missense mutations. The genes affected by missense 
changes include some that are compatible with the pathophysiology of 
schizophrenia. These include NOTCH2, OR2T2, ZNF717, MUC4, MUC6, 
OR4C3, UBTFL1, TAS2R46 and KRT6B. Additionally, this patient also carried 
frameshift mutations that affected PCDHGA, MUC6 and OR4C45 (Table 3.3b). 
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Figure 3.6. Chromosomal distribution of small sequence changes (SNVs, Indels, Block Substitutions) across 6 
samples. 
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Figure 3.7. Identity of de novo (Family 1) and provisional de novo (Family 2) Variants Identified in the Affected 
Twin of Family 1 (I-2-1) and the Affected Twin of Family 2 (II-2-1) (not found in co-twin).
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(ii) Copy Number Variants (CNVs) 
The complete genome sequences of the six individuals were used to 
identify individual specific CNVs. Table 3.4 shows the distribution of observed 
CNVs in MZ twins representing the two families. The analysis allowed 
classification of CNVs representing inherited (present in at least one parent) and 
de novo (not present in either parent and also not present in co-twin) for family 1 
and unshared between twins in family 2. It shows that monozygotic twins shared 
~95% of called CNVs. Of these, ~90% of them were inherited from the parent 
and ~10% were not seen in either parent. Further, of the rare CNVs that were not 
shared between twins, some represented inherited events and others 
represented non-inherited and de novo events that must have occurred during 
independent mitosis (Table 3.5a and 3.5b). In Family 1, five of the seven unique 
CNVs were also not found in either parent (de novo). Discordant CNVs between 
twin pairs were annotated and are presented in Table 3.5a and 3.5b, for the 
affected twin from family 1 and 2, respectively. Three genes overlapped unique 
CNVs in Family 1. The PDSS1, and LOC642131 genes represented de novo 
events, as they were not present in either parent while the CNV that overlapped 
CES1 was present in one parent and was viewed as inherited. Although the 
affected twin of family 2 also carried 5 CNVs that were not present in her 
unaffected twin, these regions did not directly overlap any genes.  
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Table 3.5. Copy Number Variants Unique to Affected Twins. !
Table 3.5a. Copy Number Variants unique to the affected member of Family 1 (I-2-1). The parental sequences 
have been used to establish the de novo (absent in parent(s)) or inherited (present in parent(s)) nature of each 
CNV. Shared identity is based on a 50% reciprocal overlap rule. (NCBI Build 37/hg19) 
Chr Start End Cytoband Size (bp) 
CNV 
Type Identity 
Overlapping 
genes 
5 119380128 119382128 5q23.1 2000 Del de novo None 
9 6700000 6710000 9p24.1 10000 Del de novo None 
10 26998675 27002675 10p12.1 4000 Del de novo PDSS1 
14 20314000 20328000 14q11.2 14000 Amp Inherited None 
15 22422114 22492114 15q11.2 70000 Amp de novo LOC642131 
16 34467150 34515150 16p11.2 48000 Amp de novo None 
16 55841801 55855801 16q12.2 14000 Amp Inherited CES1 
 
Table 3.5b. Copy Number Variants unique to the affected member of Family 2 (II-2-1) as compared to unaffected 
MZ twin. Shared identity is based on a 50% reciprocal overlap rule. (NCBI Build 37/hg19) 
Chr Start End Cytoband Size (bp) CNV Type 
Overlapping 
genes 
5 17612657 17620657 5p15.1 8000 Del None 
5 46244657 46246657 5p11 2000 Amp None 
5 135114128 135120128 5q31.1 6000 Del None 
12 114521470 114529470 12q24.21 8000 Amp None 
14 106926000 106930000 14q32.33 4000 Amp None 
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(iii) Structural Variants (SVs) 
The complete genome sequences of the six individuals were also used to 
identify individual specific deletions, tandem duplications, distal duplications, 
inter-chromosomal variations and inversions in comparison to NCBI Build 
37/hg19. They were grouped as structural variants. In this analysis, the SVs 
ranged from 50 bp to 218 Mb in length. Table 3.6 shows that ~85% of the SVs 
were shared between co-twins in family 1 as well as in family 2. Also, most 
(>96%) of these were present in parent(s) and a small fraction (<4%) were not 
present in any parent. They were considered familial and de novo, respectively. 
Interestingly, 10-15% of SVs were not shared between twins, making a 
significant proportion de novo variations that originated after the separation of the 
twins during their independent development. Most of the SVs in family 1 (total 
138) and 2 (total 141) represented deletions (78% and 86%), followed by tandem 
duplications (6% and 10%) and distal duplications (6.5% and 3.5%). Also, I found 
one inter-chromosomal move involving a translocation of CDC27 from 
chromosome 2 to 17 to be unique to the patient in family 1. 
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Table 3.6. Shared and unshared Structural Variation (SV) identified in blood as compared to NCBI Build 37/hg19.  
Sample Total SVs 
Shared with 
Co-twin 
Unshared 
with Co-twin 
Shared with Co-twin Unshared with Co-twin 
Inherited De novo Inherited De novo 
Family 1 
Affected  
(I-2-1) 
919 781 (85.0%) 
138 
(15.0%) 
750 
(96.0%) 
31 
(4.0%) 
97 
(70.3%) 
41 
(29.7%) 
Family 1 
Unaffected 
(I-2-2) 
893 781 (87.5%) 
112 
(12.5%) 
750 
(96.0%) 
31 
(4.0%) 
66 
(58.9%) 
46 
(41.1%) 
Family 2 
Affected 
(II-2-1) 
996 855 (85.8%) 
141 
(14.2%) N/A N/A N/A N/A 
Family 2 
Unaffected 
(II-2-2) 
977 855 (87.5%) 
122 
(12.5%) N/A N/A N/A N/A 
!
Note: Structural variants fell under five categories - deletions, tandem duplications, distal duplications, inter-
chromosomal variations and inversions. There were no inversion differences found between twins in either family 
and therefore were not included in subsequent analyses. 
!
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Further, I characterized the genomic details of individual SVs that were unique to 
the affected twins of the two families (Appendix C and D). For family 1 where parental 
sequences are available I was able to eliminate familial events and concentrate on de 
novo events. I note that these changes have affected two genes (ANKS1B and CLCN5) 
via deletion, four genes (LOC285768, NTM, SNORD115-29 and GZMM) due to tandem 
repeats and a 5 Mb tandem duplication on chromosome 1 (825765) affecting 101 
genes. Similarly, I identified SV differences between twins in family 2, but in the 
absence of parental sequences I could not characterize them further. Consequently, the 
SV differences between twins in family 2 are viewed as provisional de novo. Similarly to 
family 1, they affected 47 genes by deletion, 7 genes at 7 sites by tandem duplication 
along with a 3 Mb tandem duplication on X (52886720) overlapping 39 genes and 2 
genes by distal duplication.  
Also, the genomes carried rare (two or three) inversions, both twin pairs shared 
them with their co-twin and all inversions were inherited in Family 1. Finally, the sharing 
of CNVs and SVs between any two individuals is directly correlated with their genetic 
relatedness; high but not 100% between monozygotic twins, low across unrelated 
individuals and intermediate between a parent and an offspring, as expected. 
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3.3.1.5 Independent confirmation of NGS results 
I sought to confirm a subset of CNVs, SVs and SSCs by independent 
experiments involving Sanger Sequencing (Appendix E), PCR Amplification of Specific 
Alleles (PASA) (Table 3.7) (Figure 3.8a and 3.8b) and Real Time PCR (Table 3.8). They 
represented 4 CNVs, 6 SVs and 24 SSCs. Further, the RealTime PCR for CNVs and 
SVs using blood DNA confirmed 5/10 variants, three of which were also confirmed on 
the DNA from buccal swabs from the same individuals. The use of buccal swabs allows 
for assessment of the timing of de novo mutation. Because blood and buccal cells arise 
from two different germ layers, namely, the mesoderm and ectoderm, variants that are 
found in both tissues would be expected to have arisen very early in development, 
before the separation of the germ layers. Similarly, the results of PASA followed by 
Sanger Sequencing confirmed 2 SSCs identified by NGS (Appendix E). 
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Table 3.7. Regions analyzed using PCR Amplification of Specific Alleles (PASA). 
Gene Original Forward Original Reverse Allele Specific Forward PASA Result 
ZNF595 5’TCGTTTTACATGTCACACCTAACT3’ 
5’TTATGTTCGTTC
AGAACTGTGG3’ 
5’CAGCAGGAATAAC
AGGTACAAATA*3’ Confirmed, see Figure 3.8a 
PDE4DIP 5’CCTGAGGAGTATGGGGTAATCA3’ 
5’TGCCTCCACTT
CTTTGTTCC3’ 
5’CTACCTGTCAAAA
CCTCCAGTA*3’ Confirmed, see Figure 3.8b 
PLIN4 5’ATTTACGGCACCAGTGACTC3’ 
5’GACCCAAAATA
TCGCAACAG3’ 
5’ACGCCGGTCTGGA
CAGTCCCTG*3’ 
Was not able to amplify 
correct product 
QRICH2 5’TACCTTGCTGACCTATTCCAG3’ 
5’AGATTGATGTG
GTGCAACCT3’ 
5’CACGCTGATCCAC
TCCC*3’ Heterozygote in both twins 
MUC19 5’TAGAACATCGGTTGAAGAATCA3’ 
5’AGCTGATGGCC
GAATTGT3’ 
5’CAGCAGGAATAAC
AGGTACAAATA*3’ Heterozygote in both twins 
 
Note: The asterisk indicates the allele specific nucleotide.
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Figure 3.8. Presence of Mosaicism in Sanger Sequencing Results (PASA). 
 
Figure 3.8a. Confirmed mosaic variant between monozygotic twins in Family 1 in 
the 4th exon of the ZNF595 gene. This variant changes isoleucine to serine. The 
mother and father both have a T at this location (ATT - Isoleucine, I) in their 
complete genomics results. 
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Figure 3.8b. Confirmed mosaic variant between monozygotic twins in Family 2 in 
the 13th exon of the PDE4DIP gene. This variant changes Tryptophan to a 
premature stop codon. There is no information available for the mother and 
father at this location. 
 
!
!
!
!
!
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Table 3.8. Regions predicted by NGS to be unshared between twins and selected for assessment by Real Time 
Quantitative PCR Analysis. (NCBI Build 37/hg19) 
Gene/ 
Region 
LT Product 
Number Chr Start End Size (bp) Family Type Prediction  
Result in 
Blood  
Result in 
Buccal  
GABRD Hs01969851 1 825765 5726936 4901171 1 SV Increase 2.62* 2.65* 
CLSTN2 Hs04743760 3 139670597 139674454 3857 2 SV Increase 1.16* 1.64 
OPRM1 Hs06783090 6 154446930 154447253 323 2 SV Decrease 2.15 N/A 
STX1A Hs01848137 7 66193913 73382120 7188207 1 SV Decrease 2.75* 1.98 
12q24.21 Hs06365560 12 114521470 114529470 8000 2 CNV Increase 1.33* 0.82* 
ANKS1B Hs03835432 12 99793948 99802771 8823 1 SV Decrease 1.9^ N/A 
15q11.2 Hs03896607 15 22422114 22492114 70000 1 CNV Increase 2.69* 2.58* 
CES1 Hs00139541 16 55841801 55855801 14000 1 CNV Increase 1.56 N/A 
16p11.2 Hs03313918 16 34467150 34515150 48000 1 CNV Increase 1.8 N/A 
PLTP Hs07203816 20 44535505 44535941 436 1 SV Decrease 2.1 N/A 
 
Note: LT=Life Technologies, ^=Correct direction. Prediction is based on sequencing result. Regions were first 
assessed on blood DNA; regions that confirmed in blood DNA were then assessed in buccal DNA. The asterisk 
refers to a significant difference. Significance was defined as a Z-Score <1.75 and 95% confidence level.
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3.3.2 Genetic differences between MZ twins and their discordance for 
schizophrenia 
The results also allowed for assessment of any involvement of genetic 
differences between MZ twins in the development of schizophrenia using a 
threshold model (McGue et al., 1983). It assumes that both members of the 
monozygotic discordant twins will carry family specific genetic predisposition for 
the disease and additional changes in the affected twin will swing the 
predisposition to a threshold that will be sufficient for the onset of the disease. 
This model is testable given near complete coverage of genetic changes in the 
affected as well as unaffected members of the two MZD twin pairs. It begins with 
development of a list of all genes that are affected by a variety of mutational 
mechanisms in four members of the two MZD twin pairs. This list is rather 
comprehensive and individual specific. I have used this list to assess the effect of 
these differences using Ingenuity Pathway Analysis (IPA). It moves the analysis 
from a focus on affected genes to affected pathways. 
Table 3.9 shows the top 20 individual specific canonical pathways in two 
affected individuals belonging to the two families. Figure 3.9 outlines my strategy 
in assessing the nature of the threshold model in the two patients. Of the top 20 
pathways in patient 1 and patient 2, 10 are shared between them (Figure 3.10). 
Also, 8 of the 10 pathways shared by the two patients are present in either of the 
two unaffected members of the two twin pairs. This results in 2 pathways that 
may be viewed as highly specific to the two patients (Figure 3.9). They represent 
Dopamine-DARPP32 Feedback in cAMP Signaling (Figure 3.11a, Family 1, 
p=2.28E-04; Family 2, p=5.84E-03) and Glutamate Receptor Signaling (Figure 
3.11b, Family 1, p=1.46E-03; Family 2, p=3.88E-05). I note that 13 and 29 genes 
of the two pathways respectively are affected in the patient of family 1 (Table 
3.10). The corresponding numbers for the patient in family 2 are 15 and 23 genes 
for the two pathways, respectively (Table 3.10). Although few of the mutated 
genes are patient specific, the two patients share a large number of affected 
molecules in Glutamate Receptor Signaling as well as Dopamine-DARPP32 
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Feedback in cAMP Signaling pathways. Further, I note that four of the top five 
pathways in the patient of family 1 and three of the top five canonical pathways in 
the patient of family 2 are relevant to neural functions and have the potential to 
contribute to the disease in a threshold model discussed in the next section 
(Table 3.9). 
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Figure 3.9. Approach for analysis of Ingenuity Pathway Results.  
Blue line represents disease threshold (T). 
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Table 3.9. Top 20 Canonical Pathways identified by Ingenuity Pathway Analysis 
(IPA) in the affected twin of each family. 
Canonical Pathways - Family 1 Affected (1A) Shared With p-value 
1. CREB Signaling in Neurons 2A, 2U 0.0000041687 
2. Neuropathic Pain Signaling In Dorsal Horn 
Neurons 2A, 1U, 2U 0.0000083176 
3. Axonal Guidance Signaling 2A, 1U 0.0000630957 
4. Cellular Effects of Sildenafil (Viagra) 2A, 1U 0.0001479108 
5. Role of NFAT in Cardiac Hypertrophy - 0.0001513561 
6. Dopamine-DARPP32 Feedback in cAMP 
Signaling 2A 0.0002290868 
7. Synaptic Long Term Depression 2A, 1U, 2U 0.0002398833 
8. Wnt/Ca+ pathway - 0.0003630781 
9. Synaptic Long Term Potentiation 2A, 2U 0.0008511380 
10. PPARÎ±/RXRÎ± Activation 2U 0.0011748976 
11. Gap Junction Signaling - 0.0013803843 
12. Glutamate Receptor Signaling 2A 0.0014791084 
13. 14-3-3-mediated Signaling - 0.0020417379 
14. Netrin Signaling 2A, 1U, 2U 0.0022908677 
15. Leptin Signaling in Obesity - 0.0024547089 
16. Nitric Oxide Signaling in the Cardiovascular 
System 2A, 1U 0.0024547089 
17. Hepatic Cholestasis 2U 0.0026915348 
18. Uracil Degradation II (Reductive) 2U 0.0029512092 
19. Thymine Degradation 2U 0.0029512092 
20. Melatonin Signaling 1U 0.0033113112 
Canonical Pathways - Family 2 Affected (2A) Shared With p-value 
1. Sperm Motility 1U 0.0000053703 
2. Glutamate Receptor Signaling 1A 0.0000389045 
3. Neuropathic Pain Signaling In Dorsal Horn 
Neurons 1A, 2U, 1U 0.0000575440 
4. Cellular Effects of Sildenafil (Viagra) 1A, 1U 0.0002238721 
5. Nitric Oxide Signaling in the Cardiovascular 
System 1A, 1U 0.0002884032 
6. Synaptic Long Term Depression 1A, 2U, 1U 0.0003235937 
7. CREB Signaling in Neurons 1A, 2U 0.0003630781 
8. Synaptic Long Term Potentiation 1A, 2U 0.0005888437 
9. Phospholipase C Signaling - 0.0008709636 
10. Netrin Signaling 1A, 2U, 1U 0.0010964782 
11. G-Protein Coupled Receptor Signaling 2U 0.0012589254 
12. Î±-Adrenergic Signaling - 0.0016595869 
13. Protein Kinase A Signaling 2U, 1U 0.0023442288 
14. nNOS Signaling in Neurons - 0.0040738028 
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15. Huntington's Disease Signaling - 0.0042657952 
16. Dopamine-DARPP32 Feedback in cAMP 
Signaling 1A 0.0058884366 
17. Cardiac Î²-adrenergic Signaling 2U 0.0067608298 
18. Calcium Signaling 2U 0.0077624712 
19. Breast Cancer Regulation by Stathmin1 - 0.0087096359 
20. Axonal Guidance Signaling 1A, 1U 0.0089125094 
Note: 1A=Family 1- Affected, 1U=Family 1- Unaffected, 2A=Family 2- Affected, 2U=Family 2- Unaffected. 
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!
 
Figure 3.10. Venn diagram of the top 20 canonical pathways found to be 
overrepresented by variants in the sequencing dataset of affected and unaffected 
twins. 
Note: The pathways from the unaffected twin in Family 1 and Family 2 have been 
merged to represent 36 unique pathways (4 shared). The 18 pathways unique to 
unaffected twins are broken down into 11 from Family 1 and 7 from Family 2. 
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Figure 3.11. Ingenuity Pathways Analysis Identified Pathways in Affected Twins 
Only. Legend for symbols available in Appendix L. 
a.#
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Figure 3.11a. Dopamine Feedback in cAMP Signaling pathway identified using 
Ingenuity Pathway Analysis (IPA). This pathway emerged independently in both 
affected twins. This pathway was also not found to be enriched in unaffected 
twins in the study. Purple represents genes harboring a unique high confidence 
variant (Family 1, p=2.28E-04; Family 2, p=5.84E-03). 
a.#continued#
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b.#
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Figure 3.11b. Glutamate Receptor Signaling pathway identified using Ingenuity Pathway Analysis (IPA). This 
pathway emerged independently in both affected twins. This pathway was also not found to be enriched in 
unaffected twins in the study. Purple represents genes harboring a unique high confidence variant (Family 1, 
p=1.46E-03; Family 2, p=3.88E-05).  
b.#continued#
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Table 3.10. Genes affected in two pathways (Glutamate Receptor Signaling and Dopamine Feedback in cAMP 
Signaling) unique to the two unrelated schizophrenia patients representing family 1 and family 2. !
Pathway 
Family 1: Genes in Pathway Family 2: Genes in Pathway 
Common to 
both Affected 
Twins 
Number of 
genes 
affected 
Identity 
Number 
of genes 
affected 
Identity 
Dopamine 
Feedback in 
cAMP 
Signaling 
29 
PRKG2, PPP2R1U, 
GUCY1A3, PRKAG2, 
ADCY3, PRKCB, 
PRKAR1B, KCNJ12, 
ADCY2, PRKCZ, ADCY8, 
PLCL1, CACNA1D, 
DRD3, PLCB1, 
GUCY1A2, EP300, 
PRKG1, PPP3CA, 
CACNA1A, GRIN2U, 
PLCG2, KCNJ3, PRKCA, 
PLCH2, CACNA1C, 
PLCL2, PLCZ1, KCNJ10 
23 
PLCB1, PRKG2, PRKG1, 
PPM1L, CAMK4, PLCE1, 
PRKAG2, PPP2R2C, 
ADCY10, PPP1R14C, 
GRIN2A, CREB5, 
PRKCA, CACNA1C, 
PRKCB, KCNJ12, ITPR1, 
PRKAR1B, PRKCI, 
PRKCZ, ADCY8, 
PRKCG, DRD3 
12 
(PRKG2, 
PRKAG2, 
PRKCB, 
PRKAR1B, 
KCNJ12, 
PRKCZ, 
ADCY8, DRD3, 
PLCB1, 
PRKG1, 
PRKCA, 
CACNA1C) 
Glutamate 
Receptor 
Signaling 
13 
GRIA1, GRIK2, GRID1, 
GNB1, GRIN2U, SLC1A7, 
GRIK1, GRIK4, GRM7, 
GRM1, GRM5, GRM8, 
GRIK3 
15 
GRID1, GNG7, CAMK4, 
SLC1A2, HOMER1, 
SLC1A7, GRIK1, 
GRIN2A, GRM4, GRIK4, 
SLC1A1, GRM7, GNG2, 
GRM5, GRM6 
6 
(GRID1, 
SLC1A7, 
GRIK1, GRIK4, 
GRM7, GRM5) 
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3.4 Discussion 
The search for genetic causes of disease, that has accelerated with our 
ability to genotype individuals with and without the disease, has concluded that 
not all genetic diseases are caused by a single mutation in a single gene (Kong 
et al., 2014). In fact, most complex diseases have heterogeneous causation and 
every individual is genetically unique. It makes experimental matching of patients 
and controls a difficult proposition and studies on ever increasing numbers of 
patients and controls do not always meet the objectives. With this in mind, I 
focused this research on the assessment of genome-wide mutations for two 
unrelated pairs of MZD twins. Using complete genome sequences, I identified 
individual specific genome-wide gene mutations (SSCs, CNVs and SVs) that are 
exceptionally comprehensive and reflect the highest resolution currently available 
for individual genomes. Caution must be taken in interpretation of the results due 
to the persistence of false positives found in large-scale sequencing studies. 
However, the results allow for the appraisal of the nature and source of genetic 
variation in individual genomes. Also, given the discordance of MZ twins for 
schizophrenia, the results are valuable in assessing the threshold model for the 
development of this disease, that has been previously suggested (Gottesman 
and Shields, 1967; McGue et al., 1983) but remained untested. I will present a 
model to show how my data on mutations observed in individual genomes and 
their relationship involving MZ twins offers novel insight into the development of 
schizophrenia. First, I will discuss the observations on the individual genome 
sequences. 
 
3.4.1 Individual human genomes contain extensive variability 
In general, the identity and distribution of variations in this study follow the 
results on 1000 genomes data and expected distributions based on chromosome 
size (Figure 3.6 and 3.7). The data is accumulating in the literature that every 
individual harbors hundreds of rare variants (Abecasis et al., 2012). Even in 
healthy individuals, approximately 300 to 500 missense mutations are identified 
!! 137!
per genome, and it is estimated that each individual carries approximately 60 
missense mutations that damage protein structure as well as approximately 100 
loss of function variants (Xue et al., 2012). My results are consistent with 1000 
genomes pilot data which found that individual genomes have on average, 3.6 
million SNVs, 344 thousand indels and 717 large deletions (Abecasis et al., 
2012). My results are also consistent with findings of de novo variation within 
families; current results in the field show that both somatic and germline de novo 
variation can be identified in offspring. However, the rate of de novo mutation 
appears to be variable and may be family specific (Project et al., 2011). 
Unfortunately, this variability is not always easy to discern. Studies of twin 
sequencing data in the literature have noted validation rates of variants as low as 
1/15 and groups continue to confirm the high error rates of current next 
generation sequencing technologies (Dal et al., 2014). In addition, validation 
rates for data from the 1000 genomes project averaged a validation rate of 1.8%, 
and similar to my study, large SVs were easier to validate (2.1%) than other 
types of variation. My analysis also focused on the use of higher quality variant 
calls as was done in the 1000 genomes pilot study to evaluate the likelihood of a 
candidate variant call being a real event (Abecasis et al., 2012). The results show 
that individual genomes harbor extensive variability and that this variability can 
be measured both within and between generations.  
 
3.4.2 MZ twins are genetically different 
Results included in this report also show that the genome sequences of 
pairs of MZ twins although similar, are not identical. It follows a number of recent 
reports on identical twins (Kondo et al., 2002; Reumers et al., 2012; Vadlamudi et 
al., 2010; Weber-Lehmann et al., 2014; Ye et al., 2013). Although likely to be a 
conservative estimate, Krawczak et al has predicted that there exists at minimum 
an average of >1.3 SNVs discriminating MZ twins in each tissue type (Krawczak 
et al., 2012). The results of one forensic study found DNA sequence differences 
between identical twins that appear to reflect mosaicism in that the newly arisen 
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allele was generally only found in a small fraction (approximately 20% of the cells 
assayed) as estimated by Sanger Sequencing results (Weber-Lehmann et al., 
2014). Many reports have now identified genetic and epigenetic differences 
between identical twins (Dempster et al., 2011, 2014; Ehli et al., 2012). For 
example, Bruder et al (2008) reported that all of 19 MZ twins studied differed in 
CNVs (Bruder et al., 2008) and Forsberg et al confirmed 10 post-twinning CNV 
mutations in 159 MZ twin pairs (Forsberg et al., 2012). Many post-twinning single 
nucleotide mutations have also been reported (Kondo et al., 2002; Reumers et 
al., 2012; Vadlamudi et al., 2010; Ye et al., 2013), however these are expected to 
be rarer than post-twinning CNVs. It is likely that older twin pairs will have 
accumulated more de novo mutations over time (Ye et al., 2013) and this will be 
expected to affect the degree of somatic mosaicism across tissues (Piotrowski et 
al., 2008). Additionally, my previous research on MZ twin pairs proposes that de 
novo copy number variants can be identified by comparison of the genomes of 
MZ twins with their parents (Maiti et al., 2011). Although the exact contribution of 
de novo differences to disease has not been identified for most diseases, one 
disease, Mayer-Rokitansky-Kuster-Hauser syndrome, has been found to arise 
from a patient-specific duplication in the affected monozygotic twin in a tissue 
specific manner leading to disease manifestation (Rall et al., 2015). In addition, a 
recent report that identified somatic mutations at the base-pair level in 
monozygotic twins found two de novo somatic mutations that appear to have 
occurred early in embryonic development, suggesting that early development 
may be enriched for de novo change (Li et al., 2014). Although one group 
concluded that there are no differences between the genomes of co-twins 
discordant for multiple sclerosis (Baranzini et al., 2010), it has subsequently been 
suggested that the analytical methods used, particularly the low average 
sequence coverage (22-fold), was not sufficiently powerful to reveal rare somatic 
mutations (Handunnetthi et al., 2010). It has been suggested that a fold coverage 
of 30x or greater is necessary to identify true somatic mutations (Bentley et al., 
2008) in the genome, which this current study reflects. 
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This study, with complete genome sequences of pairs of MZD twins offers 
a number of advantages. First, it focuses on individual patients and matches the 
patient with her unaffected monozygotic twin; nature’s near perfect genetic 
match. The consequence is that it drastically reduces genetic heterogeneity 
between a case and the matched control. Also, it focuses on the genetic factors 
of schizophrenia in an individual patient rather than grouping together 
heterogeneous cases of schizophrenia. Second, the availability of complete 
genome sequences allows for identification of almost all forms of genetic 
mutations per individual. Third, the identification of all affected genes in a patient 
allows for further identification of canonical pathways that may be affected by 
individual specific gene mutations. Finally, it assesses the sum combination of 
affected pathways that are specific to the patient(s) versus pathways that are 
also overrepresented in the unaffected twin.  
The analysis of affected pathways began with identification of genes that 
were affected by any mutational mechanisms in each patient and not found in 
their co-twin. The genes that met this criteria were used in pathway analysis. This 
analysis yielded a set of pathways for four individuals representing two twin pairs. 
The top 20 pathways identified in four members of the two twin pairs are given in 
Table 3.9. Interestingly, a number of pathways were shared across all four 
individuals. Next, I focused on affected pathways that were shared or not shared 
in the two MZD twins. I then assessed the data to evaluate the threshold model 
of schizophrenia (Figure 3.9). Within twin pair sharing of pathways was viewed to 
represent “genetic predisposition” and were considered to not be sufficient to 
cause the disease; I labeled these as genetic-predisposition pathways (gp1 and 
gp2 for each family, respectively). The composition of the genetic-predisposing 
pathways was expected to differ between unrelated pairs.  
Further, I selected pathways that were unique to the two patients in this 
study. In my model, these additional defects are needed to cross the liability 
threshold and manifest the disease. Any potential disease-associated pathways 
were labeled gpd. The composition of disease-associated pathways may vary 
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across families. In this analysis I identified two potential pathways in both families 
that could be contributing to disease causation (due to their exclusive presence 
in affected twins); Dopamine Feedback in cAMP Signaling Pathway (Figure 
3.11a) and Glutamate Receptor Signaling (Figure 3.11b).  
Interestingly, a number of pathways labeled as genetic predisposing (gp1 
and gp2) have been previously implicated in this heterogeneous disease 
including CREB Signalling in Neurons as blocking of this pathway is thought to 
be associated with a decrease in BDNF transcription that may contribute to 
disease (Katanuma et al., 2014). In addition, Axonal Guidance Signalling and 
Netrin Signaling, have been labelled as potential predisposing pathways in this 
study and have also been found in the literature to be targeted pathways of 
schizophrenia associated genes such as PCDH12 (Gregório et al., 2009). 
Another interesting link to the literature is nNOS Signalling in Neurons, which 
was labeled as potentially predisposing in this analysis and has been previously 
found to have increased activity in affective disorders (Oliveira et al., 2008) . 
Novel and informative additional complete genome level studies using a larger 
number of samples will be needed to support this theoretical model.  
 
A. Dopamine Feedback in cAMP signaling in Schizophrenia 
The dopamine feedback in cAMP signalling pathway is one of the 
pathways that has emerged independently in both schizophrenia-affected twins 
in this study (Figure 3.11a). This pathway has been shown to be associated with 
psychiatric disorders due to the fact that it has critical function in integrating 
dopaminergic and glutamatergic signalling, and in turn affecting striatal function 
and plasticity (Kunii et al., 2014; Meyer-Lindenberg et al., 2007). The leading 
theory to account for the pathophysiology of schizophrenia involves an excess of 
the neurotransmitter dopamine, either through excess production or postsynaptic 
dopamine over-activity possibly mediated by increased receptor density (Abi-
Dargham and Laruelle, 2005).  Recent reports reinforce the importance of 
dopamine in schizophrenia, including strong associations with Dopamine 
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Receptor D2 (DRD2), a target of many antipsychotic drugs (Ripke et al., 2014). 
The results support the contention that the defects associated with this pathway 
have the potential to contribute to schizophrenia in the two patients studied.  
 
B. Glutamate Receptor Signalling in Schizophrenia 
A glutamate receptor-signalling pathway is the second pathway that is 
found only in the two patients studied (Figure 3.11b). The significance of this 
pathway in this disease is backed by the underlying neurochemical basis of 
schizophrenia that includes a hypofunctional glutamate system (Labrie and 
Roder, 2010). Many genes associated with glutamatergic neurotransmission 
have been previously implicated in schizophrenia, including GRM3, GRIN2A, 
SRR and GRIA1 (Ripke et al., 2014). Further, morphological alteration of 
dendrites of glutamatergic neurons in the cerebral cortex of schizophrenia-
affected individuals has been reported (Hu et al., 2015), suggesting a role for 
glutamate signalling in the etiology of schizophrenia. Interestingly, schizophrenia 
patients show enriched de novo mutations in genes regulating the postsynaptic 
density at glutamatergic synapses (Hall et al., 2015). Furthermore, small de novo 
mutations were found to be overrepresented among glutamatergic postsynaptic 
proteins (Fromer et al., 2014) and genes harbouring detrimental de novo 
mutations were reported to be enriched in networks affecting protein interactions 
(Mostafavi et al., 2008). In addition, a recent study investigating rare mutations in 
exonic regions of genes implicated in schizophrenia and autism spectrum 
disorder (ASD) revealed that post-synaptic glutamate receptor complexes are 
key molecular mechanisms associated with schizophrenia and ASD (Kenny et 
al., 2014).  
I propose that the two pathways described above have the potential to at 
least partially contribute to the disease in these two patients. More important, the 
gene defects associated with these two pathways in both patients may have 
allowed for crossing of the liability threshold and manifestation of the disease. 
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3.5 Conclusion 
The genome-wide results included in this report are compatible with a 
threshold model for schizophrenia. They involve a number of pathways and an 
even larger number of genes. Most of the mutations involved may provide a 
family specific liability that may (e.g. Concordant MZ twins) or may not be alone 
sufficient (e.g. Discordant MZ twins) to develop the disease. In cases where it is 
not sufficient, additional aberrations (genetic, epigenetic or environmental) can 
shift the liability beyond the threshold for the development of disease. 
Interestingly, some of these changes may represent de novo mutations during 
ontogeny involving a variety of mutational mechanisms. I note that the effect of a 
de novo mutation may or may not be apparent depending on the degree of 
mosaicism caused by its timing and the organ system affected, but necessitate 
more intensive investigation. Finally, the comprehensive genomic results per 
individual included in this report provide a promising approach to the 
understanding of schizophrenia and may apply to other related disorders.   
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A version of this chapter has been published in Castellani et al., BMC Medical Genomics (2015)  
Chapter 4!- DNA Methylation Analysis of Families with Monozygotic Twins 
Discordant for Schizophrenia Identifies Psychosis Related Genes and 
Networks 
4.0 Overview 
The involvement of DNA methylation in schizophrenia appears logical, but 
remains to be established. I have used blood DNA from two pairs of monozygotic 
twins discordant for schizophrenia and their parents in order to assess genome-
wide methylation using a NimbleGen 720k Methylation Promoter Microarray. 
The genome-wide results show that differentially methylated regions 
(DMRs) exist between members representing discordant monozygotic twins. 
Some DMRs are shared with parent(s) and others appear to be de novo. I found 
twenty-seven genes affected by DMR changes that were shared in the affected 
member of two discordant monozygotic pairs from unrelated families. 
Interestingly, the genes affected by pair-specific DMRs share networks. 
Specifically, this study has identified two networks; ‘cell death and survival’ and 
‘cellular movement and immune cell trafficking’. These two networks and the 
genes affected have been previously implicated in the etiology of schizophrenia. 
The results are compatible with the suggestion that DNA methylation may 
contribute to the discordance of monozygotic twins for schizophrenia. Also, this 
may be accomplished by the effect of gene specific methylation changes on 
specific biological networks rather than individual genes.  
 
4.1 Introduction 
Results during the last few years have established that differences 
between MZ twins exist at the genetic (Bruder et al., 2008; Maiti et al., 2011) as 
well as epigenetic (Fraga et al., 2005; Ling and Groop, 2009; Petronis, 2010) 
levels. In fact, methylation differences between identical twins have been 
reported as early as in newborns (Ollikainen et al., 2010). Also, DNA methylation 
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is reported to increase with age (Levesque et al., 2014; Fraga et al., 2005). 
Epigenetic differences between MZ twins include features like X-inactivation, 
genomic imprinting, or differential methylation of genes, and may cause MZ twin 
pairs to diverge, leading to disease discordance (Dempster et al., 2011; Singh et 
al., 2002). Studies of this kind have concluded that no two individuals are alike; 
not even identical twins (Maiti et al., 2011). However, the genetic similarity 
between MZ twins is comparable to no other two individuals. In addition, identical 
twins are matched for age, sex, maternal environment, and population cohort 
effects - making them the best matched control available (Bell and Spector, 
2011). Indeed, MZ twins provide a unique backdrop to assess epigenetic states 
that are shared due to inheritance or common environments, as well as 
differences that may be in response to individual specific exposures or random 
events (Fraga et al., 2005; Ling and Groop, 2009; Manikkam et al., 2012; 
Petronis, 2010; Wong et al., 2010). These changes, affecting critical cellular 
processes, may allow monozygotic twins to develop discordance for almost any 
trait through reprogramming of gene expression via epigenetic mechanisms 
which may increase liability to disease (Xu et al., 2014). This is particularly 
relevant in neurodevelopmental disorders, especially schizophrenia, and reports 
are now accumulating from twin studies to support an epigenetic model of 
disease contribution. For instance, a schizophrenic twin from a pair of discordant 
MZ twins is epigenetically more similar to affected concordant MZ twins than to 
their own unaffected co-twin at the DRD2 gene (Petronis et al., 2003). In 
addition, methylation of genes in blood samples of twins discordant for 
schizophrenia, including medication free patients, shows hypermethylation and 
hypomethylation of several genes (Bonsch et al., 2012; Kinoshita et al., 2013). 
Indeed, the molecular results accumulating on schizophrenia are encouraging 
and include many recent reports of associations between DNA methylation and 
schizophrenia (Abdolmaleky et al., 2004; Dempster et al., 2011; Wockner et al., 
2014).  
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The research presented here identifies genes whose methylation is 
altered in schizophrenia patients as compared to their unaffected MZ twin. It uses 
blood DNA from two sets of monozygotic twin pairs discordant for schizophrenia 
and their parents. The results identify DNA methylation differences between MZD 
twins in two families discordant for schizophrenia. Also, the patients across 
families share affected genes, and more importantly, biological networks.  
 
4.2 Methods 
4.2.1 Subjects 
This study on monozygotic twins received ethics approval by the 
University of Western Ontario’s Committee on research involving human subjects 
(Appendix B). All subjects provided written informed consent to participate in this 
study. All of the patients were adults at the time of consent. Capacity for consent 
was ensured using three measures 1) Schizophrenic patients gave consent only 
during a “normal” phase (no psychosis present), 2) Both twins of the twin pair 
were present and gave consent at the same time (the normal twin and their 
affected sibling), 3) If R.O’Reilly felt that the capacity to consent was 
compromised, the patients were not included in the study. They were interviewed 
and clinically assessed by a single senior Psychiatrist (R. O’Reilly) using the 
SCID-I and SCID-II (First et al., 1996, 1997). Past clinical notes were available to 
aid in diagnosis. Both families were comprised of identical female twins. The 
twins from Family 1 (Figure 4.1) were Afro-American females aged 53. The 
affected member of twin pair 1 was diagnosed with schizophrenia at age 22. The 
twins were discordant for 31 years at the time of sample collection. The twins 
from Family 2 (Figure 4.1) were Caucasian females aged 43. The affected 
member of twin pair 2 was diagnosed with schizoaffective disorder at age 27. 
The twins were discordant for 16 years at the time of sample collection. It should 
be noted that the Father of Twin Pair 1 was diagnosed with Chronic Leukemia 
(CLL) at age 69. The affected patient from Family 1 was treated for 
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schizophrenia symptoms using a combination of the medications Clozapine, 
Divalproex and Benztropine. The affected patient from Family 2 was treated for 
schizophrenia symptoms using a combination of the medications Seroquel, 
Effexor and Topiramate. 
 
4.2.2 DNA Collection and Array Processing 
The twins and their parents (Figure 4.1) included in this study contributed 
whole blood samples. DNA was extracted from whole blood using the 
PerfectPure DNA Blood Kit (Gaithersburg, MD, USA), following the 
manufacturer’s protocol. Zygosity was confirmed by Affymetrix 6.0 microarray 
and specifically using the Affymetrix Genotyping Console 4.0 concordance 
feature (Maiti et al., 2011). 
The genomic DNA was processed at ArrayStar Inc (Rockville, MD, USA); 
this included the methylated DNA immunoprecipitation (MeDIP), sample labeling, 
and hybridization to the NimbleGen Human DNA Methylation Promoter Plus CpG 
Island 720k Array. The NimbleGen Human DNA Methylation 3x720k CpG Island 
Plus RefSeq Promoter Microarray is a multiplex slide with 3 identical arrays per 
slide. Each Roche Nimblegen Inc (Madison, MI, USA) array covers 27,728 
annotated CpG islands as well as 22,532 promoters of the RefSeq genes derived 
from the UCSC RefFlat files. Median-centering, quantile normalization, and linear 
smoothing was performed by Bioconductor packages Ringo, limma, and MEDME 
at ArrayStar. Lastly, in order to compare the two groups’ differentially enriched 
regions the average of the log2-ratio values for each group (i.e. experimental 
patient [E] and healthy control [C]) was used to calculate an M’ value (defined by 
the following equation) for each probe: 
 
M’ = Average (log2 MeDIPE / InputE) – Average (log2 MeDIPC / InputC) 
The differential enrichment peaks were filtered according to the following criteria: 
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i) At least one of the two groups has a median (log2 MeDIP/Input) > =0.3 and 
M’> 0. 
ii) At least half of probes in a peak may have coefficient of variability (CV) < = 0.8 
in both groups. 
Before hybridization to the array, genomic DNA was sonicated to random 
fragments in size of about 200–1000 bp. Immunoprecipitation of methylated DNA 
was performed using Biomag™ magnetic beads coupled to a mouse monoclonal 
antibody against 5-methylcytidine. The immunoprecipitated DNA was eluted and 
purified by phenol chloroform extraction and ethanol precipitation. The total input 
and immunoprecipitated DNA were labeled with Cy3- and Cy5-labeled random 9-
mers. Scanning was performed with the Axon GenePix 4000B microarray 
scanner. Raw data was extracted as pair files by NimbleScan software. 
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Figure 4.1. Pedigrees of families included in the study. 
Shaded circles represent affected twins. 
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4.2.3 Microarray Analysis 
The pair files were analyzed with the tiling workflow in Partek Genomics 
Suite® version 6.6 (St. Louis, Missouri, USA). Nimblegen scan pair files (635 nm 
and 532 nm) for each sample were annotated against NCBI Build 36/hg18 and 
enriched regions were detected using a two-way ANOVA between an affected 
twin and their unaffected co-twin. The enriched regions settings were set at a 
minimum p-value of 0.001 and the number of probes to call a region was set at a 
minimum of 4. MAT scores were generated for each differentially methylated 
region. Overlapping genes were then identified as those RefSeq (2014-04-29 
version) genes that were either within the gene or 5000 bp upstream or 3000 
downstream of the gene. Differentially methylated regions (DMRs) in each 
affected twin were identified in relation to the pattern in the well twin. Also, the 
presence or absence of each DMR was assessed as familial or de novo based 
on their presence or absence in Mom and/or Dad. 
The identified genes with significant changes in DNA methylation between 
twins discordant for schizophrenia (DMRs) were then analyzed using Ingenuity 
Pathway Analysis (Ingenuity Systems Inc, CA, USA) towards identification of 
networks and canonical pathways overrepresented in the enriched genes. Also, 
pathway analysis and gene ontology analysis were conducted using Partek 
Pathways (Fishers Exact Test) and Enrichr (Chen et al., 2013). Shared genes 
were annotated with imprinting data from GeneImprint 
(http://www.geneimprint.com) and The Catalogue of Parent of Origin Effects 
(http://igc.otago.ac.nz/home.html). 
 
4.3 Results 
I report the genome-wide analysis of methylation differences in two 
families with monozygotic twins discordant for schizophrenia using the 
NimbleGen Human DNA Methylation Promoter Plus CpG Island 720k Array. I 
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analyzed the data with Partek Genomics Suite and yielded three main lines of 
results presented below: 
 
4.3.1 MZ twins show differences in DNA Methylation profiles 
The genome-wide DNA methylation profiles have revealed differentially 
methylated regions (DMRs) between the MZ twin pairs in the study (p ≤ 0.001). 
These differences were widespread and distributed across all chromosomes. 
Further, the availability of parental data has allowed for assessment of each 
DMR for its presence/absence in the two parents. The results show that 
methylation profiles in twins include both shared and de novo events. I note that 
in Family 1 as well as in Family 2, most of the DMRs appear de novo (are not 
found in Mom or Dad).  Only 13% and 25% of the DMRs in each family, 
respectively, were present in at least one parent. The results have also allowed 
identification of specific genes that are differentially methylated between the 
affected twin and their identical unaffected twin. Specifically, I note that 330 
genes are differentially methylated in the twin pair from Family 1 (Appendix F) 
and 138 genes are differentially methylated in Family 2 (Appendix G). A visual 
representation of these results is given in Figure 4.2. As might be expected, 
some of the DMRs were increased in methylation when compared to co-twin and 
others were decreased in methylation when compared to co-twin. An overlap 
between the DMRs present in the affected member of the two unrelated families 
(Figure 4.3) suggests that most (80-92%) DMRs are twin pair specific. 
Chromosome 1 (36 and 19 DMRs respectively) and Chromosome 15 (30 and 21 
DMRs respectively) harbour a large proportion of DMRs in Family 1 as well as in 
Family 2. Family 1 also has a large number of DMRs on Chromosome 19 (30 
DMRs). 
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Figure 4.2. Differential methylation in two twin pairs visualized in a Circos plot 
covering all chromosomes. 
Red represents a decrease in methylation in the affected twin and blue 
represents an increase in methylation in the affected twin. The outside track 
represents differentially methylated regions in the affected member of Family 1, 
the middle track represents differentially methylated regions in the affected 
member of Family 2 and the inside track represents the shared regions found in 
both unrelated affected twins. Shared genes are labeled. 
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Figure 4.3. Overlap of differentially methylated regions between two families. 
Venn diagram showing the number of genes differentially methylated in each 
patient (138 and 330, respectively) as well as the genes enriched in both affected 
twins in this study (27). 
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4.3.2 MZ twins discordant for schizophrenia share genomic regions of 
differential methylation 
Figure 4.3 highlights 27 genes that were differentially methylated in the 
affected twin in both families. Consequentially, there are 303 genes that are only 
differentially methylated in Family 1 and 111 genes that are only differentially 
methylated in Family 2 (Figure 4.3). Of the 27 genes that showed methylation 
differences in both sets of twins, 24 were increased in methylation status in the 
affected twins and the remaining showed a decrease in methylation. The genes 
identified included five HIST (Chromosome 1 and 6) and 17 SNORD115-116 
genes (Chromosome 15). Also, the imprinted gene GNAS (Chromosome 20) as 
well as XIST (Chromosome X) were found to share DMR regions between the 
two patients. PTPRN2 and TTYH3, both found on Chromosome 7, as well as 
ZFP41 (Chromosome 8), are the remaining shared DMRs. The list of genes 
(Table 4.1) identified share common regions with exact DMR beginning/end 
locations in the two patients. The exception to this pattern was the PTPRN2, 
TTYH3 and ZFP41 regions where the beginning/end locations were found to be 
different but nearby (Table 4.1). As expected, all DMRs identified are specific to 
the promoter regions.  
As stated, five of the common genes identified belong to either the 
HIST2H cluster on Chromosome 1 or the HIST1H region on Chromosome 6 
(Table 4.1). Further, 17 of the 27 genes belong to either the SNORD115 or 
SNORD116 clusters on chromosome 15. All seventeen of the SNORD genes 
identified in two patients are known to be genomically imprinted and are thought 
to produce ncRNA transcripts that undergo extensive processing (Table 4.1). A 
Manhattan Plot of the region encompassing the SNORD genes is presented in 
detail in Figure 4.4, this region extends from the SNRPN gene to the UBE3A 
gene and encompasses both the SNORD115 and SNORD116 gene families. In 
addition, a Manhattan Plot of the HIST region on Chromosome 1 is presented in 
Figure 4.5.
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Table 4.1. Differentially methylated regions identified in two affected MZD twins belonging to two unrelated 
families. (NCBI Build 36/hg18) 
Transcript Chr Region Start Region End Methylation Status 
MAT 
Score 
Family 1 
MAT 
Score 
Family 2 
DMR In Family 1 
Parental 
DMR in Family 2 
Parental 
HIST2H2AA3 1 148085850 148085870 Increase 12.7557 8.45215 YES (Mom) YES (Both) 
HIST2H2AA4 1 148085850 148085870 Increase 12.7557 8.45215 YES (Mom) YES (Both) 
HIST2H3A 1 148085850 148085870 Increase 12.7557 8.45215 YES (Mom) YES (Both) 
HIST2H3C 1 148085850 148085870 Increase 12.7557 8.45215 YES (Mom) YES (Both) 
HIST1H1C 6 26164302 26164322 Increase 7.54892 6.0215 NO NO 
PTPRN2 7 F1: 157352628 F2: 157141154 
F1:157352648 
F2:157141174 Increase 7.11519 2.41616 NO NO 
TTYH3 7 F1: 2664585 F2: 2653547 
F1: 2664605 
F2: 2653567 
F1:Decrease 
F2:Increase −2.82779 2.47725 NO NO 
ZFP41 8 F1: 144409425 F2: 144403919 
F1:144409445 
F2:144403939 Increase 15.1625 2.05379 NO NO 
SNORD115-10 15 22983806 22983826 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD115-11 15 22983806 22983826 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD115-12 15 22983806 22983826 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD115-29 15 22983806 22983826 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD115-33 15 23030052 23030072 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD115-34 15 23030052 23030072 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD115-35 15 23030052 23030072 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD115-36 15 22983806 22983826 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD115-37 15 23030052 23030072 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD115-43 15 22983806 22983826 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD115-5 15 22983806 22983826 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD115-9 15 22983806 22983826 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD116-10 15 22868070 22868090 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD116-11 15 22868070 22868090 Increase 7.49051 7.8983 YES (Both) YES (Both) 
!! 163!
!!
Note: Chr = Chromosome; F1 = Family 1; F2 = Family
SNORD116-3 15 22868070 22868090 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD116-8 15 22868070 22868090 Increase 7.49051 7.8983 YES (Both) YES (Both) 
SNORD116-9 15 22868070 22868090 Increase 7.49051 7.8983 YES (Both) YES (Both) 
GNAS 20 56879799 56879819 F1:Increase F2:Decrease 17.2187 −10.7502 YES (Both) YES (Both) 
XIST X 72974756 72974776 F1:Increase F2:Decrease 12.1903 −7.36623 NO YES (Both) 
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Ingenuity Pathway Analysis (IPA) with the 27 shared genes has identified 
‘Protein Kinase A Signaling’ as the most enriched canonical pathway (p = 3.09E-
04). In addition, ‘Granzyme A Signaling’ (p = 6.83E-03), ‘G Protein Signaling 
Mediated by Tubby’ (p = 1.24E-02), ‘Serotonin Receptor Signaling’ (p = 1.72E-
02) and ‘UVB-Induced MAPK Signaling’ (p = 2.12E-02) were identified as 
canonical pathways of interest (Table 4.2C). IPA also identified DRD4, a 
dopamine receptor gene, to be the top upstream regulator of these twenty-seven 
genes. 
Similarly, IPA identified ‘Developmental Disorders’ (p = 4.03E-04-1.21E-
03) as a top disease associated with this gene set. In addition, ‘Cell Signaling’ (p 
= 4.03E-04-3.73E-02), ‘Nucleic Acid Metabolism’ (p = 4.03E-04-3.73E-02) and 
‘Gene Expression’ (p = 3.62E-03-9.63E-03) were the most significant molecular 
and cellular functions. Interestingly, ‘Nervous System Development and Function’ 
(p = 1.61E-03) and ‘Immune Cell Trafficking’ (p = 6.43E-03) were two top 
physiological systems related to this gene set. Further, Infectious Disease, 
Hereditary Disorders, Embryonic Development and Cell Death and Survival were 
associated network functions related to the differentially methylated gene set that 
overlapped in both schizophrenic twins. A full summary of the IPA results on 
these 27 genes can be found in Table 4.2C. 
When the 27 genes were analyzed using Enrichr (Chen et al., 2013), 
expression in whole brain was identified as the top human gene atlas finding. 
Enrichr also identified OMIM disease classifications related to neurodevelopment 
to be enriched in the gene list; these included Asperger’s Syndrome (p = 0.039) 
and Mental Retardation (p = 0.065).
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Figure 4.4. Manhattan plot representing methylation in the 15q11.2-15q12 region 
(Chr 15:17527952-25617776). 
This region spans from SNRPN to UBE3A and encompasses members of the 
SNORD115 and SNORD116 gene families. A red dot indicates an increase in 
methylation in the affected twin. A blue dot indicates a decrease in methylation in 
the affected twin. This region contains a complex regulatory ncRNA involved in 
imprinting control and neurodevelopment. 
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Figure 4.5. Manhattan plot representing methylation in the 1q21.1-1q21.3 region 
(Chr 1:143518837-152631162). 
This region includes many genes including the histone genes discussed in this 
report. A red dot indicates an increase in methylation in the affected twin. A blue 
dot indicates a decrease in methylation in the affected twin.  
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4.3.3 MZ twins discordant for schizophrenia have differentially methylated 
networks and pathways; some (i) Pair-specific and others (ii) Shared 
i. Pair-Specific Networks and Pathways 
IPA analysis on the DMRs identified in Family 1 implicates ‘Skeletal and 
Muscular Disorders’ (p = 9.34E-04-4.07E-02) as a top disorder. In addition, 
‘Cancer’ (p = 2.09E-04-4.07E-02), ‘Gastrointestinal Disease’ (p = 8.86E-04-
4.07E-02) and ‘Organismal Injury and Abnormalities’ (p = 9.34E-04-3.94E-02) 
were identified as top diseases or disorders overrepresented in Family 1. 
Similarly, in Family 2 the pathway analysis of DMR associated genes highlights 
‘Developmental Disorders’ (p = 3.93E-03-3.21E-02), ‘Hereditary Disorders’ (p = 
3.93E-03-4.58E-02), ‘Skeletal and Muscular Disorders’, (p = 3.93E-03-3.21E-02) 
and ‘Neurological Disease’ (p = 4.77E-03-3.54E-02) as top associated diseases 
and disorders (Table 4.2A and B). The analysis also identified a number of 
interesting canonical pathways in Family 1 including ‘Hepatic Cholestasis’ (p = 
1.05E-04), ‘Granzyme A Signaling’ (p = 1.51E-03) and the ‘STAT3 Pathway’ (p = 
3.31E-03). In Family 2, ‘Human Embryonic Stem Cell Pluripotency’ (p = 6.45E-
05), ‘Tec Kinase Signaling’ (p = 1.51E-04) and ‘IL-4 Signaling’ (p = 6.49E-03) 
were the top canonical pathways identified.  
Also, in Family 1, ‘Embryonic Development’ emerged as an 
overrepresented physiological system in the gene list (p = 1.88E-04-4.07E-02). In 
Family 2, the ‘Immune Cell Trafficking’ physiological system was identified by this 
analysis (p = 5.20E-03-4.13E-02).  
A number of additional pair-specific networks also emerged from this 
analysis of DMRs in each family including ‘Hereditary Disorder, Developmental 
Disorder’ in Family 2 and ‘Connective Tissue Development and Function’ in 
Family 1. 
These and other twin specific networks and functions can be found in 
Tables 4.2A and B. 
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Table 4.2. Ingenuity Pathway Analysis (IPA) results A) Family 1 B) Family 2 C) 
Subset of 27 genes found in both affected twins. 
 
4.2A. Family 1 
 
Associated Network Functions IPA Score 
Cell Death and Survival, Cellular Development, Connective 
Tissue Development and Function 
Score=39 
Cellular Movement, Immune Cell Trafficking, Hematological 
System Development and Function 
Score=12 
Cancer, Organismal Injury and Abnormalities, Reproductive 
System Disease 
Score=11 
Cell Death and Survival, Cellular Movement, Renal 
Necrosis/Cell Death 
Score=11 
Cell Morphology, Cellular Function and Maintenance, Cell Cycle Score=9 
Biological Function p-value Genes 
Physiological System Development and Function 
Cardiovascular System 
Development and Function 
1.88E-04 - 4.07E-02 10 
Digestive System 
Development and Function 
1.88E-04 2 
Embryonic Development 1.88E-04 - 4.07E-02 14 
Organ Development 1.88E-04 - 4.07E-02 6 
Molecular and Cellular Functions 
Lipid Metabolism 1.88E-04 - 4.07E-02 7 
Molecular Transport 1.88E-04 - 4.07E-02 9 
Small Molecule Biochemistry 1.88E-04 - 4.07E-02 19 
Cellular Growth and 
Proliferation 
3.06E-04 - 4.07E-02 21 
Cell Morphology 5.59E-04 - 3.63E-02 10 
Diseases and Disorders 
Cancer 2.09E-04 - 4.07E-02 204 
Gastrointestinal Disease 8.86E-04 - 4.07E-02 29 
Organismal Injury and 
Abnormalities 
9.34E-04 - 3.94E-02 46 
Skeletal and Muscular 
Disorders 
9.34E-04 - 4.07E-02 36 
Canonical Pathways 
Hepatic Cholestasis  1.05E-04 9/141 
(0.064) 
Granzyme A Signaling 1.51E-03 3/17 
(0.176) 
Ovarian Cancer Signaling 2.24E-03 7/138 
(0.051) 
STAT3 Pathway 3.31E-03 5/74 
(0.068) 
Colorectal Cancer Metastasis 
Signaling 
4.9E-03 9/244 
(0.037) 
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4.2B. Family 2 
Associated Network Functions IPA Score 
Cell Death and Survival, Cellular Movement, Cellular Function 
and Maintenance 
Score=19 
Cellular Movement, Immune Cell Trafficking, Hematological 
System Development and Function 
Score=17 
Hereditary Disorder, Skeletal and Muscular Disorders, 
Developmental Disorder 
Score=9 
Connective Tissue Disorders, Dermatological Diseases and 
Conditions, Hematological System Development and Function 
Score=2 
Organ Morphology, Reproductive System Development and 
Function, Cellular Function and Maintenance 
Score=2 
Biological Function p-value Genes 
Physiological System Development and Function 
Cardiovascular System 
Development and Function 
5.20E-03 - 3.58E-02 1 
Hair and Skin Development 
and Function 
5.20E-03 - 4.58E-02 2 
Hematological System 
Development and Function 
5.20E-03 - 4.13E-02 7 
Immune Cell Trafficking 5.20E-03 - 4.13E-02 3 
Molecular and Cellular Functions 
Carbohydrate Metabolism 7.88E-04 - 2.06E-02 3 
Lipid Metabolism 7.88E-04 - 2.06E-02 3 
Small Molecule Biochemistry 7.88E-04 - 4.58E-02 7 
Gene Expression 2.63E-03 - 4.58E-02 18 
Cell Death and Survival 5.20E-03 - 3.16E-02 13 
Diseases and Disorders 
Developmental Disorder 3.93E-03 - 3.21E-02 10 
Hereditary Disorder 3.93E-03 - 4.58E-02 19 
Skeletal and Muscular 
Disorders 
3.93E-03 - 3.21E-02 5 
Neurological Disease 4.77E-03 - 3.54E-02 13 
Canonical Pathways 
Human Embryonic Stem Cell 
Pluripotency 
6.45E-05 6/149 (0.04) 
Tec Kinase Signaling  1.51E-04 6/175 (0.034) 
Sphingosine-1-phosphate 
Signaling 
2.42E-03 4/115 (0.035) 
Renal Cell Carcinoma 
Signaling 
5.55E-03 3/71 (0.042) 
IL-4 Signaling  6.49E-03 3/75 (0.04) 
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4.2C. Shared Differentially Methylated Regions (DMRs) In Both Families 
Associated Network Functions IPA Score 
Cell Death and Survival, Cellular Function and Maintenance, 
Connective Tissue Development and Function 
Score=3 
Infectious Disease, Cancer, Gastrointestinal Disease Score=3 
Tissue Morphology, Organismal Survival, Gene Expression Score=3 
Hereditary Disorder, Gene Expression, Embryonic Development Score=3 
DNA Replication, Recombination, and Repair, Gene 
Expression, Cancer 
Score=3 
Biological Function p-value Genes 
Physiological System Development and Function 
Nervous System Development 
and Function 
1.61E-03 1 
Hematological System 
Development and Function 
6.43E-03 - 2.47E-02 1 
Immune Cell Trafficking 6.43E-03 1 
Behavior 2.04E-02 1 
Molecular and Cellular Functions 
Cell Signaling 4.03E-04 - 3.73E-02 1 
Nucleic Acid Metabolism 4.03E-04 - 3.73E-02 1 
Small Molecule Biochemistry 4.03E-04 - 3.73E-02 1 
Gene Expression 3.62E-03 - 9.63E-03 1 
Cellular Movement  6.43E-03 1 
Diseases and Disorders 
Cancer 4.03E-04 - 4.50E-02 5 
Connective Tissue Disorders 4.03E-04 - 8.05E-04 1 
Developmental Disorder 4.03E-04 - 1.21E-03 1 
Endocrine System Disorders 4.03E-04 - 4.50E-02 2 
Canonical Pathways 
Protein Kinase A Signaling 3.09E-04 3/368 (0.008) 
Granzyme A Signaling 6.83E-03 1/17 (0.059) 
G Protein Signaling Mediated 
by Tubby 
1.24E-02 1/31 (0.032) 
Serotonin Receptor Signaling 1.72E-02 1/43 (0.023) 
UVB-Induced MAPK Signaling 2.12E-02 1/53 (0.019) 
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ii. Shared Networks and Pathways 
When Ingenuity Pathways Analysis (IPA) was used on the independent 
gene sets identified in each family, some of the identified networks arose as top 
results in both families. This differs from the previous focus on 27 shared genes 
between families by focusing on the shared pathways that emerged from the 
independent gene lists (Figure 4.6). The shared pathways include a ‘Cell Death 
and Survival’ network (ratio of differentially methylated genes to total number of 
genes in the network was 9/35 and 12/35, in Family 1 and 2, respectively) 
(Figure 4.6a) and a ‘Cellular Movement and Immune Cell Trafficking’ network 
(ratio of differentially methylated genes to total number of genes in the network 
was 11/35 and 14/35 in Family 1 and 2, respectively) (Figure 4.6b). In Family 1, 
the ‘Cell Death and Survival’ network identified TP53 as the primary hub gene of 
the network, while in Family 2 IL1B was identified as the primary hub gene in this 
network. Similarly, the ‘Cellular Movement and Immune Cell Trafficking’ networks 
revealed IGF1R and EGFR as hub genes in Family 1 and TNF and IFNG as hub 
genes in Family 2.  
The disorder classification ‘Skeletal and Muscular Disorders’ was 
identified in both affected twins. Also, two shared molecular and cellular functions 
of interest were identified in both Family 1 and Family 2, namely ‘Lipid 
Metabolism’ (F1, p = 1.88E-04-4.07E-02; F2, p = 7.88E-04-2.06E-02) and Small 
Molecular Biochemistry (F1, p = 1.88E-04-4.07E-02; F1, p = 7.88E-04-4.58E-02).   ! !
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Figure 4.6. Common networks identified in both families. Legend for symbols 
can be found in Appendix L. 
a. 
!
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4.6a. Two ‘Cell Death and Survival’ networks independently identified in each 
affected twin in the study. Ingenuity Pathway Analysis (IPA) identified the 
networks in both affected twins in the study. Shading represents genes in this 
study that are differentially methylated.  
 
 
 
 
 
 
 
 
a. continued 
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b. 
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4.6b. Two ‘Cellular Movement and Immune Cell Trafficking’ networks 
independently identified in each affected twin in the study. Ingenuity Pathway 
Analysis (IPA) identified the networks in both affected twins in the study. Shading 
represents genes in this study that are differentially methylated. 
b. continued 
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4.4 Discussion 
The results included in this section show that a) monozygotic twins differ 
in DNA methylation, b) that this difference is genome-wide, c) that it includes a 
relatively large number of provisional de novo events, and d) with some 
exceptions, the differences are pair-specific. The results support the argument 
that de novo methylation changes are common during development and aging 
(Abdolmalcky et al., 2004; Wockner et al., 2014). Further, the results obtained in 
this report are specific to the two patients and will not necessarily cover the 
whole spectrum of the disease. Although the two MZD pairs for schizophrenia 
are unrelated, they share differences in DNA methylation in 27 genes and 
genomic locations. Also, the differentially methylated genes in each family affect 
two shared networks that are compatible with the development of this 
neurodevelopmental disease. Finally, the genes identified have the potential to 
explain the discordance of both twin pairs studied. The two patients share 
identified networks affecting cell death and immune cell trafficking. Of special 
interest to this discussion are (i) HIST genes primarily located on chromosome 1 
and (ii) SNORD115 and SNORD116 genes located on chromosome 15.  
 
i. HIST Genes 
It is noteworthy that my analysis identified 5 HIST genes as genes of 
interest in the discordance for schizophrenia. The histone coding gene family, 
has already been implicated in the causation of schizophrenia (Dempster et al., 
2011; Mill et al., 2008; Wockner et al., 2014). A Histone gene cluster on 
Chromosome 6p22.1 has also been implicated in a meta-analysis of 
schizophrenia associated loci in individuals of European ancestry (Shi et al., 
2009). In addition, altered histone methylation has been found in olfactory cells, 
implicating oxidative stress in schizophrenia (Kano et al., 2013). Lastly, post-
mortem brain tissue from schizophrenia patients has been found to have higher 
levels of histone deacetylase, HDAC1, and the level of HDAC1 has been shown 
to be inversely correlated with GAD67 protein expression, which tends to be 
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decreased in schizophrenia patients (Gavin and Sharma, 2010; Sharma et al., 
2008). Together, these results argue that histones may play a role in this 
complex disease. As mentioned, my observation on altered methylation of a 
HIST cluster follows previous reports and argues that this alteration may also 
contribute to the discordance of these two twin pairs for schizophrenia.  
 
ii. SNORD Genes 
The SNPRN-UBE3A locus, which encompasses the SNORD115 and 
SNORD116 gene families, is a complex non-coding RNA region that spans 
15q11-q13 (Runte et al., 2001). Noncoding RNAs, including miRNAs, are known 
to fine-tune gene expression through transcriptional and post-transcriptional 
regulations including RNA stability and protein translation (Gavin and Akbarian, 
2012). In addition to serving as an antisense RNA for UBE3A, the polycistronic 
transcript also undergoes extensive processing, including the production of a 
number of small nucleolar RNA species (snoRNAs). The HBII-52 snoRNAs (also 
known as the SNORD115 family) regulate the alternative splicing of the 5HTR2C 
serotonin receptor and result in an increased serotonin response in neurons 
(Leung et al., 2009). SNORD115 is further processed into processed snoRNAs 
(psnoRNAs) that go on to regulate alternative splicing in a number of other 
transcripts, including epigenomic modifiers (Kishore et al., 2010). However, a 
conflicting report emerged in 2012 that showed evidence against psnoRNAs, 
indicating that SNORD115 and SNORD116 may generate genuine snoRNAs 
(Bortolin-Cavaille and Cavaille, 2012). A novel ncRNA species, LncRNAs with 
snoRNA ends, also originates from this loci. They are functionally distinct from 
snoRNAs and lncRNAs and are associated with the FOX family of splicing 
regulators that alter the alternative splicing of a number of other genes. In 
addition to psnoRNAs, snoRNAs, and lnc-snoRNAs, the snoRNAs are even 
further processed into snoRNA-derived RNAs (sdRNAs). These sdRNAs are 
proposed to come in two variations: some resembling miRNAs that associate 
with argonaute proteins to regulate translation and another longer type that form 
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complexes to influence gene expression (Falaleeva and Stamm, 2013). Further 
investigation into the locus has shown that it produces even more ncRNA 
products, with the introns forming the snoRNA derivatives and the exons forming 
two distinct but overlapping neuronal lncRNA clouds from the SNORD115 and 
SNORD116 regions that are involved in modulating circadian rhythm and energy 
expenditure (Powell et al., 2013a, 2013b). The lncRNAs are functionally distinct 
from the earlier identified ncRNA species and are also primarily expressed in 
developing neurons (Powell et al., 2013a). 
Interestingly, the lncRNA from the SNPRN-UBE3A region has been 
suggested to regulate another imprinted locus, the DLK1-DIO3 region, which is 
the only other known imprinted cluster of ncRNA that produces lncRNA, miRNA, 
and snoRNA. It is also involved in neurodevelopment and suggests that 
imprinted ncRNAs are capable of ‘genomic cross-talk’ (Murrell, 2014; Stelzer et 
al., 2014). Interestingly, while imprinting disorders are known to originate from 
these loci, a highly resolved and restricted deletion in the SNORD116 region was 
identified as the minimal mutation to cause Prader-Willi Syndrome (Bieth et al., 
2014).  
Apart from the HIST and SNORD genes identified and discussed above, 
there are five other gene promoters that were differentially methylated in both 
families. These were PTPRN2, TTYH3, ZFP41, GNAS and XIST. PTPRN2 is a 
phosphatase that is thought to be involved in the regulation of insulin secretion. 
TTYH3 is a member of the Tweety family of proteins, which functions as a 
chloride anion channel. ZFP41 is a zinc finger protein; this class of proteins has 
been reported to be associated with psychosis and related disorders (Sun et al., 
2015). GNAS, an imprinted gene, has been previously associated with deficit 
schizophrenia in an Italian population (Minoretti et al., 2006). Lastly, XIST, on 
chromosome X, is essential for the initiation and spread of X-inactivation. 
Also, DRD4, which was identified as a top upstream regulator of the 
shared DMR gene set, has been previously implicated in schizophrenia, and is 
thought to be the target of many antipsychotics (Lai et al., 2010). 
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The identified networks across unrelated twins share common functions 
supporting the hypothesis that a different set of patient-specific gene insults may 
lead to disease symptoms. There has been a long held linkage between 
schizophrenia and immune cell function. This theory gained further support as 
novel functions of immune molecules in the brain and cross-talk between the 
immune system and the central nervous system (Debnath et al., 2013). In 
addition, a number of studies have shown up-regulation of immuno-inflammatory 
genes in the CNS (Debnath et al., 2013; Saetre et al., 2007; Soderlund et al., 
2009) as well as immune system gene modulation of synaptic function (Schmitt 
et al., 2011). In the ‘cellular movement and immune cell trafficking’ networks 
identified in Family 2, two genes (TNF and IFNG) immerged as hub genes. The 
tumor necrosis factor (TNF) had been associated with schizophrenia and it has 
also been reported that immune dysregulation could have a genetic component 
in schizophrenia patients (Boin et al., 2001). In addition, a single nucleotide 
polymorphism in the interferon gamma gene (IFNG) had been associated with 
paranoid schizophrenia in males (Paul-Samojedny et al., 2011), however, the 
role of these gene in the pathophysiology of the disease remains to be 
elucidated. Similarly, the other hub gene of the ‘cellular movement and immune 
cell trafficking’ network, EGFR, identified in Family 1 has also been previously 
associated with schizophrenia (Benzel et al., 2007). 
The human p53 tumor suppressor gene (TP53), which is identified as a 
primary hub gene in the ‘cell death and survival’ network of Family 1 in this study, 
plays a role in neurodevelopment and was previously associated with 
schizophrenia (Ni et al., 2005). Similarly, the primary hub gene in the ‘cell death 
and survival’ network, IL1B, which is differentially methylated in Family 2, has an 
important role in the development of the central nervous system. The IL1B gene 
is also reported to be associated with schizophrenia (Hanninen et al., 2008).  
Finally, the question of the effect of the observed DNA methylation on 
disease must be interpreted with caution. I may add that most schizophrenia 
patients are exposed to antipsychotic drugs in North America. The patients were 
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under treatment with medications, though not consistently. I note that such drugs 
and cellular heterogeneity of the studied samples (Liu et al., 2013) may also 
affect DNA methylation (Melka et al., 2014) as confounding factors. Further, 
although practical, I recognize the use of blood to make inferences regarding a 
brain-based disorder is not without caution and recommend that this discovery 
study be complemented by population studies of larger sample size on this 
disease as well as confirmation of the findings using alternative technologies. At 
this time, it is not possible to eliminate these and other confounding factors that 
may affect the results. The epigenetic changes I have identified would not 
necessarily be expected to remain stable over time nor continue to show 
specificity for pathways relevant to schizophrenia. However, the observations on 
genes and pathways relevant to the disease, lend support to the complexity of 
this neurodevelopmental disorder and its etiology. 
 
4.4.1 Conclusions 
I report genome-wide methylation differences between monozygotic twins 
discordant for schizophrenia. A number of genes and networks identified are twin 
pair-specific, while others are shared between two unrelated patients. 
Specifically, the results identify three sets of gene clusters, HIST (Chromosome 
1), SNORD115 and SNORD116 (Chromosome 15), which are differentially 
methylated in the two twins with schizophrenia as compared to their unaffected 
counterpart. I also report common networks identified independently in the two 
patients that relate to cell death/survival and immune cell trafficking networks 
disrupted in schizophrenia. The results on monozygotic discordant twins argue 
for a network based rather than gene focused approach in the understanding of 
schizophrenia and related disorders. !!
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A version of this chapter has been submitted for publication in Schizophrenia Research 
Chapter 5!- Integration of Genome-Wide DNA Sequence and DNA 
Methylation Changes in Two Unrelated Monozygotic Twin Pairs Discordant 
for Schizophrenia 
5.0 Overview 
Most genetic disorders are associated with aberrant functioning of genes 
and pathways that may be caused by a variety of mechanisms including 
sequence changes and aberrant expression caused by epigenetic change (which 
may arise from environmental factors). In this chapter, I have focused on genes 
that are affected by sequence changes between co-twins together with DNA 
methylation differences between co-twins (the most well studied epigenetic 
alteration). This approach focuses on genes that are variable and pathways that 
are affected by multiple mechanisms in the patient as compared to her 
unaffected monozygotic twin. The goal is to identify highly variable genes and 
pathways that may play a significant role in the development of schizophrenia in 
a specific patient. 
The dataset for this analysis uses the gene lists from the Affymetrix 
Human SNP 6.0 analysis (Chapter 2), the Complete Genomics Sequencing 
analysis (Chapter 3) and the MeDIP Microarray analysis (Chapter 4). It includes 
any gene that showed at least one sequence variant (in the case of the 
Affymetrix and Complete Genomics data) and at least one differentially 
methylated region (in the case of the MeDIP data) that was not shared with its 
co-twin. It has yielded patient-specific genes that differ between the affected twin 
and her unaffected matched monozygotic twin. This list of genes was used to 
model the development of schizophrenia in individual patients. This approach 
has become plausible with our ability to assess genetic and epigenetic variations 
in individuals, both completely and comprehensively. 
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5.1 Introduction 
Schizophrenia is a complex mental disorder with high heritability (80%), 
extensive genetic heterogeneity, environmental contributions and only 50% 
concordance in monozygotic (MZD) twins. The disappointing success in search 
of the causations of schizophrenia may be due to the limited scope of current 
lines of investigation that evaluate genetic, epigenetic or environmental 
contributors individually. They are not suited to fully unravel the complex 
interaction between DNA sequence as well as their epigenetic modifications. 
Integration across multiple “omic” datasets is now becoming an informative 
approach for unraveling complex disorders. In particular, evidence is emerging 
that epigenetic states may serve to directly mediate the relationship between 
certain genetic polymorphisms and phenotype (McVicker et al., 2013). The 
proportion of inter-individual variation in methylomes that may be driven by 
genotype as well as environment is currently unknown. What is known is that 
DNA methylation plays a critical role in the regulation of gene expression (Razin 
and Kantor, 2005). DNA methylation is one of the most well investigated 
epigenetic modifications and is involved in a number of critical biological 
processes including embryonic development, X-inactivation and imprinting. 
Individual differences in DNA methylation have been correlated with DNA 
sequence polymorphism, labeled as Methylation Quantitative Trait Loci 
(methQTLs) (Teh et al., 2014). As might be expected, genetic variants at CpG 
sites are able to alter methylation status at that site (Bell et al., 2011; Gertz et al., 
2011; Gibbs et al., 2010; Hellman and Chess, 2010). In addition, genotype at one 
SNV may affect methylation status at multiple neighbouring CpGs (Eckhardt et 
al., 2006; Zhi et al., 2013). Accordingly, in humans, inter-individual variation in 
DNA methylation could be a consequence of nucleotide polymorphism 
influencing methylation of cytosines, both directly and indirectly (Liu et al., 2013). 
In fact, methQTLs in adult adipose tissue have been shown to correlate with 19% 
of observed variance in methylation levels (Grundberg et al., 2013).  
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DNA variations leading to both methylation and expression variation at the 
same locus appear relatively rare but are reproducible findings (Wagner et al., 
2014). For example, Patel et al (2013) show that candidate SNP and CpG loci 
with marginal associations in GWAS and EWAS (Epigenome-Wide Association 
Studies) are correlated with type 2 diabetes (Patel et al., 2013). Also, a SNP 
within the IL4R gene combined with methylation at a CpG site within the same 
gene is predictive of childhood asthma risk (Soto-Ramírez et al., 2013). Further, 
widespread relationships exist between DNA methylation and gene expression 
especially in developmentally significant genes, including HOX clusters (Wagner 
et al., 2014). Additionally, recent studies describe evidence for gene by 
environment interactions on DNA methylation (Yousefi et al., 2013). This 
evidence is consistent with the emerging view that genotype can determine the 
degree of environmentally induced phenotypic plasticity via allele specific 
variation. In humans, where manipulative experiments are out of the question, a 
logical approach is the use of monozygotic twins.  
Combined with our ability to identify almost all genetic variation per 
individual, MZD twins provide an exceptional opportunity to assess patient 
specific changes that may account for the disease phenotype. A combined 
analysis of genetic and epigenetic changes on the same twin pairs is expected to 
provide a more effective approach for two reasons. First, it is now possible to 
generate relatively reliable complete genome sequences as well as promoter 
methylation states on an individual level and second, the unaffected twin that 
originated from the same zygote provides a near perfect genetic match for 
contrast and comparison. Here, I report on the joint analysis of sequence 
variations including structural changes (Complete Genomics Sequencing), and 
genome-wide DNA methylation (NimbleGen Human DNA Methylation 
Microarray) in two families with monozygotic twins discordant for schizophrenia. 
Monozygotic twins showed differences in DNA sequence as well as DNA 
methylation and some of these differences were co-localized. The results allow 
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consideration of the interaction of DNA methylation and sequence changes in 
schizophrenia.  
Specifically, results on family 1 show that 58 genes differ in DNA 
sequence as well as promoter methylation in a schizophrenia-affected twin as 
compared to her healthy co-twin. The corresponding number for family 2 was 13. 
The two lists are over represented by neuronal genes and include a number of 
known schizophrenia candidate genes and drug targets. The results argue that 
changes in multiple genes via co-localized genetic and epigenetic alteration 
contribute to a liability threshold that is necessary for development of 
schizophrenia. This novel hypothesis, although logical, remains to be validated. 
 
5.2 Methods 
The experiments performed received approval by the University of 
Western Ontario’s Committee on research involving human subjects. The 
families in the study provided written informed consent for participation. Once 
again, the capacity for consent was ensured using three measures 1) 
Schizophrenic patients gave consent only during a “normal” phase (no psychosis 
present), 2) Both twins of the twin pair were present and gave consent at the 
same time (the normal twin and their Schizophrenic sibling), and, 3) If Dr. 
O’Reilly felt that the capacity to consent was compromised, the patients were not 
included in the study. They were interviewed and clinically assessed by a single 
senior Psychiatrist (R. O’Reilly) using the SCID-I and SCID-II. A second senior 
psychiatrist independently reviewed videotapes of the structured interviews of the 
twins and confirmed the diagnoses. 
The two discordant twin pairs in this study were female monozygotic twins. 
The twins from Family 1 were Afro-American females aged 53 and the twins from 
Family 2 were Caucasian females aged 43. The affected member of twin pair 1 
was diagnosed with schizophrenia at age 22 and the affected member of twin 
pair 2 was diagnosed with schizoaffective disorder at age 27. The twins and their 
parents contributed whole blood samples for DNA isolation. DNA was extracted 
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from whole blood using the PerfectPure DNA Blood Kit (Gaithersburg, MD), 
following the manufacturer’s protocol. Zygosity was confirmed by Affymetrix 6.0 
microarray and specifically using the Affymetrix Genotyping Console 4.0 
concordance feature. 
As fully described in Chapter 2B, whole genome microarray analysis using 
the Affymetrix Genome-Wide Human SNP Array 6.0 was performed at the 
London Regional Genomics Centre (LRGC) following the manufacturer’s 
protocol. For downstream analysis of CEL files, Affymetrix Genotyping Console 
4.1.1 (A), Partek Genomics Suite (P), and PennCNV (p) were used. Only variants 
that were greater than 1 kb in size were classified as CNVs for the purposes of 
this study and only those identified by all three software programs in the same 
individual were included in subsequent analysis. Calls were merged if they were 
adjacent (gap ≤ 20% and of the same gain/loss state) and overlapping calls were 
identified as such both between programs and between subjects using a 50% 
reciprocal overlap rule. !
As fully described in Chapter 3, the genome sequence of the twin pairs 
was generated at Complete Genomics Inc. (Mountain View, CA). The sequences 
met the criteria of high accuracy (99.999%) and were considered suitable for 
identification of rare variants including somatic mutations as described by 
Drmanac et al (Drmanac et al., 2010). These variants included single nucleotide 
variants (SNVs), indels and block substitutions as well as larger variants 
classified as Copy Number Variants (CNVs) and Structural Variants (SVs) that 
were called in comparison to reference sequence (NCBI Build 37/hg19). A read 
depth of 50 and a call quality of 100 (calculated by complete genomics and 
based on a phred scale) were chosen as parameters for initial variant filtering. !
As fully described in Chapter 4, I assessed genome-wide methylation in 
the two twin pairs using the NimbleGen Methylation Promoter Microarray. The 
NimbleGen Human DNA Methylation 720k CpG Island Plus RefSeq Promoter 
Microarray is a multiplex slide with 3 identical arrays per slide. Each Roche 
Nimblegen Inc (Madison, MI) array covers 27,728 annotated CpG islands as well 
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as 22,532 promoters of the RefSeq genes derived from the UCSC RefFlat files. 
Briefly, the pair files were analyzed with the tiling workflow in Partek Genomics 
Suite version 6.6 (St. Louis, Missouri). Genes that overlapped differentially 
methylated regions were annotated.  
 
5.2.4 Annotation and candidate gene analysis 
This analysis is based on within-pair differences between two pairs of 
monozygotic twins discordant for schizophrenia. It included a DNA microarray, 
complete genome sequence features as well as a genome-wide DNA promoter 
methylation microarray. The results identified gene specific sequence differences 
that are associated with corresponding differences in DNA methylation. I have 
annotated the genes identified with two features: schizophrenia related candidate 
genes published in the literature and gene ontology. 
First, OMIM (omim.org) and SZGene (szgene.com) databases were 
chosen as the starting point for this analysis. Second, three primary articles were 
chosen on the basis of three main criteria: 1. They were published in a reputable 
journal (impact factor >15), 2. They included large sample sizes (>2,500 cases) 
and 3. They were published within the last six years. It included three GWAS 
studies (Ayalew et al., 2012; Ripke et al., 2014; Stefansson et al., 2009). Genes 
overlapping in at least two of the five literature/database sources were compiled 
into a list of candidate genes to be evaluated in this analysis (34 genes).  
Second, I used Ingenuity Variant Analysis (QIAGEN; Redwood City, CA) 
to annotate the gene lists with links to schizophrenia or neurological disease and 
related functions. Genes had to have a direct connection to these phenotypes 
(no hops allowed). Genes were also annotated with direction of methylation, 
imprinting database information (http://www.geneimprint.com/ and 
http://igc.otago.ac.nz/), variation type, position, breakpoints, reference calls, gene 
region identity of variant, SIFT functional prediction, PolyPhen-2 functional 
prediction, call quality, read depth, dbSNP entry, 1000 genomes frequency and 
complete genomics public genomes frequency.  
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5.3 Results 
5.3.1 Twin Pair 1 
Table 5.1 presents a list of 58 genes that showed changes in DNA 
sequence as well as DNA methylation between the members of twin pair 1 
(Figure 5.1). The observed sequence differences include insertions, deletions, 
substitutions, single nucleotide variants (SNVs) and tandem duplications, most of 
which are associated with intronic or intergenic sequences. Of special interest 
are sequence differences in the FAM120B and ZNF717 genes that are located in 
exonic regions. Also, OR6B3 has a sequence difference in the promoter region 
and ZNF717 and AHRR show differences in the 3’UTR regions. Additionally, 
SNV and substitutions were observed in the 5’ UTR region of the HNRNPCL1 
gene and six sequence differences were found in the exonic regions of the 
ZNF717 gene that were characterized as missense mutations (Appendix H).  
As shown in Table 5.1, a number of genes in this list are related to drug 
response in schizophrenia or have been previously implicated in psychosis. 
These include GABRB3, OPRD1, RXRA and SCN5A. Besides sequence 
changes, these genes also showed decreased methylation in their promoter 
regions. Specifically, GABRB3 and OPRD1 harbor insertions, RXRA has a multi 
base-pair substitution and SCN5A has a single nucleotide variant, all of which 
are intronic. Yet another feature of the 58 genes is that 30 of them have an 
increase and 28 of them have a decrease in methylation in their promoter region 
in the affected twin as compared to their unaffected co-twin (Table 5.1). 
Interestingly, ANKLE2, SNORD115-29 (an imprinted gene) and TSNARE1 are 
differentially methylated in both the mother and father (Appendix I). Table 5.1 
also shows that among the 30 genes that had increased methylation in the 
patient, CACNA1B, DIP2C and RASA3 are also differentially methylated in the 
father (Appendix I). Next, I used the 58 genes in Ingenuity Pathway analysis 
(Table 5.2). The results show that among the most significant findings are ‘PPAR 
signaling’ (p=2.52E-03), ‘neurological diseases’ (p=2.04E-05 - 4.71E-02) and 
‘psychological disorders’ (p=2.77E-05 - 4.71E-02). Interestingly, they affected a 
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number of molecular and cellular pathways including ‘cell-to-cell signaling and 
interaction’ (p=2.55E-03 - 3.26E-02), ‘molecular transport’ (p=2.55E-03 - 4.13E-
02) and ‘cell cycle’ (p=3.01E-03 - 6.01E-03).  
Among the genes affected by sequence variations in Family 1, eight of 
them have been implicated in schizophrenia (Figure 5.1). The specific features of 
the mutations associated with the eight genes are detailed in Table 5.3. It shows 
that four de novo events affect DISC1, all confined to introns, of which three 
(dbSNP: rs821635, rs116832039 and rs200784958) represent polymorphisms 
and one represents a rare event (Chr 1: 231868731). Six of the other 
schizophrenia gene variations also differ in common polymorphisms and may or 
may not be relevant to disease (DRD3, GRIA1, GRIN2B, DTNBP1, DGKI, and 
NLGN4X). The remaining difference is a deletion in the intronic region of FXR1 
(Chr 3:180657418) that is a rare event and may contribute to disease 
discordance (Table 5.3). 
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Figure 5.1. Differences between the MZD pair in Family 1 in sequence changes 
(1896) and changes in DNA methylation (330).
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Table 5.1. Genes (58) affected by de novo methylation and de novo sequence changes in Family 1. 
Gene  Neurological Function (from IVA) Methylation  
Result 
NGS Variation 
Type 
NGS Gene 
Region 
Affected 
ABCG8 No known neurological function Decrease SNV Intronic 
ACSM5 Mutant human ACSM5 gene is associated with CTCAE grade 
4 astrocytoma in human brain. 
Increase Insertion Intronic 
ADARB2 Mutant human ADARB2 gene (rs7073579) is observed with 
sleepiness in human (unknown geographic location). Mutant 
human ADAR3 [ADARB2] protein is observed with early-onset 
obsessive-compulsive disorder in humans. 
Increase SNV Intronic 
AHRR Mutant human AHRR gene (germline c.505C>G) is observed 
with autism spectrum disorder in humans. 
Increase Insertion Intronic 
ANKLE2 No known neurological function Increase Substitution Intronic 
ATP6V1E1 Downregulation of human ATP6V1E1 mRNA in substantia 
nigra from human is associated with Parkinson's disease in 
human. 
Decrease Substitution Intronic 
BANP Upregulation of human BANP mRNA in vastus lateralis muscle 
is associated with Huntington's disease in human. 
Increase Deletion Intronic 
C7orf50 No known neurological function Increase SNV Intronic 
CACNA1B Mutant human CACNA1B gene (germline c.5199G>A) is 
observed with schizophrenia in human. 
Increase SNV Intronic 
CAMTA1 Downregulation of human CAMTA1 mRNA in peritumoral white 
matter is associated with glioblastoma in human. 
Mutant human CAMTA1 gene is associated with 
nonprogressive cerebellar ataxia with mental retardation. 
Decrease SNV Intronic 
CBFA2T3 No known neurological function Decrease SNV Intronic 
CD2AP Mutant human CD2AP gene (SNP substitution mutation 
(rs9349407)) is associated with Alzheimer's disease in human. 
Decrease Deletion Intronic 
CLN6 Change of function germline mutant human CLN6 gene is 
observed with childhood-onset recessive variant late-infantile 
neuronal ceroid-lipofuscinosis in human. 
Decrease Insertion Intronic 
CNPY1 No known neurological function Increase Substitution Intronic 
COL20A1 No known neurological function Decrease Deletion Intronic 
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CSMD2 Mutant human CSMD2 gene (germline c.6329A>G) is 
observed with schizophrenia in humans. 
Decrease Deletion Intronic 
DFFB No known neurological function Decrease Tandem 
Duplication 
N/A 
DIP2C Mutant human DIP2C gene (germline c.1969dupG) is 
observed with autism in human. Upregulation of human 
KIAA0934 [DIP2C] mRNA in Brodmann's area 10 from 
prefrontal cortex is associated with major depression in adult 
human. Mutant human DIP2C protein (rs10904051) is 
observed with early-onset obsessive-compulsive disorder in 
human. 
Increase Substitution Intronic 
DVL1 No known neurological function Decrease Tandem 
Duplication 
N/A 
EXOC2 No known neurological function Increase Deletion Intronic 
FAM120B Mutant human FAM120B gene (germline c.1178C>G 
(rs200873057)) is observed with autism spectrum disorder in 
human. 
Increase SNV Exonic; 
Intronic 
GABRB3 Olanzapine, an antagonist of human GABRB3 protein -l for the 
treatment of schizophrenia in human. 
Muscimol, an agonist of human GABRB3 protein, has been 
approved for the treatment of schizophrenia. 
Decrease Insertion Intronic 
GRID2IP Downregulation of mouse Delphilin [Grid2ip] mRNA in 
cerebellum is associated with purkinje cell degeneration in 
mouse. 
Decrease SNV Intronic 
HMHA1 Mutant human HMHA1 gene (germline c.1577T>C) is 
observed with autism in human. 
Decrease Deletion Intronic 
HNF1A Loss-of-function change of function heterozygous germline 
mutant human HNF1A protein (p.M626K) is observed with mild 
mental retardation in humans. 
Germline mutant human HNF1A protein (p.G574S) is observed 
with diabetic neuropathy in humans. 
Decrease Substitution Intronic 
HNRNPCP5 Mutant human HNRNPCL1 gene (SNP substitution mutation, 
allelic variations: A/G (rs1856638)) is associated with bipolar 
affective disorder in human. 
Increase Substitution; 
SNV 
Intronic; 5'UTR 
IL1RAPL2 In mouse, homozygous mutant mouse Il1r gene(s) (knockout) 
decreases experimental autoimmune encephalomyelitis in 
mouse. 
Increase SNV Intronic 
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KATNAL2 Mutant human KATNAL2 gene (germline c.510+1G>A) is 
observed with autism in human. 
Increase SNV Intronic 
KAZN Downregulation of mouse W84167 [Kazn] mRNA in striatum 
from brain is associated with Huntington's disease in 6 week-
old r6/2 mouse. 
Increase SNV Intronic 
KIAA1751 No known neurological function Increase Tandem 
Duplication 
N/A 
MAD1L1 No known neurological function Increase SNV Intronic 
MYT1L Mutant human MYT1L gene (germline c.2636+1G>A) is 
observed with intellectual disability in human. Downregulation 
of human MYT1L mRNA in caudate is associated with 
Huntington's disease in human. 
Increase Substitution; 
Deletion 
Intronic; N/A 
NFATC1 No known neurological function Increase Substitution Intronic 
NGFR Mutant human NGFR gene (germline c.364T>C) is observed 
with intellectual disability in human. Mutant human NGFR gene 
(common germline c.614C>T (rs2072446)) is associated with 
familial Alzheimer's disease in human. 
Decrease Substitution Intronic 
OBSCN Mutant human OBSCN gene (germline c.6839G>A 
(rs562143677)) is observed with schizophrenia in human. 
Decrease Insertion Intronic 
OCA2 No known neurological function Decrease Deletion Intronic 
OPRD1 Naltrexone, an antagonist of human OPRD1 protein, has been 
approved for the treatment of schizophrenia. Mutant human 
OPRD1 gene (allelic variations: C/T (rs678849)) is associated 
with amyotrophic lateral sclerosis in humans. 
Decrease Insertion Intronic 
OR6B3 No known neurological function Increase SNV Promoter 
PPP1R13L No known neurological function Decrease SNV Intronic 
PRKAR1B Blockade of active mouse Pka complex(es) prevents loss of 
cholinergic fibers in lesioned ipsilateral region cerebral cortex 
from mouse missing a ovary that is decreased by injection of 
E2 [beta-estradiol]. 
Decrease Insertion; 
Tandem 
Duplication 
Intronic; N/A 
PTPRN2 Downregulation of human PTPRN2 mRNA in clonal cultured T 
lymphocytes is associated with Rett syndrome in humans. 
Increase SNV Intronic 
RAB40C No known neurological function Increase SNV Intronic 
RASA3 No known neurological function Increase SNV Intronic 
RPH3AL No known neurological function Increase SNV Intronic 
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RPTOR In mouse oligodendrocytes, homozygous mutant mouse 
Raptor [Rptor] gene increases dysmyelination in mouse spinal 
cord dorsal column. 
In neuronal progenitor cells from 17.5-19.5 day-old embryonic 
mouse of CNS, homozygous mutant mouse Rptor gene 
(knockout) increases microencephaly in 17.5-19.5 day-old 
embryonic mouse. 
Decrease SNV Intronic 
RXRA Bexarotene, an activator of human RXRA protein, is in Phase 
III clinical trial for the treatment of schizophrenia in human 
(Bexarotene). 
Upregulation of human Rxr protein(s) in brain from human is 
associated with Alzheimer's disease in human. 
Decrease Substitution Intronic 
SCN5A Gain-of-function germline mutant human SCN5A protein 
(p.R800L, alternately c.2399G>T) is observed with 
schizophrenia in human (Caucasian). 
Oxcarbazepine, an inhibitor of human SCN5A protein, is in 
Phase 2/Phase 3 clinical trial for the treatment of schizophrenia 
in human. 
Decrease SNV Intronic 
SHOX No known neurological function Decrease SNV Intronic 
SLC4A3 In 129S1/Sv * 129X1/SvJ * C57BL/6 mouse, homozygous 
mutant mouse Slc4a3 gene (allele 
Slc4a3tm1Cahb/Slc4a3tm1Cahb) (knockout) increases 
seizures in mice. 
Decrease Deletion Intronic 
SLC6A3 Mutant human DAT [SLC6A3] gene is associated with 
schizophrenia in human. 
Modafinil, an inhibitor of human SLC6A3 protein, is in Phase IV 
clinical trial for the treatment of schizophrenia in human. 
Sibutramine, an inhibitor of human SLC6A3 protein, is in 
Phase IV clinical trial for the treatment of schizophrenia in 
human.  
Increase Insertion Intronic 
SNORD115-29 No known neurological function Increase Tandem 
Duplication 
N/A 
SNX29 No known neurological function Increase Insertion Intronic 
STXBP2 No known neurological function Decrease SNV Intronic 
TMEM255B No known neurological function Decrease SNV Intronic 
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TRAPPC9 Mutant human TRAPPC9 gene (germline c.3203G>A) is 
observed with schizophrenia in human. Mutant human 
TRAPPC9 gene (germline c.1708C>T (rs267607137)) 
increases the risk of autosomal recessive nonsyndromic 
mental retardation in human. 
Decrease Substitution Intronic 
TSNARE1 No known neurological function Increase Insertion Intronic 
TSSC1 No known neurological function Increase SNV Intronic 
ZNF717 No known neurological function Increase SNV; 
Substitution; 
Deletion; 
Insertion 
Exonic; 
Intronic 
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Table 5.2. Ingenuity Pathway Analysis results showing the most significant pathways and networks for co-localized 
sequence variations and promoter methylation differences in Family 1. 
Diseases and disorders  # of molecules 
Neurological Disease 2.04E-05 - 4.71E-02 18 
Skeletal and Muscular Disorders 2.76E-05 - 3.91E-02 15 
Psychological Disorders 2.77E-05 - 4.71E-02 12 
Molecular and Cellular Functions  # of molecules 
Cell-To-Cell Signaling and Interaction 2.55E-03 - 3.26E-02 5 
Molecular Transport 2.55E-03 - 4.13E-02 10 
Small Molecule Biochemistry 2.55E-03 - 4.42E-02 8 
Cell Cycle 3.01E-03 - 6.01E-03 2 
Cell Morphology 3.01E-03 - 1.50E-02 2 
Top networks Score 
Tissue morphology, cell death and survival 7 
Neurological diseases 2 
Canonical pathways p-value Ratio 
Hepatic Cholestasis 7.76E-06 6/158 (0.038) 
Role of Osteoblasts, Osteoclasts and 
Chondrocytes in Rheumatoid Arthritis 4.54E-04 5/214 (0.023) 
LXR/RXR Activation 4.81E-04 4/121 (0.033) 
Role of Macrophages, Fibroblasts and Endothelial 
Cells in Rheumatoid Arthritis 1.69E-03 5/287 (0.017) 
PPAR Signaling 2.52E-03 3/90 (0.033) 
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5.3.2 Twin Pair 2 
Figure 5.2 includes a number of genes that differ for sequence changes 
and methylation differences between the members of twin pair 2. The observed 
sequence differences included insertions, deletions, substitutions and SNVs. 
Once again, most of these differences are confined to introns or intergenic 
regions. In total, 13 genes are affected by both mechanisms; sequence change 
and DNA methylation. The specific features of the 13 genes are detailed in Table 
5.4. It shows that only the MUC4 and UBTFL1 genes contained sequence 
differences in exonic regions and that AK2 has a sequence difference in the 
3’UTR region (Appendix J).  
Two of the genes identified in Family 2 have been previously related to 
schizophrenia. These include SORBS2 and RBFOX1 that showed increased 
methylation in their promoter regions and corresponding de novo sequence 
variations in the affected twin (Table 5.4). Specifically, SORBS2 harbors a 13 bp 
insertion and a single base pair substitution; similarly RBFOX1 harbors 8 
sequence variations in intronic regions throughout the gene comprising small 
sequence deletions, substitutions and single base pair variants (Appendix J). 
Yet another feature of the 13 genes is that 11 of them have an increase 
and 2 of them (BCOR and PLEC) have a decrease in methylation in their 
promoter region in the affected twin as compared to their unaffected co-twin 
(Table 5.4). Interestingly, BCOR and PLEC were also differentially methylated in 
both Mom and Dad of twin pair 2 (Appendix K). In addition, one of the 13 genes, 
PRDM16, is an imprinted gene (http://www.geneimprint.com). Ingenuity Pathway 
Analysis using the 13 genes did not yield any statistically significant pathways or 
networks of interest, likely due to the small number of genes inputted. 
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Table 5.3. De novo sequence variations in the affected twin in Family 1 which have been previously associated 
with schizophrenia. (NCBI Build 37/hg19) 
Chr Start Gene Ref Affected Twin Type 
Gene 
Region dbSNP ID 
1000 
Genomes 
Frequency 
CG 
Genomes 
Frequency 
1 231868731 DISC1  
TAGGAGTGGTG
GTGGTGATGA Insertion Intronic    
1 231869328 DISC1 G A SNV Intronic 116832039   
1 232006400 DISC1  C Insertion Intronic 200784958 1.38 0.92 
1 232149541 DISC1 C T SNV Intronic 821635 38.56 33.33 
3 113852521 DRD3 T A SNV Intronic 12491384  42.59 
3 180657418 FXR1 AG  Deletion Intronic    
5 152929315 GRIA1 AGATC TT Substitution Intronic 386693748  23.14 
6 15636417 DTNBP1  CTCT Insertion Intronic 58627855   
7 137140536 DGKI G A SNV Intronic 2351386 62.4 63.88 
12 13779752 GRIN2B  T Insertion Intronic 151115453 86.38 76.85 
X 5952756 NLGN4X T G SNV Intronic 10284218   
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Figure 5.2. Differences between the MZD pair in Family 2 in sequence changes 
(1682) and changes in DNA methylation (138). 
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Among the genes affected by sequence variations only in Family 2, seven 
of them have been previously implicated in schizophrenia (Figure 5.2). The 
specific features of the mutations associated with the seven genes are listed in 
Table 5.5. It shows that three de novo events affect SLC1A2, all confined to 
introns, of which all have been found in dbSNP and represent polymorphisms 
(dbSNP: rs4755399, rs4755400, rs386752435). Four of the other variations in 
schizophrenia genes between affected and unaffected twins of this family also 
differ in well-known polymorphisms and may or may not be relevant to disease 
(DRD3, IMMP2L, NRG1, DISC1). I note that the remaining differences include 
two rare changes affecting DGK1 (Chr 7: 137483119) with a three base-pair 
intronic substitution, and DAOA (Chr 13: 106118100), which has a unique 
deletion in its promoter region. These rare variations may partially explain 
disease discordance in this family (Table 5.5).  
 
5.3.3 Twin Pair 1 and Twin Pair 2 
The results have also allowed me to assess sharing of changes seen in 
the two patients from two different MZD twin pairs. This analysis has identified 
one gene, PTPRN2. Here, the two patients harbor unique sequence variants in 
their intronic sequences as well as increased methylation of the promoter region 
of this gene.  
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Table 5.4. Genes (13) affected by de novo methylation and de novo sequence changes in Family 2. 
Gene Neurological Function (from IVA) Methylation 
Result 
NGS 
Variation 
Type 
NGS 
Gene 
Region 
Affected 
AK2 Downregulation of human AK2 mRNA in prefrontal cortex is 
associated with bipolar disorder in human. 
Increase SNV ncRNA; 
3'UTR 
BCOR Somatic mutant human BCOR gene is associated with 
medulloblastoma in human. 
Decrease Insertion Intronic 
KCNT1 Heterozygous de novo mutant human KCNT1 protein (p.R428Q, 
alternately c.1283G>A) is observed with malignant migrating partial 
seizures of infancy syndrome in human (France). 
Germline mutant human KCNT1 gene (c.2800G>A (rs397515403)) 
increases early infantile epileptic encephalopathy type 14 in human. 
Increase Deletion Intronic 
MUC4 Mutant human MUC4 gene (silent somatic c.6783C>T translating to 
p.D2261D) is associated with neuroblastoma in human autonomic 
ganglion (observed in 2 of 238 samples). 
Increase SNV Intronic; 
Exonic 
PLEC Germline mutant human PLEC1 [PLEC] protein (frameshift 
p.E4015Gfs*69, alternately c.12043dupG) is observed with 
childhood-onset myasthenic syndrome in human (African 
American). 
Decrease Insertion Intronic 
PRDM16 Mutant human PRDM16 gene (rs2651899) is observed with 
migraine with aura in human 
Increase Deletion Intronic 
PTPRN2 Downregulation of human PTPRN2 mRNA in clonal cultured T 
lymphocytes is associated with Rett syndrome in human.  
Increase Substitution; 
Deletion 
Intronic; 
N/A 
RBFOX1 Mutant human A2BP1 [RBFOX1] gene is associated with sporadic 
schizophrenia in male human. 
Downregulation of human A2BP1 [RBFOX1] mRNA in caudate 
nucleus from brain is associated with Huntington's disease in 
human. Mutant human A2BP1 [RBFOX1] gene is observed with 
childhood-onset autism in human. 
Increase Deletion Intronic 
RSU1 Downregulation of human RSP-1 [RSU1] mRNA in Brodmann's 
area 10 from prefrontal cortex is associated with major depression 
in adult human. 
Increase SNV Intronic 
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SETD5 Mutant human SETD5 gene increases the risk of intellectual 
disability in human. Mutant human SETD5 gene (germline 
c.1405G>A) is observed with autism in human. 
Increase Deletion Intronic 
SORBS2 Mutant human SORBS2 gene (germline c.2451G>T) is observed 
with schizophrenia in human. 
Increase Insertion Intronic 
TENM2 Mutant human TENM2 gene is associated with glioma in human 
brain (observed in 5 of 268 samples). 
Mutant human TENM2 gene is associated with CTCAE grade 4 
astrocytoma in human brain (observed in 6 of 298 samples). 
Increase Insertion Intronic 
UBTFL1 No known neurological function Increase SNV Exonic 
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Table 5.5. De novo sequence variations in the affected twin in Family 2 which have been previously associated 
with schizophrenia. (NCBI Build 37/hg19) 
 
 
Chr Start Gene Ref Affected 
Twin 
Type Gene 
Region 
dbSNP ID 1000 
Genomes 
Project 
CG 
Genomes 
Frequency 
1 232167072 DISC1  AAAGGA Insertion Intronic 147764269  7.4 
3 113883058 DRD3 C A SNV Intronic 111248254 32.13 35.18 
7 110651008 IMMP2L G  Deletion Intronic 59572830 31.67 33.33 
7 137483119 DGK1 CC ACA Substitution Intronic    
8 32170561 NRG1 C T SNV Intronic 4336564 27.06 26.85 
11 35425416 SLC1A2 T A SNV Intronic 4755399  30.55 
11 35425423 SLC1A2 T C SNV Intronic 4755400  31.48 
11 35425428 SLC1A2 TAA GGC Substitution Intronic 386752435  37.97 
13 106118100 DAOA GTATCCA  Deletion Promoter    
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5.4 Discussion 
The results included in this chapter identify almost all genes that differ 
between the affected and unaffected members of two monozygotic twin pairs 
discordant for schizophrenia. These genes harbor sequence differences as well 
as differences in DNA promoter methylation between MZD twins. The results 
highlight four insights. First, MZ twins differ in rare DNA sequences as well as 
DNA methylation caused by de novo events. Second, some genes that are 
affected by differential promoter methylation between MZD twins also harbor 
various types of sequence variations between the same twins. These genes may 
be viewed as highly variable in structure and expression, where some of the 
variation may represent de novo events. Third, a number of the changes 
identified are in known candidate genes for schizophrenia. Therefore, the genes 
affected in this study may contribute to neuropsychiatric disorders, particularly 
schizophrenia. Additionally, when the DNA sequence differences are analyzed 
independently, additional previously identified schizophrenia candidate genes 
arise. The latter finding may be due to the fact that most candidate genes 
reported to date have been identified by their differences in DNA sequences. 
Finally, the comprehensive data on all possible sequence and methylation 
differences between an affected and unaffected monozygotic twin pair is 
compatible with a threshold model for this complex disease (Hennah et al., 2009; 
McGue et al., 1983). Specifically, it may explain the etiology of schizophrenia in a 
given patient. In the threshold model, any sequence variation or promoter 
methylation not shared between the patient and her healthy co-twin is labeled as 
a potential predisposing factor for the disease. An accumulation of predisposing 
factors and additional factors would lead to the critical threshold of variation 
necessary for disease manifestation. The results on the two patients in this report 
are encouraging and support this assertion.  
In Family 1, 32 of the 58 genes with co-localized sequence and 
methylation differences are implicated in neurologically related functions, 
including schizophrenia. This overrepresentation of neurological genes in this list 
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is highly suggestive. Specifically, I identified patient-specific pathways, such as 
‘PPAR signaling pathway’ (p=2.52E-03). In addition, I found that ‘Neurological 
Diseases’ (p=2.04E-05 - 4.71E-02) and ‘Psychological Disorders’ (p=2.77E-05 - 
4.71E-02) were two of the top three diseases and disorders identified. Further to 
the pathways identified, it also includes a number of genes that have been the 
focus of attention in studies on neurodevelopmental disorders including 
schizophrenia. In fact, a number of them have been specifically implicated in the 
features that separate the affected and healthy members of this twin pair. For 
example, SNORD115 is differently methylated in this twin pair and also has an 
observed de novo CNV difference that covers this gene. Functionally, 
SNORD115 changes the alternative splicing of the serotonin receptor 2C pre-
mRNA, a receptor that is known to be involved in mental disorders including 
autism and schizophrenia (Feinberg et al., 2015; Kishore et al., 2010). Yet 
another example is the sequence variations and altered promoter methylations 
observed in GABRB3 in this study. This gene is known to be involved in a 
number of mental disorders including schizophrenia. De novo mutations in 
GABRB3 have been reported in panic disorders (Hodges et al., 2014) and 
intellectual disability (Hamdan et al., 2014). Also, olanzapine, an antagonist of 
human GABRB3 protein and pregnenolone, an inhibitor of human GABRB3, 
have been used in the treatment of schizophrenia and bipolar/major depressive 
disorder, respectively (Mosby, 2003). Additionally, the genomic region that 
harbors SNORD115 and GABRB3 (15q11) has been shown to have strong 
genetic and epigenetic underpinning for simultaneous presentation of Prader-
Willi syndrome (PWS) and psychosis (Krefft et al., 2014).  
Similarly in Family 1, a de novo sequence variation (insertion) was 
observed in the opioid receptor gene, OPRD1, in this study. Naltrexone, an 
antagonist of human OPRD1 protein, is a schizophrenia drug (Mosby, 2003) and 
mutant human OPRD1 gene was found to be associated with amyotrophic lateral 
sclerosis in human, which is a fatal neurological disorder that attacks neurons 
(Lin et al., 1995).  
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Support from the literature is also provided for a number of other systems 
affected in twin pair 1 including GABAergic signaling molecules (Fujimori and 
Yoneda, 2004) and oxcarbazepine, an inhibitor of human SCN5A protein that is 
in clinical trials to treat schizophrenia (http://clinicaltrials.gov/). Moreover, loss-of-
function germline mutant human SCN5A protein has been implicated in 
schizophrenia in a Caucasian population (Hu et al., 2013). The RXRA gene is 
also a target of Bexarotene, a schizophrenia drug (Xiong et al., 2008). Therefore, 
the disease state of the patient in this study could be hypothesized to reach the 
disease threshold by some or all of the changes in sequence variations and DNA 
methylations observed in the patient as compared to her unaffected MZ twin 
sister. 
The conclusions are also compatible with observations on Family 2 that 
has yielded 13 genes that carry differences in DNA sequences and promoter 
methylations in the affected as compared to unaffected MZD twin discordant for 
schizophrenia. Twelve of the 13 genes identified are involved in neurological 
functions and abnormalities including schizophrenia. Although the number of 
genes affected is not sufficient to assess them in pathway analysis, gene specific 
functions further support their potential involvement in schizophrenia. For 
example, BCOR, that carries an insertion and hypermethylation of its promoter in 
the patient has been shown to form a complex (BCL6/BCOR/SIRT1) which 
serves as a potent repressor of the SHH pathway in neural development (Tiberi 
et al., 2014). Further, BCOR specific class I and II histone deacetylases (HDACs) 
have been shown to interact with this protein, which suggests a possible link 
between the two classes of HDACs.  
Of particular relevance is Disrupted-in-Schizophrenia-1 (DISC1) that 
harbors an insertion in the patient of Family 2 as well as an insertion and SNV in 
the patient of Family 1. DISC1 is known to be involved in cell proliferation, 
differentiation, and migration as well as neuronal axon and dendrite outgrowth 
(Ozeki et al., 2003). This gene is also involved in neural development and has an 
established role in the etiology of schizophrenia (Tohyama et al., 2015). 
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Furthermore, other genes implicated in schizophrenia include DRD3 (Dai et al., 
2014) and DAOA (Bass et al., 2009; Muller et al., 2011; Prata et al., 2008; Shi et 
al., 2009).  
Interestingly, I found both sequence and methylation changes in the 
PTPRN2 gene in both patients. This gene is thought to be a protein tyrosine 
phosphatase and has been shown to be associated with Rett syndrome, yet 
another neurodevelopmental disorder (Delgado et al., 2006). In addition, rare 
CNVs related to ADHD have been identified to overlap the PTPRN2 gene (Lionel 
et al., 2011), making this gene a potential contributor to the disease liability for 
schizophrenia, specifically in these patients. 
The identification of CNVs from Affymetrix Human SNP 6.0 arrays did not 
yield any shared gene regions with the methylation dataset. This is likely due to 
the reduced genomic coverage of the microarray as compared to DNA 
sequencing. 
 
5.5 Conclusion 
Most research in search of genes causing schizophrenia has used limited 
DNA sequence differences in a large number of patients matched with unaffected 
controls from a variety of collections and populations. The results argue for 
extensive heterogeneity of causation even within a single family making every 
patient different and any definitive conclusions about this disorder problematic. 
This research has identified all/almost all changes in the patient in contrast to 
matched unaffected MZ co-twins. The results have identified a number of genes 
that differ in DNA sequence as well as promoter methylations. As expected, the 
list of genes differs between two MZD pairs. They predominantly represent genes 
involved in neurodevelopment and function. More importantly, a number of genes 
affected by DNA sequence changes have been implicated in schizophrenia and 
related disorders. The results confirm uniqueness of individual patients whose 
etiology could be explained by a threshold model involving multiple genes in this 
complex disorder. Also, it supports the suggestion that a variety of mechanisms 
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including genetic, epigenetic and environmental factors could contribute to this 
threshold and may be co-localized. Although logical, this model remains to be 
experimentally authenticated.  
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Chapter 6!- Discussion 
6.0 Overview 
The studies presented in this PhD Thesis have identified CNV (Chapter 2), 
genome sequence (Chapter 3) and methylation (Chapter 4) alterations between 
sets of monozygotic twins that are discordant for schizophrenia. We have 
followed the families for over five years since sample collection and established 
that the twins have remained discordant. The analysis used three technologies: a 
CNV array, whole genome sequencing and a DNA methylation array. The results 
have identified genomic variations between twin pairs. Where possible, based on 
availability of parental data, these variations were established to be de novo. A 
number of exonic regions were affected as well as intergenic and intronic 
regions. Some of the affected genes and regions have been previously reported 
to be involved in schizophrenia and others are presented here for the first time. 
Together, these genes and regions may serve as candidate genes for future 
studies. Further, the presence of multiple variations with possible links to 
schizophrenia pathology supports the contention that they may in fact be 
involved in the development of schizophrenia in these patients.  
Further, I have modeled the results in a threshold model for schizophrenia 
where an accumulation of variation increases the liability towards disease 
(McGue et al., 1983). I postulate that genetic or epigenetic changes can act as 
the source of variation that increases the liability towards disease. Also, in some 
cases the mutations may be co-localized and affect the same genes. The model 
assumes that the inherited predisposition towards disease may lie in both 
monozygotic twins. However, the threshold is reached in the affected twin only by 
virtue of additional changes (Figure 6.1). The results also offer a number of 
insights into twin genomics as discussed below. 
 
 
 
 
!! 219!
A number of major conclusions can be drawn from the research presented 
in this thesis: 
First, the results presented here confirm that rare de novo events are 
relatively common. They take place during growth, development and aging 
making even MZ twins genetically discordant. If a mutation occurs in the early 
stages of development it may result in distinct differences between monozygotic 
twins while a later occurrence may generate twins with mosaicism.  
Second, the study design has enabled the identification of a wide variety 
of genome differences. These include CNVs, genome sequence variation and 
DNA methylation changes. 
Third, monozygotic twin pairs discordant for schizophrenia show de novo 
differences at the genetic and epigenetic levels. Many of these differences are 
rare and patient-specific. Further, some of these differences are shared between 
unrelated affected twins. This comprehensive and complete assessment of 
individual genomes is unique in the literature: for the first time it has offered a 
near complete genetic/epigenetic profile of changes between monozygotic twins. 
Collectively, the results argue that genetic models and interpretations used over 
the last 100 years, that are based on 100% genetic concordance of monozygotic 
twins, deserve reevaluation.  
Fourth, many of the de novo genes and pathways unique to the affected 
twin(s) are involved in neurodevelopmental networks/pathways relevant to 
disease manifestation or have previously been implicated in schizophrenia. 
These include ‘cell death and survival’, ‘cellular movement and immune cell 
trafficking’, ‘glutamate receptor signaling’ and ‘dopamine feedback in cAMP 
signaling’, among others.  
Finally, the genomic results on families with monozygotic twins discordant 
for schizophrenia are compatible with a threshold model where the accumulation 
of variants increases the liability towards schizophrenia. 
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6.1 Threshold Model 
The model proposed (Figure 6.1) states that inherited mutations (Girard et 
al., 2011; Gulsuner et al., 2013; Xu et al., 2011) place an individual on a liability 
scale for the development of schizophrenia. Additional contributors to this scale 
may include de novo mutations, environmental factors and/or epigenetic 
(McCarthy et al., 2014) events, most occurring during ontogenic development 
(Singh and O’Reilly, 2009). The model predicts that the liability threshold may be 
met by inherited factors alone or require additional random genetic and 
epigenetic events, including environmental events. I have tested this model using 
monozygotic twins discordant for schizophrenia with the assumption that any 
inherited components will be shared and that non-inherited components (de novo 
mutations, epigenetic and environmental) will be acquired during ontogenetic 
development (Figure 6.1). The model also argues that the determinants of the 
disease may be individual-specific and differ across patients. The results 
included in this thesis identify a number of events that may have played a role in 
the development of schizophrenia in the affected member of the two twin pairs 
studied. A large majority of the genes/regions identified are involved in post-
synaptic complexes (Kirov et al., 2012) and synaptic strength (Szatkiewicz et al., 
2014); processes that are known to be defective in patients with schizophrenia. 
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Figure 6.1. Visual representation of the proposed threshold model. 
This model was first suggested by McGue et al, (McGue et al., 1983). Here, I 
apply its principles to monozyotic twin concordance/discordance for 
schizophrenia. A blue dot indicates a well twin and a red dot indicates an affected 
twin. MZC = Monozygotic Concordant, MZD = Monozygotic Discordant. 
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Thus, the development of schizophrenia is compatible with a threshold 
model. Previous population and family studies have implicated a number of 
mutational mechanisms, as well as many genes of small effect, in the causation 
of this disease (Kendler, 2015; Picchioni and Murray, 2007; Ripke et al., 2013). 
Conceptually, an accumulation of mutations affecting a number of genes and/or 
regions affecting disease-specific pathways may establish a genetic liability 
gradient for schizophrenia where a critical threshold is required for the 
manifestation of the disease state (Bouchard and McGue, 1981; McGue et al., 
1983). Further, the underlying genetic liability is expected to be higher in families 
with schizophrenia patients. At the individual level, this liability will be much 
higher if a family history is observed. In the case of MZ twins where one is 
affected with the disease, the affected member is expected to have acquired 
additions to the liability scale via genomic mutations and/or environmental factors 
that contribute to threshold crossing and thus to the development of the disease. 
It remains an attractive hypothesis but has remained untested, primarily because 
of the lack of appropriate data. It should also be noted that threshold models are 
often assessed at the level of the population. This study is unique in that it 
applies this model to cases representing individual patients representing MZD 
twins. 
The model argues that a gene or region involved in a critical pathway may 
be affected by mutations involving different sets of variants in different 
individuals. More importantly, the two members of a MZD twin pair would share a 
common genetic liability for the disease with the affected twin acquiring additional 
defects causing him/her to cross the disease threshold on the liability continuum 
and develop schizophrenia. 
 
6.1.1 Role of de novo Genetic and Epigenetic Mutations in the Threshold 
Model of Schizophrenia 
The results included in this thesis, therefore, show that de novo genetic 
and epigenetic mutations may play a significant role in the development of 
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schizophrenia. These observations are backed by extensive literature that argue 
for the existence of somatic mutation in our genomes (Breckpot et al., 2012; Li et 
al., 2014; O’Huallachain et al., 2012; Weber-Lehmann et al., 2014). In this model, 
MZD twins with the disease are argued to have acquired additional de novo 
errors onto an already existing background of genetic and epigenetic 
predisposition and thus contributing to disease liability, as discussed above. 
These de novo errors must involve somatic changes during ontogeny (Maiti et 
al., 2011; Singh et al., 2009). Such rare post-zygotic variants have been ignored 
in the past. Mutations that occur later in development are likely to be very low in 
frequency and may even resemble technological error (Insel, 2014). I propose 
that de novo genetic and epigenetic mutations in the affected twin are 
responsible for the generation of threshold reaching insults in monozygotic twins 
discordant for schizophrenia and thus contribute to disease manifestation and 
ultimately, disease discordance.  
 
6.1.2 Further Support for The Threshold Model of Schizophrenia 
This model will account for a variety of results and observations in the 
literature. For example, de novo mutations have been found to be more likely to 
occur in schizophrenia patients as compared to unaffected siblings (Gulsuner 
and McClellan, 2014). In addition, damaging de novo mutations have been found 
in postmortem brains of schizophrenia patients that disrupted genes regulating 
neurogenesis in the prefrontal cortex (Gulsuner et al., 2013) and an increased 
number of de novo CNVs have been implicated in schizophrenia and bipolar 
disorder patients (Georgieva et al., 2014). Further, schizophrenia has not been 
the only neurodevelopmental disorder to implicate de novo mutation, it has also 
been shown that patients with autism or intellectual disability have more de novo 
mutations than matched controls (Insel, 2014).  
Also, the involvement of a relatively large number of gene mutations 
reported in comprehensive publications have been difficult to replicate (Farrell et 
al., 2015) and argue for far-reaching heterogeneity and patient-centered 
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approaches towards the understanding of this neurodevelopmental disease. In 
addition, various phenotypic variables have been investigated through genome-
wide association studies and results reveal that the patients who carried de novo 
CNVs and SNVs displayed the most severe phenotypes (for example, learning 
disabilities leading to reduced work skills) (Malherbe et al., 2015). Interestingly, 
the genes harboring de novo mutations in schizophrenia studies, including those 
involving twins, have been found to be enriched in networks and pathways 
relevant to psychiatric disorders (Bloom et al., 2013; Castellani et al., 2014, 2015; 
Kirov, 2010; Maiti et al., 2011).  
Of critical importance is the ability of this model to explain the persistance 
of schizophrenia in the population despite its reduced fecundity. In fact, the 
presence of somatic mutation has been suggested to explain the limited 
heritability of many cancers (Insel, 2014) and somatic mutations (particularly after 
inheritance of a predisposition) are believed to be the driving force behind the 
manifestation of a number of cancers (Lengauer et al., 1998). Further, mosaicism 
is a well-known occurrence that has been associated with at least 30 Mendelian 
diseases (O’Huallachain et al., 2012) which supports the primary mechanism 
implicated in the threshold model of schizophrenia: de novo genetic and 
epigenetic change. 
 
6.2 Context of Study Findings 
Evidence from a variety of sources suggests that schizophrenia is a highly 
heterogeneous neurodevelopmental disorder, caused by many different genes 
with small effects (Craddock et al., 2006; Kendler, 2015; Schwab and 
Wildenauer, 2013). The genes and regions identified in this study to be affected 
by de novo genetic and epigenetic mutations in the affected co-twins are the 
most likely candidates to contribute to observed discordance for schizophrenia 
through the accumulation of small effects contributing to a threshold. Rare, low 
frequency variations are enriched for potentially functional mutations because 
they are under weak purifying selection and have increased levels of population 
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variation due to the fact that they are recent in origin (Mathieson and McVean, 
2012; Nelson et al., 2012). Moreover, the function of the genes and 
pathways/networks identified from de novo mutation in the affected co-twins were 
more likely than genes from the unaffected co-twins to be associated with 
schizophrenia and more likely to have been previously identified as 
schizophrenia candidates in the literature, lending support for their potential 
contribution to schizophrenia manifestation in these discordant pairs. 
Differential de novo mutations offer an alternative explanation for the 
discordance of MZ twins. They would add new somatic genetic and epigenetic 
mutations to individual twins with identical predisposing genotypes. Depending 
on the developmental time of mutation (very early causing all cells to be affected 
versus later causing mosaicism) and tissue/organ involved, these de novo 
mutations will accumulate and help reach or cross the threshold producing the 
disease. The novel results could also explain comparable risk of the disease in 
the offspring of affected as well as unaffected twins. The findings presented in 
this thesis suggest that every individual will have a unique combination of 
inherited and acquired gene mutations, with the potential to make each 
individual, even from a single family, genetically unique. This notion is supported 
by recent evidence from the 1000 Genomes Pilot Project which has found 
considerable variation in mutation rates within and between families (Conrad et 
al., 2011). 
 Our group has previously suggested that the presence of de novo CNV 
showers (Singh et al., 2009) might help explain both the discordance of MZ twins 
and the persistent high prevalence of schizophrenia despite its selective 
disadvantage. In this study, an increased burden of de novo mutation was not 
identified between affected twins and their unaffected co-twin. However, other 
groups have reported a significant difference in the level of de novo mutation in 
cases versus controls. For example, increased de novo mutations in exome 
sequences in schizophrenia (Girard et al., 2011; Xu et al., 2011).  
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Many genes implicated in schizophrenia have also been implicated in 
autism, intellectual disability, bipolar disorder and major depressive disorder 
(Kavanagh et al., 2014), suggesting that similar de novo insults may be relevant 
to multiple complex disorders, including schizophrenia.  Further, despite clear 
genetic contributions to the causation of schizophrenia, fecundity in 
schizophrenia is significantly reduced (Nimgaonkar, 1998), yet the lifetime 
morbidity risk remains high at approximately 0.75% (Saha et al., 2005). As 
previously mentioned, one possible explanation for this combination of selective 
disadvantage and high prevalence is de novo mutation which would act against 
selection pressure (Doi et al., 2009). 
 
6.3 Methodological Considerations 
 Any study of this magnitude is not without its strengths and limitations. 
Here, I discuss a few major strengths of the experiments presented in this thesis 
as well as some caveats. 
 
6.3.1 Study Strengths  
 First, the use of monozygotic twins and parental samples (where 
available) allows for the assessment of a patient with schizophrenia as compared 
to nature’s best possible matched control – their identical twin. Although 
heterogeneity in environmental and random effects cannot be eliminated, a 
significant reduction in heterogeneity is achieved given that twins start life from 
the same egg and sperm cell and have shared in-utero environments, maternal 
nutrition, gestation lengths, and early life experiences, among other similarities. 
 Second, the technologies used to generate the datasets in this thesis 
comprise some of the most comprehensive and highest resolution methods 
currently available in this field, allowing for the assessment of the genome at the 
single base pair level.  
 Finally, the results allow for the interpretation and analysis of genomic 
change at the individual/patient-specific level, which is important when assessing 
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causation to a disease that presents with a wide spectrum of symptoms and 
manifestations. 
  
6.3.2 Study Caveats 
There are a number of added considerations that must be taken into 
account in the interpretation of the results generated during this Ph.D. research. 
Firstly, most schizophrenia patients, including those analyzed in this thesis, are 
treated with antipsychotic medications prior to the time of sample collection for 
genomic analysis. It is understood that drugs used to treat psychiatric disorders 
may cause epigenetic changes in the genome (Dong et al., 2009) and thus it will 
be expected that some of the epigenetic changes presented in this report may 
have arisen as a result of the effect of medication (Melka et al., 2013, 2014a, 
2014b). The questions remain: are these changes the causes or the effects of 
the disease process and what is the role, if any, of drugs used by patients? 
However, it should be noted that the possibility that all of the observed 
differences are an effect of medication is not compatible with several facts: firstly, 
the novel differences that have been detected in patients affect genes and/or 
pathways that are implicated (and affected) in schizophrenia and secondly, 
studies on medication-free patients have shown aberrant genomic profiles 
between schizophrenic patients and healthy controls (Bönsch et al., 2012; 
Kinoshita et al., 2013). 
Second, this study primarily used blood samples for assessment of 
genetic and epigenetic profiles of participants. It is important to note that it is 
likely that some de novo mutation would exist in all/most tissues of the same 
individual and that other de novo mutation would exist only in a subset of tissue, 
or just one tissue depending on the timing of the mutation. However, with current 
methods and limited tissue types, I cannot precisely ascertain the timing of de 
novo change. As mentioned above, the additional use of buccal cells for 
confirmatory experiments did allow the estimation of timing for some variants. I 
note that some of the variants identified in this study occurred before the 
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differentiation of these two tissues and others occurred after. Thus, I would 
expect some variants to be brain-specific (which I have not been able to measure 
in this study) (Poduri et al., 2013). Of note however, is the increased potential for 
de novo mutation to occur during development due to the high rates of replication 
observed at this critical time. Genome-wide studies have suggested that the 
methylation status of blood reflects that in the brain, which supports the use of 
blood as a surrogate tissue (Aberg et al., 2013). However, until the field’s 
understanding of somatic change is more thoroughly defined, the precise validity 
of surrogate tissues in studies of disease etiology remains unclear. In fact, 
evidence is beginning to emerge for the potential that even at the neuronal level, 
one neuron may be distinctly different in DNA sequence from another neuron 
directly beside it (Insel, 2014).  
 Third, the use of twins addresses the issue of heterogeneity in 
schizophrenia patients, allowing for a significant reduction in inter-individual 
variability. However, despite this unique match between a schizophrenic twin and 
their healthy co-twin, there is no precedent with regards to sample size of twins 
needed to detect potential disease contributing variations. Rather than assessing 
a fraction of variations in an increasing number of samples to increase 
effectiveness, my focus is to assess all variations in individual patients and 
genetically matched controls. In theory, a single pair may be enough to identify a 
causal element(s). I have demonstrated the effectiveness of this approach by 
reporting on Cadherin as a candidate gene for schizophrenia (Singh et al., 2010).  
For this reason, I have chosen to primarily report patient and family-specific 
profiles in each family. In cases where I have identified shared variants between 
unrelated patients, I have proceeded with caution and identified these variants 
only as potential candidates for the disease that require further assessment in 
population level GWAS analysis.   
Finally, the current resolution available in the area of genetics and 
genomics is limiting. For example, somatic variants could be present in just a few 
reads in a tissue sample but still be important for disease causation, yet current 
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technologies will likely identify mosacism as nothing more than sequencing or 
hybridization error. Thus, as technology progresses so too will the reliability with 
which we can ascertain precise information about the genome.  
Whole genome sequencing is estimated to have an error rate ranging from 
0.1-0.6% (Wall et al., 2014). The technology used for sequencing in this study 
from Complete Genomics has an estimated error rate of 0.001% (Drmanac et al., 
2010). When the size of the genome is taken into account, this means that there 
are up to 3 million potential errors in each genome sequence analyzed. This 
reminds us to proceed with caution when interpreting large-scale databases and 
reinforces the importance of downstream confirmatory methods. 
 In fact, most groups that are working with large-scale datasets report 
concerning results with regards to validation rates in population studies as well 
as twin studies. For example, a genome-wide CNV study using Affymetrix 6.0 
array in 1,097 monozygotic twins chose 20 CNV candidates for confirmation (of 
153 putative de novo CNVs) and were able to validate 2 of the 20 candidates 
(Abdellaoui et al., 2015). In addition, a comprehensive report by Dal et al 
uncovered de novo SNVs through whole genome deep sequencing in two twin 
pairs and were able to validate 8 of 19 variants in one twin pair and 1 of 15 
variants in another twin pair (Dal et al., 2014). In addition, the latter report 
describes the presence of mosaicism at twin-specific de novo SNVs (Dal et al., 
2014). These results in the literature are very similar to the validation rates that I 
have identified in my Affymetrix 6.0 and whole genome sequencing datasets in 
this thesis.  
The sequencing dataset poses a particular challenge as regions of low 
sequence complexity, satellite regions and large repeats, continue to present 
major difficulty for short read sequencing technologies such as the Complete 
Genomics method. Despite an average fold coverage of over 47x in this study, 
this average is not equally distributed along each and every chromosome; some 
repeat regions have significantly less while other euchromatic regions have 
significantly more fold coverage. 
!! 230!
6.4 Implications 
The results have provided a reminder that clinical research should no 
longer be about nature versus nurture, but instead about the complex interplay of 
nature and nurture. The findings have a number of potential implications. First, 
these conclusions may help develop earlier and/or better diagnosis and have the 
potential to identify diagnostic sub-groups through the grouping of patients with 
similar genetic and epigenetic profiles. Earlier diagnosis alone could assist 
greatly in disease management and early treatment strategies. Second, the 
findings may help to identify better therapeutic strategies through the 
identification of drug targets as well as candidate regions for targeted methylation 
and/or genetic therapy strategies. Finally, the findings contribute to the 
understanding of schizophrenia causes. Knowledge of the causes of 
schizophrenia will assist patients in uncovering the factors behind why they are 
experiencing symptoms of this life-altering mental health disorder. 
The identification of genetic and epigenetic changes involved in even a 
subset of schizophrenia patients will be a major breakthrough. Identification of 
genomic changes that are contributing to this disease also have the potential to 
identify affected pathways and etiological mechanisms that will allow 
characterization of cytoarchitecture with diagnostic and therapeutic implications.  
 
6.5 Future Directions 
 The field of psychiatric genetics is vast and incredibly complex. Although 
genetic technologies and advances are moving forward at unprecedented rates, 
the challenges that lie ahead are many. Expanding on the research presented 
here is paramount to understanding the genetic variation between and within 
individuals, as well as the critical drivers of disease manifestation. Future studies 
should focus on the following objectives: 
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1.! Gene expression and other functional studies on the candidate genes and 
regions presented in this study to uncover which of the identified changes 
may be causal to the disease. 
2.! Further characterization of schizophrenia patients into more homogenous 
clinical subgroups would allow for genetic studies to be performed that 
focus on one subtype of schizophrenia at a time thus significantly reducing 
clinical heterogeneity. This aim will also lead to better diagnosis of 
patients. 
3.! Technological advances that will allow for better identification of the timing 
of de novo genetic/epigenetic mutations and a significant reduction in the 
error rates of sequencing and array-based technologies.  
4.! Investigation of somatic variation in the brains of monozygotic twins, 
particularly using single cell technologies that are now emerging. 
5.! Assessment of other types of epigenetic modifications including histone 
modification, DNA hydroxymethylation, and MicroRNA profiles between 
identical twins discordant for schizophrenia. 
6.! As our understanding of non-coding regions of the genome becomes 
clearer, the impact of non-coding variants on disease will be revealed. 
Studies which focus on the potential for non-coding variants to have a 
regulatory effect on important genes may uncover novel genomic 
candidates for disease presentation. 
7.! Expanded studies on medication-free patients will allow for better 
assessment of epigenetic responses to treatment. A database of 
epigenetic profiles in healthy controls, patients treated with antipsychotics 
and patients without medication may assist in this aim. 
8.! Combination of multiple data types towards an integrative genomics 
approach that includes better understanding of the functional biological 
pathways using functional studies, gene expression, DNA sequence and 
epigenetic data. 
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9.! Experiments that work towards better understanding of the interactions 
between environmental factors and genomic insults will provide the 
background for better understanding of how environmental factors 
mediate the risk of schizophrenia. 
 
6.6 Final Conclusions 
In conclusion, these collective experiments using a unique twin model and 
experimental design, alongside comprehensive genomic techniques, identified 
differences between monozygotic twins at both the genetic and genomic level. 
These findings highlight the variability that exists in our genomes and 
emphasizes that no two individuals are identical; not even twins who begin life as 
a single zygote. In addition, the results presented in this thesis identify genetic 
candidates for the development of schizophrenia in monozygotic twins discordant 
for schizophrenia with some of these candidates having been previously 
identified and others being novel. These novel insults may act on an already 
existing background of predisposition via a threshold model (McGue et al., 1983) 
(Castellani et al., 2015, under review). 
The inherent dynamic and responsive nature of the landscape of the 
human genome makes it a candidate for the explanation of disease discordance 
in monozygotic twins for a number of phenotypes, yet also presents an 
experimental challenge given its complexity and the vast number of factors that 
are known to contribute to genomic change. Discordant twins and their parents 
provide exceptionally matched controls for assessment of genomic contributors 
to disease. Accordingly, the approach presented here may be applied to other 
complex diseases that show twin discordance. 
The human genome is not static. We do not simply acquire parental 
genomes and then pass them on to the next generation; rather, the genome 
undergoes a variety of alterations at the genetic and epigenetic level. These 
changes may represent a way for our genomes to remain both fluid and 
malleable as we encounter a variety of environmental impacts, however, these 
!! 233!
changes have the potential to be detrimental and may be leading factors towards 
the formation of complex diseases.  
Furthering our knowledge of genomic architecture and change, as well as 
the timing and source of genomic change, will help to lead to a better 
understanding of the dynamic nature of the human genome. Ultimately, 
determining the contributing factors to complex diseases, like schizophrenia, will 
aid in the diagnosis, treatment and understanding of this and other life-altering 
disorders.  
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Appendix A - Availability of Supporting Data 
 The datasets supporting the results of this thesis are available in the Gene 
Expression Omnibus (GEO) repository, [GSE61862, 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE61862] and 
[GSE33598, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33598].  
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Appendix C - Structural Variants unique to affected member of Family 1. (NCBI Build 37/hg19) 
Chr Start End Size (bp) SV Type Gene(s) Father Mother Inheritance 
1 5717300 5725895 8595 Deletion 0 Present Absent Inherited 
1 5727877 5728315 438 Deletion 0 Present Present Inherited 
1 26460142 26464816 4674 Deletion 0 Present Absent Inherited 
1 57242625 57242964 339 Deletion C1orf168 Present Present Inherited 
1 62654769 62657187 2418 Deletion 0 Present Absent Inherited 
1 71237363 71240327 2964 Deletion 0 Present Absent Inherited 
1 112691792 112704705 12913 Deletion 0 Present Present Inherited 
1 144894289 144895285 996 Deletion PDE4DIP Present Present Inherited 
1 145026746 145027069 323 Deletion PDE4DIP Present Present Inherited 
1 158867539 158869984 2445 Deletion 0 Present Present Inherited 
1 238852322 238853265 943 Deletion 0 Present Absent Inherited 
1 248051492 248057652 6160 Deletion 0 Present Present Inherited 
2 1801743 1802067 324 Deletion MYT1L Present Absent Inherited 
2 3822800 3823598 798 Deletion 0 Present Present Inherited 
2 33091738 33095634 3896 Deletion LOC285045 Present Present Inherited 
2 182565264 182565592 328 Deletion 0 Present Absent Inherited 
2 239626179 239627520 1341 Deletion 0 Present Present Inherited 
3 228847 234481 5634 Deletion 0 Present Present Inherited 
3 8718847 8722982 4135 Deletion 0 Present Absent Inherited 
3 16239409 16241210 1801 Deletion GALNTL2 Present Absent Inherited 
3 49494287 49494616 329 Deletion 0 Present Present Inherited 
3 73939035 73939381 346 Deletion 0 Present Absent Inherited 
4 4568030 4568628 598 Deletion 0 Present Absent Inherited 
4 28511981 28513202 1221 Deletion 0 Present Absent Inherited 
4 59428999 59435542 6543 Deletion 0 Present Absent Inherited 
4 73831249 73831821 572 Deletion 0 Present Absent Inherited 
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4 76743108 76744645 1537 Deletion 0 Present Present Inherited 
4 80888062 80894107 6045 Deletion ANTXR2 Present Present Inherited 
4 90427886 90428672 786 Deletion 0 Present Absent Inherited 
4 190535505 190538363 2858 Deletion 0 Present Absent Inherited 
5 668063 668593 530 Deletion LOC100132605;TPPP Present Present Inherited 
5 25959078 25959871 793 Deletion 0 Present Absent Inherited 
5 42628539 42631218 2679 Deletion GHR Present Absent Inherited 
5 95343326 95343680 354 Deletion 0 Present Present Inherited 
5 112224253 112226906 2653 Deletion REEP5 Present Absent Inherited 
5 126126039 126127716 1677 Deletion LMNB1 Present Absent Inherited 
5 127172332 127173282 950 Deletion LOC728586 Present Present Inherited 
5 176387587 176390188 2601 Deletion UIMC1 Present Absent Inherited 
6 14745281 14745697 416 Deletion 0 Present Present Inherited 
6 31193512 31194660 1148 Deletion 0 Present Absent Inherited 
6 51739577 51745615 6038 Deletion PKHD1 Present Absent Inherited 
6 95193324 95194338 1014 Deletion 0 Present Present Inherited 
6 133371501 133371845 344 Deletion 0 Present Absent Inherited 
6 149409430 149410432 1002 Deletion 0 Present Absent Inherited 
6 168059226 168059550 324 Deletion 0 Present Absent Inherited 
7 33898856 33899187 331 Deletion 0 Present Present Inherited 
7 36441222 36441996 774 Deletion ANLN Present Absent Inherited 
7 66193913 73382120 7188207 Deletion 
ABHD11;AUTS2;BAZ1B;BCL7B
;C7orf42;CALN1;CLDN3;CLDN4
;DNAJC30;FKBP6;FZD9;GTF2I
RD2P;LOC100093631;LOC100
128031;LOC100131972;LOC10
0288540;LOC100289307;LOC1
00289339;LOC442572;LOC644
794;LOC729156;MLXIPL;NCF1
B;NSUN5;NSUN5C;PMS2L4;P
OM121;RABGEF1;SBDS;SBDS
P;SPDYE7P;SPDYE8P;STAG3
L3;STAG3L4;STX1A;TBL2;TRI
M50;TRIM74;TYW1;TYW1B;VP
Present Present Inherited 
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S37D;WBSCR17;WBSCR22;W
BSCR26;WBSCR27;WBSCR28 
7 81441673 81442580 907 Deletion 0 Present Present Inherited 
7 100613739 100614479 740 Deletion MUC12 Present Absent Inherited 
7 102800742 102801402 660 Deletion 0 Present Absent Inherited 
7 155199777 155201525 1748 Deletion 0 Present Absent Inherited 
8 40774677 40779833 5156 Deletion 0 Present Absent Inherited 
8 59078464 59078800 336 Deletion 0 Present Absent Inherited 
8 113085436 113085766 330 Deletion 0 Present Present Inherited 
8 144056582 144057161 579 Deletion 0 Present Absent Inherited 
9 6700565 6710685 10120 Deletion 0 Present Present Inherited 
9 24502071 24519103 17032 Deletion 0 Present Present Inherited 
9 110018286 110020857 2571 Deletion 0 Present Absent Inherited 
9 124411502 124411804 302 Deletion DAB2IP Present Absent Inherited 
9 129492472 129492919 447 Deletion 0 Present Absent Inherited 
9 135622738 135627436 4698 Deletion C9orf98 Present Absent Inherited 
10 22081665 22082212 547 Deletion DNAJC1 Present Absent Inherited 
10 78346590 78351578 4988 Deletion 0 Present Absent Inherited 
10 78800911 78801230 319 Deletion KCNMA1 Present Absent Inherited 
10 119634283 119634614 331 Deletion 0 Present Absent Inherited 
11 5784571 5809284 24713 Deletion OR52N1;OR52N5 Present Absent Inherited 
11 12152558 12152882 324 Deletion MICAL2 Present Present Inherited 
11 63698909 63701654 2745 Deletion 0 Present Present Inherited 
11 69400843 69401405 562 Deletion 0 Present Present Inherited 
11 102751130 102752828 1698 Deletion LOC100288111 Present Absent Inherited 
12 9017095 9018122 1027 Deletion A2ML1 Present Present Inherited 
12 16420123 16421283 1160 Deletion 0 Present Absent Inherited 
12 99793948 99802771 8823 Deletion ANKS1B Absent Absent De novo 
12 112296544 112297279 735 Deletion MAPKAPK5 Present Absent Inherited 
12 122634715 122650584 15869 Deletion 0 Present Absent Inherited 
!! 243!
12 127199963 127200302 339 Deletion 0 Absent Present Inherited 
13 21951418 21951834 416 Deletion ZDHHC20 Present Absent Inherited 
13 81747255 81747583 328 Deletion 0 Absent Absent De novo 
13 108560717 108561673 956 Deletion 0 Present Absent Inherited 
14 66157661 66158245 584 Deletion FUT8 Present Absent Inherited 
14 73389502 73390207 705 Deletion 0 Absent Absent De novo 
14 85139146 85139626 480 Deletion 0 Present Absent Inherited 
14 106932640 107174930 242290 Deletion 0 Absent Present Inherited 
15 39267016 39267370 354 Deletion 0 Present Present Inherited 
15 93897281 93897642 361 Deletion 0 Absent Absent De novo 
15 101051762 101052327 565 Deletion LASS3 Present Present Inherited 
16 11683765 11685325 1560 Deletion 0 Present Absent Inherited 
16 25340111 25343129 3018 Deletion 0 Present Present Inherited 
17 801626 802228 602 Deletion NXN Absent Present Inherited 
17 5587702 5588656 954 Deletion 0 Absent Absent De novo 
17 48427538 48427922 384 Deletion LOC100288444;XYLT2 Present Present Inherited 
18 108872 109083 211 Deletion 0 Absent Absent De novo 
18 52447413 52447773 360 Deletion 0 Present Absent Inherited 
18 63766868 63769201 2333 Deletion 0 Present Present Inherited 
19 1182661 1183179 518 Deletion 0 Absent Absent De novo 
19 12753340 12754497 1157 Deletion 0 Absent Absent De novo 
19 14732344 14734142 1798 Deletion EMR3 Present Present Inherited 
20 23671899 23674222 2323 Deletion 0 Present Absent Inherited 
20 26214307 26220376 6069 Deletion 0 Absent Absent De novo 
20 44535505 44535941 436 Deletion PLTP Absent Present Inherited 
22 35645166 35646141 975 Deletion 0 Absent Present Inherited 
22 43101594 43102348 754 Deletion A4GALT Present Absent Inherited 
22 49063815 49064594 779 Deletion FAM19A5 Present Present Inherited 
22 49764594 49769018 4424 Deletion 0 Absent Absent De novo 
X 899553 899984 431 Deletion 0 Present Absent Inherited 
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X 16427688 16428223 535 Deletion 0 Absent Present Inherited 
X 49731220 49733608 2388 Deletion CLCN5 Absent Absent De novo 
1 825765 5726936 4901171 Tandem Dup 
ACAP3;ACTRT2;AGRN;AJAP1;
ARHGEF16;ATAD3A;ATAD3B;
ATAD3C;AURKAIP1;B3GALT6;
C1orf159;C1orf170;C1orf174;C1
orf222;C1orf70;C1orf86;C1orf93
;CALML6;CCDC27;CCNL2;CDC
2L1;CDC2L2;CPSF3L;DFFB;DV
L1;FAM132A;FLJ14100;FLJ396
09;FLJ42875;GABRD;GLTPD1;
GNB1;HES4;HES5;ISG15;KIAA
0495;KIAA0562;KIAA1751;KLH
L17;LOC100128003;LOC10012
8838;LOC100129381;LOC1001
29534;LOC100131742;LOC100
132814;LOC100133612;LOC10
0287685;LOC100287750;LOC1
00287848;LOC100287898;LOC
100288202;LOC100288271;LO
C100288313;LOC100288379;L
OC100288479;LOC115110;LOC
148413;LOC284661;LOC38858
8;LOC401934;LOC441869;LOC
643988;LOC728661;LOC72871
6;LRRC47;MEGF6;MIB2;MMEL
1;MMP23A;MMP23B;MORN1;M
RPL20;MXRA8;NADK;NOC2L;P
ANK4;PEX10;PLCH2;PLEKHN1
;PRDM16;PRKCZ;PUSL1;RER1
;SAMD11;SCNN1D;SDF4;SKI;S
LC35E2;SSU72;TAS1R3;TMEM
52;TMEM88B;TNFRSF14;TNFR
SF18;TNFRSF4;TP73;TPRG1L;
TTLL10;UBE2J2;VWA1;WDR8 
Absent Absent De novo 
1 230107606 230107783 177 Tandem Dup 0 Absent Absent De novo 
2 1426068 1522926 96858 Tandem Dup TPO Absent Present Inherited 
2 2649502 2649583 81 Tandem Dup 0 Present Absent Inherited 
3 75699636 75699709 73 Tandem Dup 0 Present Absent Inherited 
4 80273622 80274729 1107 Tandem Dup 0 Absent Absent De novo 
!! 245!
5 178012521 178012708 187 Tandem Dup COL23A1 Absent Present Inherited 
6 1053869 1054275 406 Tandem Dup LOC285768 Absent Absent De novo 
7 605977 606269 292 Tandem Dup PRKAR1B Present Present Inherited 
7 140181586 140189220 7634 Tandem Dup 0 Present Present Inherited 
10 125919520 125919748 228 Tandem Dup 0 Absent Absent De novo 
10 132294621 132294747 126 Tandem Dup 0 Absent Absent De novo 
11 131550263 131550706 443 Tandem Dup NTM Absent Absent De novo 
14 24369410 24369615 205 Tandem Dup 0 Absent Absent De novo 
14 66258294 66258410 116 Tandem Dup 0 Present Present Inherited 
15 25468396 25470000 1604 Tandem Dup SNORD115-29 Absent Absent De novo 
15 63185677 63185745 68 Tandem Dup 0 Absent Present Inherited 
19 544936 545072 136 Tandem Dup GZMM Absent Absent De novo 
19 23262787 23265543 2756 Tandem Dup 0 Present Absent Inherited 
20 24510425 24510694 269 Tandem Dup C20orf39 Present Absent Inherited 
2 61702932/ 61700753 
61703455/ 
61700765 523 Distal Dup 0 Absent Present Inherited 
5 150319009/ 150319494 
150319103/ 
150319759 94 Distal Dup LOC134466 Present Absent Inherited 
12 12544853/ 12546495 
12544955/ 
12546622 102 Distal Dup LOH12CR1 Present Present Inherited 
12 87205701/ 87204798 
87205819/ 
87204806 118 Distal Dup MGAT4C Present Absent Inherited 
13 21538303/ 21545834 
21541177/ 
21545834 2874 Distal Dup 0 Present Absent Inherited 
16 69761819/ 69762887 
69762131/ 
69763048 312 Distal Dup 0 Absent Present Inherited 
18 69711799/ 69712885 
69712015/ 
69712888 216 Distal Dup 0 Absent Present Inherited 
23 2141240/ 2143040 
2141701/ 
2143092 461 Distal Dup 
DHRSX;LOC100288477; 
LOC100288983 Present Absent Inherited 
23 52886722/ 55678952 
52892121/ 
679111 5399 Distal Dup 
XAGE-4; 
XAGE3 Absent Present Inherited 
2 133022029 17 45213172 Interchrom CDC27 Absent Absent De novo 
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Appendix D - Structural Variants unique to affected member of Family 2. (NCBI Build 37/hg19) 
Chr Start End Size (bp) SV Type Gene(s) 
1 1142719 1143140 421 Deletion 0 
1 56401293 56401614 321 Deletion 0 
1 62390602 62390951 349 Deletion INADL 
1 85748634 85748964 330 Deletion 0 
1 91914111 91914566 455 Deletion 0 
1 207292362 207293195 833 Deletion C4BPA 
1 222034158 222034490 332 Deletion 0 
1 228572175 228572504 329 Deletion 0 
2 8616813 8617120 307 Deletion 0 
2 16271827 16274059 2232 Deletion 0 
2 39071490 39071832 342 Deletion DHX57 
2 53625772 53628009 2237 Deletion 0 
2 88821957 88822489 532 Deletion 0 
2 194689502 194698766 9264 Deletion 0 
2 206731199 206731522 323 Deletion 0 
2 226039583 226040060 477 Deletion 0 
3 10397475 10397834 359 Deletion ATP2B2 
3 23764073 23764403 330 Deletion 0 
3 144888449 144888910 461 Deletion 0 
3 185017344 185017669 325 Deletion 0 
4 3612027 3612659 632 Deletion 0 
4 29661122 29661450 328 Deletion 0 
4 43931496 43931837 341 Deletion 0 
4 44509394 44509712 318 Deletion 0 
4 58087343 58087741 398 Deletion 0 
4 92280245 92285214 4969 Deletion KIAA1680 
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4 100023050 100023385 335 Deletion 0 
4 149990582 149992581 1999 Deletion 0 
4 181549440 181549754 314 Deletion 0 
4 189969695 189970049 354 Deletion 0 
4 190624640 190624987 347 Deletion 0 
5 42165941 42167782 1841 Deletion 0 
5 45004820 45014528 9708 Deletion 0 
5 68724047 68724498 451 Deletion MARVELD2 
5 93916299 93916636 337 Deletion C5orf36 
5 127172332 127173282 950 Deletion LOC728586 
5 177821921 177823857 1936 Deletion COL23A1 
5 178106931 178111943 5012 Deletion 0 
6 857494 857907 413 Deletion 0 
6 11556106 11556426 320 Deletion TMEM170B 
6 32624895 32625860 965 Deletion 0 
6 33026728 33028610 1882 Deletion 0 
6 33125920 33126843 923 Deletion 0 
6 50765971 50766282 311 Deletion 0 
6 57297190 57301246 4056 Deletion PRIM2 
6 106983636 106983955 319 Deletion AIM1 
6 119417519 119417847 328 Deletion FAM184A 
6 133371501 133371845 344 Deletion 0 
6 134062939 134063433 494 Deletion 0 
6 154446930 154447253 323 Deletion OPRM1 
7 9634650 9635993 1343 Deletion 0 
7 42549714 42550036 322 Deletion 0 
7 158029478 158030452 974 Deletion PTPRN2 
8 98595409 98595748 339 Deletion 0 
9 71895487 71896647 1160 Deletion 0 
9 87775285 87776256 971 Deletion 0 
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9 129520461 129523267 2806 Deletion 0 
9 136379222 136379564 342 Deletion 0 
10 35593222 35593552 330 Deletion CCNY 
10 57702043 57702383 340 Deletion 0 
10 107253002 107253355 353 Deletion 0 
10 114157801 114158139 338 Deletion ACSL5 
11 7716915 7717231 316 Deletion OVCH2 
11 31916727 31917056 329 Deletion 0 
11 32286653 32286986 333 Deletion 0 
11 33537687 33538010 323 Deletion 0 
11 65642111 65643526 1415 Deletion 0 
11 104755159 104762566 7407 Deletion CASP12 
12 124458567 124496090 37523 Deletion ZNF664 
12 130060303 130060634 331 Deletion TMEM132D 
13 23055219 23055526 307 Deletion 0 
13 81747255 81747583 328 Deletion 0 
13 93056847 93057422 575 Deletion GPC5 
14 35428814 35432457 3643 Deletion 0 
14 38643511 38643828 317 Deletion 0 
14 42486335 42486650 315 Deletion 0 
14 76813774 76814209 435 Deletion 0 
14 78828245 78828596 351 Deletion 0 
14 100845014 100845347 333 Deletion WDR25 
15 22336853 22344093 7240 Deletion LOC727924 
15 39372537 39373645 1108 Deletion 0 
15 41864762 41865200 438 Deletion TYRO3 
15 42017748 42018080 332 Deletion MGA 
15 50946438 50947428 990 Deletion TRPM7 
15 67083771 67084069 298 Deletion 0 
15 83773883 83774212 329 Deletion 0 
!! 249!
15 91173990 91174326 336 Deletion CRTC3 
15 91981580 91989268 7688 Deletion 0 
15 93515798 93516111 313 Deletion CHD2 
16 12002336 12002661 325 Deletion GSPT1 
16 23910887 23911193 306 Deletion PRKCB 
16 86284321 86284629 308 Deletion 0 
17 136772 138726 1954 Deletion RPH3AL 
17 193726 197057 3331 Deletion RPH3AL 
17 41382745 41399871 17126 Deletion 0 
17 41383489 41466010 82521 Deletion LOC100130581 
17 46904824 46907714 2890 Deletion 0 
17 47228439 47228769 330 Deletion B4GALNT2 
17 57363991 57365775 1784 Deletion 0 
17 69852154 69852481 327 Deletion 0 
18 1199564 1200310 746 Deletion TFG/GPR128 
18 3997022 3997479 457 Deletion 0 
18 22892494 22892818 324 Deletion ZNF521 
18 27629690 27630016 326 Deletion 0 
18 37061646 37061962 316 Deletion LOC647946 
18 43261014 43261339 325 Deletion SLC14A2 
18 44338433 44338770 337 Deletion 0 
18 50462567 50463032 465 Deletion DCC 
19 1182661 1183179 518 Deletion 0 
19 2128535 2129051 516 Deletion AP3D1 
19 45473177 45474322 1145 Deletion CLPTM1 
20 25583242 25583678 436 Deletion 0 
20 33241939 33244364 2425 Deletion PIGU 
20 53292665 53292978 313 Deletion 0 
21 16588380 16591454 3074 Deletion 0 
21 36072707 36073562 855 Deletion CLIC6 
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21 39590542 39590888 346 Deletion 0 
22 33295772 33296090 318 Deletion SYN3 
22 49622515 49624301 1786 Deletion 0 
X 31577478 31577794 316 Deletion DMD 
X 85605177 85609869 4692 Deletion DACH2 
X 138384911 138385237 326 Deletion 0 
1 30569469 30965397 395928 Tandem Dup 0 
2 242929421 242929637 216 Tandem Dup 0 
3 139670597 139674454 3857 Tandem Dup CLSTN2 
4 190478831 190479023 192 Tandem Dup 0 
6 160877802 160956684 78882 Tandem Dup LOC100289195;LPA;LPAL2 
7 606117 606324 207 Tandem Dup PRKAR1B 
7 156124573 156124795 222 Tandem Dup 0 
9 44070664 44070787 123 Tandem Dup LOC100289454 
9 140563766 140564031 265 Tandem Dup 0 
10 27224456 27229304 4848 Tandem Dup C10orf51 
13 34811550 34815591 4041 Tandem Dup 0 
14 105943990 105944114 124 Tandem Dup CRIP2 
19 14706528 14706835 307 Tandem Dup CLEC17A 
X 52886720 55678950 2792230 Tandem Dup 
XAGE4;ALAS2;APEX2;FAM104
B;FAM120C;FAM156A;FAM156
B;FGD1;FOXR2;GNL3L;GPR17
3;HSD17B10;HUWE1;IQSEC2;I
TIH5L;KDM5C;LOC100132984;L
OC100288024;LOC100288052;
LOC100288498;LOC100288560
;LOC644893;MAGED2;MAGEH1
;PAGE2;PAGE2B;PAGE3;PAGE
5;PFKFB1;PHF8;RIBC1;SMC1A;
SNORA11;TRO;TSPYL2;TSR2;
USP51;WNK3;XAGE3 
2 16407764/ 16406392 
16407988/ 
16406410 224 Distal Dup 0 
3 194546260/ 194546429/ 169 Distal Dup 0 
!! 251!
194543294 194543309 
7 100550585/ 100551244 
100550785/ 
100551247 200 Distal Dup MUC3A 
9 107816635/ 107817341 
107816979/ 
107817348 344 Distal Dup 0 
23 17060848/ 17063276 
17061023/ 
17063295 175 Distal Dup REPS2 
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Appendix E - Selected Regions for Sanger Sequencing. (NCBI Build 37/hg19) 
Family Chr 
Position of 
Targeted 
Variant 
Gene Symbol Gene Region Forward Primer Reverse Primer 
Size  
(bp) Result 
1 3 75787298 LOC100287163 Exonic 
5'TTTCCACATTCG
TTACATGCGTAT3' 
5'GTGGAAAAACTTTT
CACTGTAAGTCAC3' 511 
Identical 
between co-
twins 
1 3 75787304 LOC100287163 Exonic 
Identical 
between co-
twins 
1 4 85996 ZNF595 Intronic; Exonic 
5'TCGTTTTACATG
TCACACCTAACT3' 
5'TTATGTTCGTT 
CAGAACTGTGG3' 199 
Identical 
between co-
twins 
1 4 86004 ZNF595 Intronic; Exonic Mosaicism? 
1 4 86022 ZNF595 Intronic; Exonic 
Identical 
between co-
twins 
1 4 86043 ZNF595 Intronic; Exonic 
Identical 
between co-
twins 
1 11 48346662 OR4C3 Exonic 5'CTCTACATGGTTTTCTCAAGTGTG3' 
5'ACAATGAGTCAG 
CAATGAGTTTAG3' 634 
Identical 
between co-
twins 
1 12 40880542 MUC19 Exonic 
5'TAGAACATCGG 
TTGAAGAATCA3' 
5'AGCTGATGG 
CCGAATTGT3' 523 
Mosaicism? 
1 12 40880545 MUC19 Exonic 
Identical 
between co-
twins 
1 13 25671607 PABPC3 Exonic 5'CCAGGCTTAC CTCACTAACG3' 
5'TCCCGCAGCA 
TATTTATACC3' 412 
Identical 
between co-
twins 
1 17 74288421 QRICH2 Exonic 5'TACCTTGCTGA CCTATTCCAG3' 
5'AGATTGATGT 
GGTGCAACCT3' 672 Mosaicism? 
1 17 74288565 QRICH2 Exonic 5'TACCTTGCTGA CCTATTCCAG3' 
5'AGATTGATGT 
GGTGCAACCT3' 672 
Identical 
between co-
twins 
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1 22 29885594 NEFH Exonic 
5'GGAAAAGGCCA
AGTCTCCAACG3' 
5'TTCCTTTTTTGG 
GATCTCCTTCTCA3' 550 
Identical 
between co-
twins 
1 22 29885599 NEFH Exonic 
Identical 
between co-
twins 
2 1 1650787 CDK11A/CDK11B Exonic; 5'UTR 
5'CTTTCAGC 
TAGTTTGCTC 
TCTCTGGTT3' 
5'TCGTTCCTATCTG 
AATCATGCATTTT3' 516 
Identical 
between co-
twins 
2 1 1650797 CDK11A/CDK11B 
Splice 
Site; 
Exonic; 
5'UTR 
Identical 
between co-
twins 
2 1 1650801 CDK11A/CDK11B Exonic; 5'UTR 
Identical 
between co-
twins 
2 1 111957583 OVGP1 Exonic 
5'TATGTTTCTG 
GAGGGGACAG3' 
5'TGTGACCACT 
GGACAGAAGA3' 241 
Identical 
between co-
twins 
2 1 111957592 OVGP1 Exonic 
Identical 
between co-
twins 
2 1 144916673 PDE4DIP Exonic 5'CCTGAGGAGTA TGGGGTAATCA3' 
5'TGCCTCCAC 
TTCTTTGTTCC3' 239 Mosaicism? 
2 8 103573011 ODF1 Exonic 5'TCAAGATCGA GTCTCCTTGC3' 
5'CTTTCACACA 
ACACCAGCAG3' 317 
Identical 
between co-
twins 
2 11 56143963 OR8U1 Exonic 5'ATGCTGGCAG TCACCATATT3' 
5'CAGAGCTTCT 
TTCACCTCCTT3' 171 
Identical 
between co-
twins 
2 19 4511197 PLIN4 Exonic 5'ATTTACGGCAC CAGTGACTC3' 
5'GACCCAAAAT 
ATCGCAACAG3' 262 Mosaicism? 
2 22 38120180 TRIOBP Exonic 5'CTCTTCTACC CAGCAGGACA3' 
5'TGTCTCGCT 
GGATGGTTC3' 1160 
Identical 
between co-
twins 
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Appendix F - Promoters differentially methylated between co-twins in Family 1. (NCBI Build 36/hg18) 
The regions represent 330 unique genes. 
Transcript Chromosome Region Start Region End p-value (region) Methylation Status 
DVL1 1 1275260 1275280 0.000909697 Decreased 
KIAA1751 1 1901884 1901904 0.000849051 Decreased 
CEP104 1 3763670 3763690 0.000606465 Decreased 
DFFB 1 3763670 3763690 0.000606465 Decreased 
CAMTA1 1 7687801 7687821 0.000363879 Decreased 
CLSTN1 1 9807577 9807597 0.000363879 Decreased 
PTCHD2 1 11461175 11461195 0.000606465 Decreased 
HNRNPCP5 1 13107459 13107479 0.000849051 Decreased 
KAZN 1 15122441 15122461 0.000121293 Decreased 
KAZN 1 15122441 15122461 0.000121293 Decreased 
RUNX3 1 25107194 25107214 0.000545818 Decreased 
RUNX3 1 25107194 25107214 0.000545818 Decreased 
HMGN2 1 26670728 26670748 0.000121293 Decreased 
WDTC1 1 27432713 27432733 0.000909697 Decreased 
RAB42 1 28790511 28790531 0.000909697 Decreased 
RAB42 1 28790511 28790531 0.000909697 Decreased 
OPRD1 1 29062206 29062226 0.000667111 Decreased 
CSMD2 1 34403910 34403930 0.000788404 Decreased 
CSMD2 1 34403910 34403930 0.000788404 Decreased 
C1orf94 1 34403910 34403930 0.000788404 Decreased 
TCTEX1D4 1 45046099 45046119 0.000970344 Decreased 
BTBD19 1 45046099 45046119 0.000970344 Decreased 
TMEM61 1 55218127 55218147 0.000788404 Decreased 
MAN1A2 1 117710682 117710702 0.000909697 Increased 
NBPF25P 1 147169424 147169444 0.000970344 Increased 
DRD5P2 1 147169424 147169444 0.000970344 Increased 
!! 255!
LOC101060524 1 147169424 147169444 0.000970344 Increased 
HIST2H2AA3 1 148085850 148085870 0.000121293 Increased 
HIST2H2AA4 1 148085850 148085870 0.000121293 Increased 
HIST2H2AA3 1 148085850 148085870 0.000121293 Increased 
HIST2H2AA4 1 148085850 148085870 0.000121293 Increased 
HIST2H3A 1 148085850 148085870 0.000121293 Increased 
HIST2H3C 1 148085850 148085870 0.000121293 Increased 
HIST2H2BE 1 148125357 148125377 0.000242586 Increased 
HIST2H2BE 1 148123735 148123755 0.000363879 Increased 
HIST2H2AC 1 148125357 148125377 0.000242586 Increased 
HIST2H2AC 1 148123735 148123755 0.000363879 Increased 
HIST2H2AB 1 148125357 148125377 0.000242586 Increased 
HIST2H2AB 1 148123735 148123755 0.000363879 Increased 
LOC100505666 1 153301911 153301931 0.000909697 Increased 
EFNA4 1 153301911 153301931 0.000909697 Increased 
CD48 1 158931804 158931824 0.000545818 Increased 
FCRLB 1 159963081 159963101 0.000788404 Increased 
FCRLB 1 159963081 159963101 0.000788404 Increased 
C1orf145 1 226467367 226467387 0.000788404 Increased 
C1orf145 1 226467367 226467387 0.000788404 Increased 
OBSCN 1 226570772 226570792 0.000909697 Increased 
OBSCN 1 226467367 226467387 0.000788404 Increased 
MYT1L 2 1920311 1920331 0.000242586 Decreased 
TSSC1 2 3270302 3270322 0.000121293 Decreased 
CCDC121 2 27705190 27705210 0.000849051 Decreased 
CCDC121 2 27705190 27705210 0.000849051 Decreased 
GPN1 2 27705190 27705210 0.000849051 Decreased 
GPN1 2 27705190 27705210 0.000849051 Decreased 
ZFP36L2 2 43307309 43307329 0.000727758 Decreased 
LINC01126 2 43307309 43307329 0.000727758 Decreased 
!! 256!
ABCG5 2 43919524 43919544 0.000606465 Decreased 
ABCG8 2 43919524 43919544 0.000606465 Decreased 
SIX2 2 45094469 45094489 0.000606465 Decreased 
PSME4 2 54052386 54052406 0.000909697 Decreased 
LIMS1 2 108517237 108517257 0.000667111 Decreased 
ACVR2A 2 148318114 148318134 0.000909697 Increased 
ACVR2A 2 148318114 148318134 0.000909697 Increased 
OBSL1 2 220136462 220136482 0.000606465 Increased 
SLC4A3 2 220199610 220199630 0.000363879 Increased 
PRR21 2 240631724 240631744 0.000424525 Increased 
OR6B3 2 240631724 240631744 0.000424525 Increased 
ANO7 2 241798453 241798473 0.000727758 Increased 
CAND2 3 12826659 12826679 0.000849051 Decreased 
SCN5A 3 38667000 38667020 0.000849051 Decreased 
SCN5A 3 38667000 38667020 0.000849051 Decreased 
RPL29 3 52005903 52005923 0.000121293 Decreased 
ARHGEF3 3 57068583 57068603 0.000909697 Decreased 
SPATA12 3 57068583 57068603 0.000909697 Decreased 
ATXN7 3 63873213 63873233 0.000909697 Decreased 
ATXN7 3 63873213 63873233 0.000909697 Increased 
ZNF717 3 75917850 75917870 0.000363879 Increased 
ZNF717 3 75917850 75917870 0.000363879 Increased 
ARGFX 3 122768542 122768562 0.000060647 Increased 
ZBTB38 3 142604007 142604027 0.000303232 Increased 
PCGF3 4 706619 706639 0.000242586 Decreased 
UVSSA 4 1356565 1356585 0.000849051 Decreased 
FGFR3 4 1774162 1774182 0.000788404 Decreased 
C4orf48 4 2012702 2012722 0.000363879 Decreased 
C4orf48 4 2012702 2012722 0.000363879 Decreased 
MSANTD1 4 3219674 3219694 0.000667111 Decreased 
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C4orf17 4 100650297 100650317 0.000545818 Decreased 
FRG1 4 191098042 191098062 0.000849051 Decreased 
LOC283788 4 191098042 191098062 0.000849051 Increased 
PDCD6 5 356365 356385 0.000667111 Decreased 
AHRR 5 356365 356385 0.000667111 Decreased 
SLC6A18 5 1296782 1296802 0.000909697 Decreased 
TERT 5 1346428 1346448 0.000242586 Decreased 
SLC6A3 5 1469888 1469908 0.000849051 Decreased 
LOC100133050 5 99752762 99752782 0.000242586 Decreased 
SOWAHA 5 132176644 132176664 0.000606465 Decreased 
TIFAB 5 134816893 134816913 0.000242586 Decreased 
DRD1 5 174804674 174804694 0.000242586 Decreased 
LOC102577424 5 176103116 176103136 0.000606465 Decreased 
PFN3 5 176763553 176763573 0.000303232 Increased 
F12 5 176763553 176763573 0.000303232 Increased 
EXOC2 6 465198 465218 0.000849051 Decreased 
TUBB2B 6 3173705 3173725 0.000909697 Decreased 
HIST1H2AA 6 25834901 25834952 0.000667111 Increased 
HIST1H2BA 6 25834901 25834952 0.000667111 Increased 
HIST1H1C 6 26164302 26164322 0.000667111 Increased 
HIST1H1E 6 26264920 26264940 0.000788404 Increased 
HIST1H2BD 6 26264920 26264940 0.000788404 Increased 
DPCR1 6 31026612 31026632 0.000545818 Decreased 
ATP6V1G2-DDX39B 6 31620675 31620695 0.000909697 Decreased 
DDX39B 6 31620675 31620695 0.000909697 Decreased 
SNORD84 6 31620675 31620695 0.000909697 Decreased 
ATP6V1G2 6 31620675 31620695 0.000909697 Increased 
NFKBIL1 6 31620675 31620695 0.000909697 Increased 
NFKBIL1 6 31620675 31620695 0.000909697 Increased 
VEGFA 6 43845650 43845670 0.000727758 Increased 
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VEGFA 6 43845650 43845670 0.000727758 Increased 
CD2AP 6 47552558 47552578 0.000667111 Increased 
DDO 6 110828027 110828047 0.000363879 Increased 
ECHDC1 6 127706751 127706771 0.000242586 Increased 
ECHDC1 6 127706751 127706771 0.000242586 Increased 
WTAP 6 160067450 160067470 0.000788404 Increased 
WTAP 6 160067450 160067470 0.000788404 Increased 
RPS6KA2-AS1 6 167234121 167234141 0.000545818 Increased 
TCP10 6 167718893 167718913 0.000667111 Increased 
FAM120B 6 170528419 170528439 0.000121293 Increased 
FAM120B 6 170528419 170528439 0.000121293 Increased 
FAM120B 6 170528419 170528439 0.000121293 Increased 
PRKAR1B 7 717528 717548 0.000667111 Decreased 
PRKAR1B 7 717528 717548 0.000667111 Decreased 
PRKAR1B 7 717528 717548 0.000667111 Decreased 
PRKAR1B 7 717528 717548 0.000667111 Decreased 
PRKAR1B 7 717528 717548 0.000667111 Decreased 
C7orf50 7 1122890 1122910 0.000121293 Decreased 
TMEM184A 7 1557219 1557239 0.000424525 Increased 
MAD1L1 7 1877342 1877362 0.000545818 Increased 
MAD1L1 7 2056253 2056273 0.000121293 Increased 
TTYH3 7 2664585 2664605 0.000606465 Decreased 
GRID2IP 7 6510144 6510164 0.000970344 Increased 
SCIN 7 12594747 12594767 0.000363879 Increased 
SCIN 7 12594747 12594767 0.000363879 Increased 
MEOX2 7 15693738 15693758 0.000849051 Increased 
LOC101927524 7 15693738 15693758 0.000849051 Increased 
HIBADH 7 27670032 27670052 0.000363879 Increased 
MYO1G 7 44986098 44986118 0.000606465 Increased 
HIP1 7 75106363 75106383 0.000667111 Increased 
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SND1 7 127423872 127423892 0.000849051 Increased 
SND1-IT1 7 127423872 127423892 0.000849051 Increased 
CNPY1 7 154995456 154995476 0.000242586 Increased 
PTPRN2 7 157352628 157352648 0.000909697 Increased 
PTPRN2 7 157941351 157941371 0.000181939 Increased 
ERICH1-AS1 8 972376 972396 0.000121293 Decreased 
ERICH1-AS1 8 1040976 1040996 0.000242586 Decreased 
ERICH1-AS1 8 977324 977344 0.000242586 Decreased 
ERICH1-AS1 8 780350 780370 0.000363879 Decreased 
ERICH1-AS1 8 905345 905365 0.000242586 Decreased 
MCPH1 8 6411949 6411969 0.000667111 Decreased 
ANGPT2 8 6411949 6411969 0.000667111 Decreased 
FAM66D 8 12025118 12025138 0.000545818 Decreased 
FAM66D 8 12034583 12034603 0.000849051 Decreased 
LOC392196 8 12025118 12025138 0.000545818 Decreased 
USP17L2 8 12034583 12034603 0.000849051 Decreased 
TACC1 8 38733972 38733992 0.000606465 Decreased 
ADAM5 8 39290413 39290433 0.000970344 Decreased 
UTP23 8 117846997 117847017 0.000727758 Decreased 
TRAPPC9 8 141428560 141428580 0.000909697 Decreased 
TRAPPC9 8 141428560 141428580 0.000909697 Decreased 
SLC45A4 8 142332019 142332039 0.000545818 Decreased 
PTP4A3 8 142509287 142509307 0.000909697 Decreased 
TSNARE1 8 143405544 143405564 0.000485172 Decreased 
PSCA 8 143757951 143757971 0.000788404 Increased 
PSCA 8 143757951 143757971 0.000788404 Increased 
SLURP1 8 143821736 143821756 0.000121293 Increased 
LOC100133669 8 144171219 144171239 0.000909697 Increased 
LY6E 8 144171219 144171239 0.000909697 Increased 
ZFP41 8 144409425 144409445 0.000121293 Increased 
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FAM83H 8 144881577 144881597 0.000727758 Increased 
SCRIB 8 144965172 144965192 0.000606465 Increased 
SCRIB 8 144959364 144959384 0.000909697 Increased 
MIR937 8 144965172 144965192 0.000606465 Increased 
PGM5-AS1 9 70162095 70162115 0.000363879 Decreased 
PGM5 9 70162095 70162115 0.000363879 Decreased 
C9orf3 9 96807113 96807133 0.000727758 Decreased 
C9orf3 9 96807113 96807133 0.000727758 Decreased 
FSD1L 9 107249215 107249235 0.000909697 Decreased 
ZBTB43 9 128635281 128635301 0.000060647 Decreased 
GPR107 9 131854890 131854910 0.000909697 Decreased 
RXRA 9 136440826 136440846 0.000667111 Decreased 
GPSM1 9 138356958 138356978 0.000909697 Decreased 
GPSM1 9 138351213 138351233 0.000909697 Increased 
INPP5E 9 138448648 138448668 0.000485172 Increased 
MAN1B1 9 139117758 139117778 0.000363879 Increased 
FAM166A 9 139263786 139263806 0.000727758 Increased 
C9orf173 9 139263786 139263806 0.000727758 Increased 
CACNA1B 9 139936085 139936105 0.000849051 Increased 
DIP2C 10 620619 620639 0.000545818 Decreased 
DIP2C 10 684962 684982 0.000849051 Decreased 
DIP2C 10 382685 382705 0.000363879 Decreased 
PRR26 10 684962 684982 0.000849051 Decreased 
PRR26 10 684962 684982 0.000849051 Decreased 
ADARB2 10 1732764 1732784 0.000242586 Increased 
PRF1 10 72030426 72030446 0.000909697 Increased 
GPR123 10 134776326 134776346 0.000242586 Increased 
GPR123 10 134776326 134776346 0.000242586 Increased 
PKP3 11 383291 383311 0.000727758 Decreased 
C11orf35 11 545626 545646 0.000909697 Decreased 
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H19 11 1974422 1974442 0.000667111 Decreased 
MIR675 11 1974422 1974442 0.000667111 Decreased 
INS-IGF2 11 2139920 2139940 0.000606465 Decreased 
INS 11 2139920 2139940 0.000606465 Decreased 
HIPK3 11 33235017 33235037 0.000909697 Decreased 
HIPK3 11 33235017 33235037 0.000909697 Decreased 
HIPK3 11 33235017 33235037 0.000909697 Increased 
TTC17 11 43336141 43336161 0.000909697 Increased 
MDK 11 46358724 46358744 0.000909697 Increased 
MDK 11 46358724 46358744 0.000909697 Increased 
MDK 11 46358724 46358744 0.000909697 Increased 
MDK 11 46358724 46358744 0.000909697 Increased 
OR5I1 11 55461357 55461377 0.000788404 Increased 
NRXN2 11 64168118 64168138 0.000363879 Increased 
NRXN2 11 64168118 64168138 0.000363879 Increased 
KCNK7 11 65123625 65123645 0.000727758 Increased 
MAP3K11 11 65123625 65123645 0.000727758 Increased 
CARNS1 11 66945049 66945069 0.000181939 Increased 
FAM86C2P 11 67330288 67330308 0.000727758 Increased 
MIR3649 12 1642474 1642494 0.000788404 Decreased 
SPX 12 21571952 21571972 0.000727758 Increased 
ASCL4 12 106693398 106693418 0.000667111 Increased 
ACADS 12 119661601 119661621 0.000727758 Increased 
HNF1A 12 119900006 119900026 0.000303232 Increased 
EP400 12 131086579 131086599 0.000667111 Increased 
ANKLE2 12 131819474 131819494 0.000242586 Increased 
DGKH 13 41512904 41512924 0.000909697 Increased 
TFDP1 13 113308369 113308389 0.000849051 Increased 
TFDP1 13 113308369 113308389 0.000849051 Increased 
TMEM255B 13 113606174 113606194 0.000606465 Increased 
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RASA3 13 113824201 113824221 0.000485172 Increased 
RASA3 13 113856967 113856987 0.000242586 Increased 
HNRNPC 14 20808383 20808403 0.000788404 Increased 
ZBTB25 14 64040665 64040685 0.000727758 Increased 
ZBTB1 14 64040665 64040685 0.000727758 Increased 
SERPINA12 14 94054839 94054859 0.000363879 Increased 
C14orf180 14 104116175 104116195 0.000667111 Increased 
C14orf180 14 104116175 104116195 0.000667111 Increased 
C14orf80 14 105036181 105036201 0.000363879 Increased 
C14orf80 14 105036181 105036201 0.000363879 Increased 
C14orf80 14 105036181 105036201 0.000363879 Increased 
SNORD116-8 15 22868070 22868090 0.000121293 Increased 
SNORD116-3 15 22868070 22868090 0.000121293 Increased 
SNORD116-9 15 22868070 22868090 0.000121293 Increased 
SNORD116-10 15 22868070 22868090 0.000121293 Increased 
SNORD116-11 15 22868070 22868090 0.000121293 Increased 
SNORD115-10 15 22983806 22983826 0.000788404 Increased 
SNORD115-12 15 22983806 22983826 0.000788404 Increased 
SNORD115-9 15 22983806 22983826 0.000788404 Increased 
SNORD115-5 15 22983806 22983826 0.000788404 Increased 
SNORD115-10 15 22983806 22983826 0.000788404 Increased 
SNORD115-11 15 22983806 22983826 0.000788404 Increased 
SNORD115-29 15 22983806 22983826 0.000788404 Increased 
SNORD115-36 15 22983806 22983826 0.000788404 Increased 
SNORD115-43 15 22983806 22983826 0.000788404 Increased 
SNORD115-10 15 22983806 22983826 0.000788404 Increased 
SNORD115-12 15 22983806 22983826 0.000788404 Increased 
SNORD115-9 15 22983806 22983826 0.000788404 Increased 
SNORD115-5 15 22983806 22983826 0.000788404 Increased 
SNORD115-33 15 23030052 23030072 0.000545818 Increased 
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SNORD115-34 15 23030052 23030072 0.000545818 Increased 
SNORD115-35 15 23030052 23030072 0.000545818 Increased 
SNORD115-11 15 23030052 23030072 0.000545818 Increased 
SNORD115-29 15 23030052 23030072 0.000545818 Increased 
SNORD115-36 15 23030052 23030072 0.000545818 Increased 
SNORD115-43 15 23030052 23030072 0.000545818 Increased 
SNORD115-37 15 23030052 23030072 0.000545818 Increased 
GABRB3 15 24425395 24425415 0.000788404 Decreased 
GABRB3 15 24425395 24425415 0.000788404 Decreased 
GABRB3 15 24425395 24425415 0.000788404 Decreased 
GABRB3 15 24425395 24425415 0.000788404 Decreased 
OCA2 15 25689155 25689175 0.000363879 Decreased 
BAHD1 15 38520115 38520135 0.000363879 Decreased 
RHOV 15 38954636 38954656 0.000727758 Decreased 
CALML4 15 66286407 66286427 0.000667111 Decreased 
CLN6 15 66286407 66286427 0.000667111 Decreased 
CELF6 15 70369057 70369077 0.000909697 Decreased 
CELF6 15 70369057 70369077 0.000909697 Increased 
CELF6 15 70369057 70369077 0.000909697 Increased 
CD276 15 71762795 71762815 0.000909697 Increased 
MTHFS 15 77977330 77977350 0.000909697 Increased 
MTHFS 15 77977330 77977350 0.000909697 Increased 
MTHFS 15 77977330 77977350 0.000909697 Increased 
ST20-MTHFS 15 77977330 77977350 0.000909697 Increased 
ZNF710 15 88345120 88345140 0.000606465 Increased 
IGF1R 15 97009952 97009972 0.000909697 Increased 
PRKXP1 15 98914519 98914539 0.000242586 Increased 
RAB40C 16 604302 604322 0.000424525 Decreased 
RAB40C 16 604302 604322 0.000424525 Decreased 
RAB40C 16 604302 604322 0.000424525 Decreased 
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RAB40C 16 604302 604322 0.000424525 Decreased 
WDR90 16 657369 657389 0.000909697 Decreased 
RHOT2 16 657369 657389 0.000909697 Decreased 
CHTF18 16 773832 773852 0.000667111 Decreased 
TRAF7 16 2155184 2155204 0.000121293 Decreased 
ZSCAN10 16 3079775 3079795 0.000909697 Decreased 
ZSCAN10 16 3079775 3079795 0.000909697 Decreased 
SNX29 16 12118466 12118486 0.000363879 Decreased 
PDILT 16 20325935 20325955 0.000667111 Decreased 
ACSM5 16 20325935 20325955 0.000667111 Decreased 
TP53TG3 16 32596474 32596494 0.000667111 Decreased 
TP53TG3B 16 32596474 32596494 0.000667111 Decreased 
TP53TG3C 16 32596474 32596494 0.000667111 Decreased 
TP53TG3 16 33111540 33111560 0.000909697 Decreased 
TP53TG3B 16 33111540 33111560 0.000909697 Decreased 
TP53TG3C 16 33111540 33111560 0.000909697 Decreased 
TP53TG3 16 33168075 33168095 0.000424525 Decreased 
TP53TG3B 16 33168075 33168095 0.000424525 Decreased 
TP53TG3C 16 33168075 33168095 0.000424525 Decreased 
CTCF 16 66153279 66153299 0.000667111 Increased 
BANP 16 86591053 86591073 0.000121293 Increased 
BANP 16 86591053 86591073 0.000121293 Increased 
BANP 16 86591053 86591073 0.000121293 Increased 
IL17C 16 87228505 87228525 0.000667111 Increased 
CBFA2T3 16 87489347 87489367 0.000667111 Increased 
CBFA2T3 16 87489347 87489367 0.000667111 Increased 
SLC22A31 16 87795446 87795466 0.000909697 Increased 
CPNE7 16 88174559 88174579 0.000424525 Increased 
SPIRE2 16 88428574 88428594 0.000242586 Increased 
TCF25 16 88488219 88488239 0.000606465 Increased 
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RPH3AL 17 206061 206081 0.000545818 Decreased 
FLJ36000 17 21827263 21827283 0.000485172 Decreased 
SRCIN1 17 33968132 33968152 0.000606465 Decreased 
CNTNAP1 17 38092471 38092491 0.000788404 Decreased 
VAT1 17 38429338 38429358 0.000909697 Decreased 
RND2 17 38429338 38429358 0.000909697 Decreased 
ATXN7L3 17 39632047 39632067 0.000909697 Decreased 
ARL17A 17 41944466 41944486 0.000545818 Decreased 
LRRC37A2 17 41944466 41944486 0.000545818 Decreased 
WNT3 17 42251986 42252006 0.000667111 Decreased 
SP6 17 43280191 43280211 0.000363879 Decreased 
SP6 17 43280191 43280211 0.000363879 Decreased 
NGFR 17 44927754 44927774 0.000667111 Decreased 
TEX2 17 59695170 59695190 0.000667111 Decreased 
RPTOR 17 76132310 76132330 0.000909697 Decreased 
CHMP6 17 76579427 76579447 0.000727758 Increased 
LDLRAD4 18 13489230 13489250 0.000363879 Decreased 
LDLRAD4 18 13252790 13252810 0.000363879 Decreased 
LDLRAD4 18 13489230 13489250 0.000363879 Decreased 
KATNAL2 18 42804957 42804977 0.000242586 Decreased 
KATNAL2 18 42810872 42810892 0.000545818 Decreased 
KATNAL2 18 42798912 42798932 0.000303232 Decreased 
TCEB3CL 18 42798912 42798932 0.000303232 Decreased 
TCEB3CL2 18 42798912 42798932 0.000303232 Decreased 
TCEB3C 18 42804957 42804977 0.000242586 Decreased 
TCEB3CL 18 42804957 42804977 0.000242586 Decreased 
TCEB3CL2 18 42804957 42804977 0.000242586 Decreased 
TCEB3C 18 42810872 42810892 0.000545818 Increased 
TCEB3CL 18 42810872 42810892 0.000545818 Increased 
RAB27B 18 50645912 50645932 0.000545818 Increased 
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BCL2 18 59136592 59136612 0.000909697 Increased 
SALL3 18 74840102 74840122 0.000667111 Increased 
NFATC1 18 75281489 75281509 0.000667111 Increased 
NFATC1 18 75281489 75281509 0.000667111 Increased 
CTDP1 18 75555426 75555446 0.000788404 Increased 
CTDP1 18 75555426 75555446 0.000788404 Increased 
PQLC1 18 75777134 75777154 0.000303232 Increased 
FSTL3 19 631247 631267 0.000667111 Decreased 
HMHA1 19 1017228 1017248 0.000909697 Decreased 
HMHA1 19 1017228 1017248 0.000909697 Decreased 
HMHA1 19 1017228 1017248 0.000909697 Decreased 
DAZAP1 19 1371068 1371088 0.000303232 Decreased 
MKNK2 19 1989481 1989501 0.000121293 Decreased 
AP3D1 19 2066512 2066532 0.000667111 Decreased 
KDM4B 19 4995039 4995059 0.000363879 Decreased 
PTPRS 19 5244600 5244620 0.000606465 Decreased 
STXBP2 19 7618186 7618206 0.000121293 Increased 
ZNF564 19 12527452 12527472 0.000363879 Increased 
FCHO1 19 17722410 17722430 0.000727758 Increased 
FCHO1 19 17722410 17722430 0.000727758 Increased 
MAST3 19 18095801 18095821 0.000909697 Increased 
POP4 19 34793172 34793192 0.000909697 Increased 
PLEKHF1 19 34847241 34847261 0.000242586 Increased 
ZNF829 19 42099041 42099061 0.000788404 Increased 
ZNF829 19 42099041 42099061 0.000788404 Increased 
ZNF568 19 42099041 42099061 0.000788404 Increased 
PPP1R13L 19 50591427 50591447 0.000909697 Increased 
PPP1R13L 19 50591427 50591447 0.000909697 Increased 
RPL13A 19 54683534 54683554 0.000849051 Increased 
RPL13AP5 19 54683534 54683554 0.000849051 Increased 
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SNORD32A 19 54683534 54683554 0.000849051 Increased 
SNORD33 19 54683534 54683554 0.000849051 Increased 
SNORD34 19 54683534 54683554 0.000849051 Increased 
SNORD35A 19 54683534 54683554 0.000849051 Increased 
PRR12 19 54789900 54789920 0.000909697 Increased 
SHANK1 19 55881768 55881788 0.000606465 Increased 
FIZ1 19 60805831 60805851 0.000667111 Increased 
ZNF524 19 60805831 60805851 0.000667111 Increased 
NLRP4 19 61061344 61061364 0.000121293 Increased 
ZNF552 19 63018998 63019018 0.000788404 Increased 
MIR4754 19 63589522 63589542 0.000909697 Increased 
RPS5 19 63589522 63589542 0.000909697 Increased 
BMP2 20 6695915 6695935 0.000363879 Decreased 
RRBP1 20 17611434 17611454 0.000727758 Decreased 
FAM182B 20 25725783 25725803 0.000485172 Decreased 
FAM182B 20 25725783 25725803 0.000485172 Decreased 
FRG1B 20 28224614 28224634 0.000545818 Decreased 
EPB41L1 20 34143906 34143926 0.000606465 Decreased 
EPB41L1 20 34143906 34143926 0.000606465 Decreased 
GNAS 20 56879799 56879819 0.000121293 Increased 
GNAS 20 56879799 56879819 0.000121293 Increased 
CABLES2 20 60405040 60405060 0.000121293 Decreased 
LOC63930 20 61145881 61145901 0.000242586 Decreased 
LINC01056 20 61145881 61145901 0.000242586 Decreased 
YTHDF1 20 61318845 61318865 0.000667111 Decreased 
ARFGAP1 20 61389848 61389868 0.000606465 Decreased 
ARFGAP1 20 61389848 61389868 0.000606465 Decreased 
MIR4326 20 61389848 61389868 0.000606465 Decreased 
COL20A1 20 61394057 61394077 0.000667111 Decreased 
ZBTB46 20 61848829 61848849 0.000909697 Decreased 
!! 268!
LINC00310 21 34473922 34473942 0.000303232 Decreased 
MORC3 21 36613431 36613451 0.000667111 Decreased 
LINC00111 21 41971605 41971625 0.000606465 Decreased 
DNMT3L 21 44507432 44507452 0.000788404 Decreased 
PCNT 21 46628030 46628050 0.000121293 Decreased 
ATP6V1E1 22 16492493 16492513 0.000909697 Decreased 
C22orf34 22 48411744 48411764 0.000667111 Decreased 
C22orf34 22 48395329 48395349 0.000242586 Decreased 
TRABD 22 48965689 48965709 0.000667111 Increased 
SHOX X 523098 523118 0.000909697 Decreased 
XAGE1A X 52277169 52277189 0.000849051 Decreased 
XAGE1A X 52277169 52277189 0.000849051 Decreased 
XAGE1A X 52277169 52277189 0.000849051 Decreased 
XAGE1B X 52277169 52277189 0.000849051 Decreased 
XAGE1B X 52277169 52277189 0.000849051 Decreased 
XAGE1B X 52277169 52277189 0.000849051 Decreased 
XAGE1C X 52277169 52277189 0.000849051 Decreased 
XAGE1C X 52277169 52277189 0.000849051 Decreased 
XAGE1C X 52277169 52277189 0.000849051 Decreased 
XAGE1D X 52277169 52277189 0.000849051 Decreased 
XAGE1D X 52277169 52277189 0.000849051 Decreased 
XAGE1D X 52277169 52277189 0.000849051 Increased 
XAGE1E X 52277169 52277189 0.000849051 Increased 
XAGE1E X 52277169 52277189 0.000849051 Increased 
XAGE1E X 52277169 52277189 0.000849051 Increased 
XAGE1A X 52550109 52550129 0.000970344 Increased 
XAGE1A X 52550109 52550129 0.000970344 Increased 
XAGE1A X 52550109 52550129 0.000970344 Increased 
XAGE1B X 52550109 52550129 0.000970344 Increased 
XAGE1B X 52550109 52550129 0.000970344 Increased 
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XAGE1B X 52550109 52550129 0.000970344 Increased 
XAGE1C X 52550109 52550129 0.000970344 Increased 
XAGE1C X 52550109 52550129 0.000970344 Increased 
XAGE1C X 52550109 52550129 0.000970344 Increased 
XAGE1D X 52550109 52550129 0.000970344 Increased 
XAGE1D X 52550109 52550129 0.000970344 Increased 
XAGE1D X 52550109 52550129 0.000970344 Increased 
XAGE1E X 52550109 52550129 0.000970344 Increased 
XAGE1E X 52550109 52550129 0.000970344 Increased 
XAGE1E X 52550109 52550129 0.000970344 Increased 
XAGE1A X 52563003 52563023 0.000545818 Increased 
XAGE1A X 52563003 52563023 0.000545818 Increased 
XAGE1A X 52563003 52563023 0.000545818 Increased 
XAGE1B X 52563003 52563023 0.000545818 Increased 
XAGE1B X 52563003 52563023 0.000545818 Increased 
XAGE1B X 52563003 52563023 0.000545818 Increased 
XAGE1C X 52563003 52563023 0.000545818 Increased 
XAGE1C X 52563003 52563023 0.000545818 Increased 
XAGE1C X 52563003 52563023 0.000545818 Increased 
XAGE1D X 52563003 52563023 0.000545818 Increased 
XAGE1D X 52563003 52563023 0.000545818 Increased 
XAGE1D X 52563003 52563023 0.000545818 Increased 
XAGE1E X 52563003 52563023 0.000545818 Increased 
XAGE1E X 52563003 52563023 0.000545818 Increased 
XAGE1E X 52563003 52563023 0.000545818 Increased 
XIST X 72974756 72974776 0.000121293 Increased 
H2BFWT X 103153633 103153653 0.000242586 Increased 
IL1RAPL2 X 104352919 104352939 0.000849051 Increased 
TEX13A X 104352919 104352939 0.000849051 Increased 
SPANXN1 X 144135873 144135893 0.000909697 Increased 
!! 270!
HCFC1 X 152873319 152873339 0.000606465 Increased 
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Appendix G - Promoters differentially methylated between co-twins in Family 2. (NCBI Build 36/hg18) 
The regions represent 138 unique genes. 
Transcript Chromosome Region Start Region End p-value (region) Methylation Status 
HIST2H2AA3 1 148085850 148085870 0.000303232 Increased 
HIST2H2AA4 1 148085850 148085870 0.000303232 Increased 
HIST2H2AA3 1 148085850 148085870 0.000303232 Increased 
HIST2H2AA4 1 148085850 148085870 0.000303232 Increased 
HIST2H3A 1 148085850 148085870 0.000303232 Increased 
HIST2H3C 1 148085850 148085870 0.000303232 Increased 
AK2 1 33275973 33275993 0.000485172 Decreased 
CNTN2 1 203305581 203305601 0.000606465 Decreased 
GCSAML 1 245778148 245778168 0.000667111 Increased 
GCSAML 1 245778148 245778168 0.000667111 Increased 
GCSAML 1 245778148 245778168 0.000667111 Increased 
LINC00466 1 63559010 63559030 0.000727758 Increased 
FOXD3 1 63559010 63559030 0.000727758 Increased 
PRDM16 1 3061919 3061939 0.000788404 Increased 
TBX19 1 166515976 166515996 0.000849051 Increased 
CMPK1 1 47571304 47571324 0.000909697 Increased 
KCNA3 1 111019682 111019702 0.000909697 Increased 
KCNA3 1 111019682 111019702 0.000909697 Increased 
KCNA3 1 111019682 111019702 0.000909697 Increased 
SLC41A1 1 204049689 204049709 0.000909697 Increased 
DIEXF 1 208067030 208067050 0.000909697 Increased 
PIK3CD 1 9638136 9638156 0.000970344 Increased 
C1orf200 1 9638136 9638156 0.000970344 Increased 
KDM4A-AS1 1 43944879 43944899 0.000970344 Increased 
ST3GAL3 1 43944879 43944899 0.000970344 Increased 
FAM98A 2 33678771 33678791 0.000727758 Decreased 
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WASH2P 2 114057003 114057023 0.000849051 Increased 
LYG1 2 99284976 99284996 0.000909697 Increased 
PTPN18 2 130846574 130846594 0.000909697 Increased 
ATP6V1B1 2 71015580 71015600 0.000970344 Increased 
SLC25A36 3 142142590 142142610 0.000485172 Decreased 
THUMPD3-AS1 3 9414278 9414298 0.000788404 Increased 
SETD5 3 9414278 9414298 0.000788404 Increased 
NKIRAS1 3 23933581 23933601 0.000909697 Increased 
RPL15 3 23933581 23933601 0.000909697 Increased 
RPL15 3 23933581 23933601 0.000909697 Increased 
RPL15 3 23933581 23933601 0.000909697 Increased 
RPL15 3 23933581 23933601 0.000909697 Increased 
MUC4 3 196975464 196975484 0.000909697 Increased 
LHFPL4 3 9569188 9569208 0.000970344 Increased 
C3orf18 3 50581039 50581059 0.000970344 Increased 
C3orf18 3 50581039 50581059 0.000970344 Increased 
HEMK1 3 50581039 50581059 0.000970344 Increased 
ALCAM 3 106567543 106567563 0.000970344 Increased 
SORBS2 4 187115769 187115789 0.000667111 Decreased 
TMEM154 4 153821546 153821566 0.000849051 Increased 
SNX25 4 186367353 186367373 0.000970344 Increased 
SMAD5-AS1 5 135499383 135499403 0.000303232 Decreased 
SMAD5 5 135499383 135499403 0.000303232 Decreased 
COMMD10 5 115447700 115447720 0.000545818 Increased 
TENM2 5 166643495 166643515 0.000909697 Increased 
TRIM27 6 29000548 29000568 0.000667111 Decreased 
HIST1H1C 6 26164302 26164322 0.000909697 Increased 
PACSIN1 6 34607414 34607434 0.000970344 Increased 
PACSIN1 6 34607414 34607434 0.000970344 Increased 
ENPP5 6 46247581 46247601 0.000970344 Increased 
!! 273!
PPIL4 6 149909769 149909789 0.000970344 Increased 
TTYH3 7 2653547 2653567 0.000667111 Increased 
PTPRN2 7 157141154 157141174 0.000667111 Increased 
KCTD7 7 65730399 65730419 0.000788404 Increased 
TBRG4 7 45112319 45112339 0.000909697 Increased 
SNORA5A 7 45112319 45112339 0.000909697 Increased 
SNORA5C 7 45112319 45112339 0.000909697 Increased 
SNORA5B 7 45112319 45112339 0.000909697 Increased 
DNAJB6 7 156895498 156895518 0.000909697 Increased 
UNCX 7 1242530 1242550 0.000970344 Increased 
GTF2I 7 73709238 73709258 0.000970344 Increased 
PLEC 8 145068180 145068200 0.000727758 Decreased 
PLEC 8 145068180 145068200 0.000727758 Decreased 
PLEC 8 145068180 145068200 0.000727758 Decreased 
PLEC 8 145068180 145068200 0.000727758 Decreased 
PLEC 8 145068180 145068200 0.000727758 Decreased 
PLEC 8 145068180 145068200 0.000727758 Decreased 
PLEC 8 145068180 145068200 0.000727758 Decreased 
PLEC 8 145068180 145068200 0.000727758 Increased 
RPL23AP53 8 169134 169154 0.000788404 Increased 
ZNF596 8 169134 169154 0.000788404 Increased 
ZNF596 8 169134 169154 0.000788404 Increased 
ZNF596 8 169134 169154 0.000788404 Increased 
ZNF596 8 169134 169154 0.000788404 Increased 
ZNF596 8 169134 169154 0.000788404 Increased 
ZFP41 8 144403919 144403939 0.000909697 Increased 
ZFP41 8 144403919 144403939 0.000909697 Increased 
ADCK5 8 145567737 145567757 0.000909697 Increased 
HEMGN 9 99747860 99747880 0.000485172 Decreased 
ZNF483 9 113326342 113326362 0.000849051 Decreased 
!! 274!
SOHLH1 9 137732516 137732536 0.000909697 Increased 
KCNT1 9 137732516 137732536 0.000909697 Increased 
PDCD4-AS1 10 112621108 112621128 0.000242586 Decreased 
PDCD4 10 112621108 112621128 0.000242586 Decreased 
C10orf111 10 15179245 15179265 0.000424525 Decreased 
RPP38 10 15179245 15179265 0.000424525 Decreased 
BEND3P3 10 81111811 81111831 0.000485172 Decreased 
RSU1 10 16900364 16900384 0.000909697 Decreased 
TEX36 10 127362608 127362628 0.000909697 Increased 
LOC283038 10 127362608 127362628 0.000909697 Increased 
INPP5F 10 121474673 121474693 0.000970344 Increased 
ADAM8 10 134941267 134941287 0.000970344 Increased 
OR5B17 11 57884023 57884043 0.000060600 Decreased 
CAPN5 11 76454714 76454734 0.000485172 Decreased 
OR52N2 11 5797216 5797236 0.000545818 Increased 
OR52N4 11 5731573 5731593 0.000788404 Increased 
EIF3F 11 7964528 7964548 0.000909697 Increased 
PANX1 11 93500851 93500871 0.000909697 Increased 
PUS3 11 125278893 125278913 0.000909697 Increased 
DDX25 11 125278893 125278913 0.000909697 Increased 
UBTFL1 11 89457840 89457860 0.000970344 Increased 
STAT6 12 55792333 55792353 0.000970344 Increased 
STAT6 12 55792333 55792353 0.000970344 Increased 
ESD 13 46270273 46270293 0.000242586 Decreased 
GAS6-AS2 13 113546285 113546305 0.000909697 Increased 
GAS6 13 113546285 113546305 0.000909697 Increased 
BTF3P11 13 76399660 76399680 0.000970344 Increased 
ADAM21 14 69993044 69993064 0.000060600 Decreased 
OR4E2 14 21202211 21202231 0.000545818 Increased 
MOK 14 101842189 101842209 0.000909697 Increased 
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FOXA1 14 37138067 37138087 0.000970344 Increased 
TICRR 15 87918941 87918961 0.000121293 Decreased 
SNORD115-33 15 23030052 23030072 0.000181939 Increased 
SNORD115-34 15 23030052 23030072 0.000181939 Increased 
SNORD115-35 15 23030052 23030072 0.000181939 Increased 
SNORD115-11 15 23030052 23030072 0.000181939 Increased 
SNORD115-29 15 23030052 23030072 0.000181939 Increased 
SNORD115-36 15 23030052 23030072 0.000181939 Increased 
SNORD115-43 15 23030052 23030072 0.000181939 Increased 
SNORD115-37 15 23030052 23030072 0.000181939 Increased 
SNORD116-8 15 22868070 22868090 0.000242586 Increased 
SNORD116-3 15 22868070 22868090 0.000242586 Increased 
SNORD116-9 15 22868070 22868090 0.000242586 Increased 
SNORD116-10 15 22868070 22868090 0.000242586 Increased 
SNORD116-11 15 22868070 22868090 0.000242586 Increased 
BUB1B 15 38295995 38296015 0.000242586 Decreased 
PAK6 15 38295995 38296015 0.000242586 Decreased 
SNORD115-10 15 22983806 22983826 0.000303232 Increased 
SNORD115-12 15 22983806 22983826 0.000303232 Increased 
SNORD115-9 15 22983806 22983826 0.000303232 Increased 
SNORD115-5 15 22983806 22983826 0.000303232 Increased 
SNORD115-10 15 22983806 22983826 0.000303232 Increased 
SNORD115-11 15 22983806 22983826 0.000303232 Increased 
SNORD115-29 15 22983806 22983826 0.000303232 Increased 
SNORD115-36 15 22983806 22983826 0.000303232 Increased 
SNORD115-43 15 22983806 22983826 0.000303232 Increased 
SNORD115-10 15 22983806 22983826 0.000303232 Increased 
SNORD115-12 15 22983806 22983826 0.000303232 Increased 
SNORD115-9 15 22983806 22983826 0.000303232 Increased 
SNORD115-5 15 22983806 22983826 0.000303232 Increased 
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DAPK2 15 62126479 62126499 0.000849051 Increased 
RBFOX1 16 6762885 6762905 0.000909697 Increased 
RBFOX1 16 6762885 6762905 0.000909697 Increased 
EXOC3L1 16 65782578 65782598 0.000970344 Increased 
E2F4 16 65782578 65782598 0.000970344 Increased 
MIR132 17 1904363 1904383 0.000545818 Increased 
MIR212 17 1904363 1904383 0.000545818 Increased 
HIC1 17 1904363 1904383 0.000545818 Increased 
HIC1 17 1904363 1904383 0.000545818 Increased 
FUT2 19 53890407 53890427 0.000303232 Decreased 
ZNF226 19 49360408 49360428 0.000485172 Decreased 
ZNF226 19 49360408 49360428 0.000485172 Decreased 
ZNF226 19 49360408 49360428 0.000485172 Increased 
SLC17A7 19 54637517 54637537 0.000788404 Increased 
S1PR2 19 10203572 10203592 0.000970344 Increased 
MIR4322 19 10203572 10203592 0.000970344 Increased 
GNAS 20 56879799 56879819 0.000181939 Decreased 
GNAS 20 56879799 56879819 0.000181939 Decreased 
SYS1-DBNDD2 20 43468281 43468301 0.000909697 Increased 
DBNDD2 20 43468281 43468301 0.000909697 Increased 
DBNDD2 20 43468281 43468301 0.000909697 Increased 
DBNDD2 20 43468281 43468301 0.000909697 Increased 
DBNDD2 20 43468281 43468301 0.000909697 Increased 
DBNDD2 20 43468281 43468301 0.000909697 Increased 
DBNDD2 20 43468281 43468301 0.000909697 Increased 
GSTTP1 22 22678163 22678183 0.000970344 Increased 
HPS4 22 25208590 25208610 0.000970344 Increased 
HPS4 22 25208590 25208610 0.000970344 Increased 
SRRD 22 25208590 25208610 0.000970344 Increased 
PDGFB 22 37969786 37969806 0.000970344 Increased 
!! 277!
PDGFB 22 37969786 37969806 0.000970344 Increased 
XIST X 72974756 72974776 0.000424525 Decreased 
BCOR X 39846274 39846294 0.000545818 Increased 
BCOR X 39846274 39846294 0.000545818 Increased 
TIMM8A X 100491393 100491413 0.000909697 Increased 
TIMM8A X 100491393 100491413 0.000909697 Increased 
BTK X 100491393 100491413 0.000909697 Increased 
BTK X 100491393 100491413 0.000909697 Increased 
DGKK X 50231382 50231402 0.000970344 Increased 
AIFM1 X 129100601 129100621 0.000970344 Increased 
AIFM1 X 129100601 129100621 0.000970344 Increased 
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Appendix H - De novo sequencing variations in the affected twin of Family 1 that show co-localized 
differential methylation and sequence variation. (NCBI Build 37/hg19) 
Chr Position Gene 
Reference 
Allele 
(Build 37) 
Sample 
Allele 
Variation 
Type 
Gene 
Region Impact 
SIFT 
Function 
Prediction 
SIFT 
Score 
PolyPhen-
2 Function 
Prediction 
dbSNP 
2 44095621 ABCG8 A G SNV Intronic     13395859 
16 20440701 ACSM5  ATCA Insertion Intronic     397733540 
10 1255477 ADARB2 G A SNV Intronic     114312758 
10 1255488 ADARB2 TGCCA CATCG Substitution Intronic      
10 1258701 ADARB2 G A SNV Intronic     113359529 
10 1258809 ADARB2 A C SNV Intronic     11250339 
10 1266123 ADARB2 GTGG A Substitution Intronic      
10 1266131 ADARB2  GTA Insertion Intronic      
10 1377512 ADARB2 G A SNV Intronic     12250711 
10 1415954 ADARB2 AT GC Substitution Intronic     386739833 
10 1418159 ADARB2  GC Insertion Intronic     60001440 
10 1486550 ADARB2 ACTCAC CCATCC  Deletion Intronic      
10 1487383 ADARB2 
CCCACCA
ACCCATC
CATCCA 
 Deletion Intronic     371456791 
5 324141 AHRR  TT Insertion Intronic      
5 324152 AHRR G C SNV Intronic     375043354 
5 426735 AHRR  AGAT Insertion Intronic     142240127 
5 436388 AHRR T  Deletion 3'UTR     5865330 
12 133319367 ANKLE2 TACCACCATCATC 
CACATC
TTCACC
ATCATC
ATCCTC
ATCAGC
ATCACA
ACCATC
ATCACT 
Substitution Intronic      
!! 279!
12 133319374 ANKLE2  
GTCATC
ACCATC
ACCATC
ACCACC
ATCATC
CTCACT
ACCACC 
Insertion Intronic      
12 133319389 ANKLE2 A C SNV Intronic     79839935 
12 133319393 ANKLE2 T C SNV Intronic      
22 18077829 ATP6V1E1 G TT Substitution Intronic      
16 88027231 BANP AG  Deletion Intronic     397782415 
7 1155219 C7orf50 G C SNV Intronic     6971277 
9 140778126 CACNA1B G C SNV Intronic     71510860 
9 140783083 CACNA1B G A SNV Intronic      
9 140843825 CACNA1B G  Deletion Intronic     375703513 
9 140843829 CACNA1B GCA TTGG Substitution Intronic      
9 140843835 CACNA1B G T SNV Intronic      
1 6997348 CAMTA1 C A SNV Intronic     200150393 
1 6997357 CAMTA1 T C SNV Intronic     114689433 
1 6997367 CAMTA1 C T SNV Intronic     202203323 
1 6997379 CAMTA1 C G SNV Intronic     200484676 
1 7000990 CAMTA1 AA 
GGGGG
GTCCTC
AGAGG
GAGAG
GGATCC
TCCCG
GGGAA
G 
Substitution Intronic      
1 7044157 CAMTA1 GGTG  Deletion Intronic      
1 7044158 CAMTA1 GTGA ATAGGTGG Substitution Intronic      
1 7513062 CAMTA1 G  Deletion Intronic      
1 7553229 CAMTA1 GC ACGT Substitution Intronic      
1 7553329 CAMTA1 A G SNV Intronic     62653661 
!! 280!
1 7553338 CAMTA1 TACA CG Substitution Intronic     386628175 
16 89041618 CBFA2T3 C T SNV Intronic     4782488 
6 47464977 CD2AP TTTCTTT TTTCCT  Deletion Intronic      
6 47524769 CD2AP G A SNV Intronic     145551659 
15 68507331 CLN6  CACCT TCCC Insertion Intronic     55798476 
7 155308003 CNPY1 CG A Substitution Intronic     386719929 
20 61958464 COL20A1 
AGGGACT
TCCTGTT
TACCACT
CAGGGA
CTTTCTG
TTGACTG
CC 
 Deletion Intronic      
1 34043170 CSMD2 C  Deletion Intronic     11291100 
1 34290740 CSMD2 T C SNV Intronic     6657112 
1 34318453 CSMD2 C T SNV Intronic     386427638 
1 34346601 CSMD2  CCAGTATGTG Insertion Intronic     112560751 
1 34349981 CSMD2  CC Insertion Intronic     61360744 
1 34592405 CSMD2  ATG Insertion Intronic     3044852 
10 491882 DIP2C GCG ACA Substitution Intronic      
10 523535 DIP2C  
GGGAG
GAAGGT
GGATG
GGT 
Insertion Intronic      
10 716205 DIP2C CACGCATGCATATA  Deletion Intronic      
6 487331 EXOC2 G  Deletion Intronic      
6 528886 EXOC2  G Insertion Intronic      
6 170627586 FAM120B G T SNV Exonic; Intronic Missense   
Possibly 
Damaging 6917485 
15 26870736 GABRB3  
TTGGCT
GTGGG
GA 
Insertion Intronic     66894857 
!! 281!
7 6546285 GRID2IP T C SNV Intronic     13233173 
19 1085509 HMHA1 T  Deletion Intronic     149458285 
12 121432669 HNF1A TCCA AT Substitution Intronic      
12 121432675 HNF1A C A SNV Intronic     56405042 
12 121432680 HNF1A C T SNV Intronic     56184283 
1 13184211 HNRNPCL1/ HNRNPCL2 GAC CAT Substitution Intronic      
1 13184230 HNRNPCL1/ HNRNPCL2  A C SNV Intronic     66601730 
1 13184274 HNRNPCL1/HNRNPCL2 TTGT GCTC Substitution 5'UTR     386628615 
1 13184283 HNRNPCL1/ HNRNPCL2 AGAA GCAG Substitution 5'UTR     386628616 
1 13184291 HNRNPCL1/ HNRNPCL2 C T SNV 5'UTR     76654751 
1 13184308 HNRNPCL1/ HNRNPCL2 G A SNV 5'UTR     72474536 
X 104360584 IL1RAPL2 A G SNV Intronic     138629862 
X 104651788 IL1RAPL2 CTCA  Deletion Intronic      
18 44553082 KATNAL2 C A SNV Intronic     150979709 
1 15374352 KAZN C G SNV Intronic     147484885 
7 1856066 MAD1L1 G A SNV Intronic     186387153 
7 1869473 MAD1L1 T A SNV Intronic     34373690 
7 1910705 MAD1L1 T C SNV Intronic     111519111 
7 1927507 MAD1L1  
TGGCTG
CCTGG
GCGTGT
GTGTG 
Insertion Intronic      
7 1927521 MAD1L1 G A SNV Intronic     112388595 
7 1953083 MAD1L1  
GCGAA
GGGAG
TGGGA 
Insertion Intronic     57726885 
7 2205259 MAD1L1  GT Insertion Intronic     59181779 
2 2283340 MYT1L TG GGAAGA Substitution Intronic      
!! 282!
18 77195348 NFATC1 GT TTGGTTTGTTTG Substitution Intronic      
18 77223426 NFATC1 C T SNV Intronic     60884900 
17 47582123 NGFR C TCTT Substitution Intronic     375870215 
17 47585127 NGFR  TATA Insertion Intronic     11466139 
1 228551859 OBSCN  
ACAGTG
CCCTCC
CCAAG
GACTGC
ACGGG 
Insertion Intronic     148845306 
15 28259023 OCA2 GT  Deletion Intronic     369589569 
1 29188423 OPRD1  CTT Insertion Intronic     372713364 
2 240985511 OR6B3 A G SNV Promoter     10933560 
19 45900730 PPP1R13L C T SNV Intronic     4803815 
7 623092 PRKAR1B  CT Insertion Intronic     200178183 
7 651882 PRKAR1B C T SNV Intronic     62431453 
7 651899 PRKAR1B C T SNV Intronic     62431454 
7 696635 PRKAR1B T C SNV Intronic     113961823 
7 697065 PRKAR1B AATGGGTGA GGTG Substitution Intronic      
7 157376644 PTPRN2 C T SNV Intronic     4716760 
7 157413940 PTPRN2 T G SNV Intronic     2906925 
7 157450528 PTPRN2 AC GCCA Substitution Intronic      
7 157738435 PTPRN2 A G SNV Intronic     62475406 
7 157821939 PTPRN2 G A SNV Intronic     9801601 
7 157923758 PTPRN2 CAC T Substitution Intronic     386720267 
7 157923771 PTPRN2 AC  Deletion Intronic     56136013 
7 157923844 PTPRN2  GAAA Insertion Intronic     56332004 
7 157923851 PTPRN2  AC Insertion Intronic      
7 157924071 PTPRN2 CACT  Deletion Intronic     76071394 
7 157948224 PTPRN2 G A SNV Intronic      
7 157948234 PTPRN2 C A SNV Intronic     112891751 
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7 157957760 PTPRN2  C Insertion Intronic      
7 157957768 PTPRN2 ATT GTC Substitution Intronic      
7 158055480 PTPRN2 CA  Deletion Intronic      
7 158055576 PTPRN2  
TCACAC
ACTGCA
CAC 
Insertion Intronic     371888713 
7 158055616 PTPRN2 T C SNV Intronic     62649324 
7 158055710 PTPRN2 AGTGCACACAT 
TGCACA
CATAGA
TTCACA
CACATT
GCACAC
ACACAT
TCACAC
ACAGTG
CAC 
Substitution Intronic      
7 158061414 PTPRN2 AGA GGC Substitution Intronic     386720307 
7 158062601 PTPRN2 
GACAGAG
AAACAGA
GA 
 Deletion Intronic      
7 158119352 PTPRN2  AC Insertion Intronic      
7 158120173 PTPRN2 ACAT  Deletion Intronic      
7 158180204 PTPRN2 TGGA CAGCTG Substitution Intronic      
7 158203643 PTPRN2 GGTAC TGCAG Substitution Intronic     386720335 
7 158203653 PTPRN2 C T SNV Intronic     4909216 
7 158233753 PTPRN2 
GGGTGG
TAGTGAT
GG 
 Deletion Intronic      
7 158246600 PTPRN2 T C SNV Intronic     1612814 
7 158288885 PTPRN2 
TGTCCCC
CTTCCCT
GCAG 
 Deletion Intronic     377678840 
16 668837 RAB40C A T SNV Intronic      
13 114795723 RASA3 A C SNV Intronic     2274709 
13 114795754 RASA3 A G SNV Intronic     2274708 
17 66675 RPH3AL G A SNV Intronic     8066107 
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17 78608052 RPTOR A G SNV Intronic     62068346 
17 78608075 RPTOR G A SNV Intronic     62641966 
17 78608076 RPTOR  
TACTGT
GTGTGT
GCG 
Insertion Intronic      
17 78608631 RPTOR TGTG TGCA 
CGTGTG
CG Substitution Intronic      
17 78608663 RPTOR TGTGTGCATAC  Deletion Intronic     147584971 
17 78674429 RPTOR CGGC T Substitution Intronic      
17 78785716 RPTOR A G SNV Intronic      
17 78785728 RPTOR C T SNV Intronic     374712081 
9 137286091 RXRA ACGGTGGTGA 
TTAATG
TTGATG
ATGGTA
GTGATG
GTGGT
GATGAT
GGTGG
TGATGA
TGC 
Substitution Intronic      
3 38621396 SCN5A A C SNV Intronic     56887724 
X 587163 SHOX C T SNV Intronic      
X 587229 SHOX C A SNV Intronic      
2 220502072 SLC4A3 T  Deletion Intronic      
5 1400943 SLC6A3  
CTGTCT
ACACCA
GCC 
Insertion Intronic     377330133 
5 1421234 SLC6A3 T A SNV Intronic     112306339 
16 12123802 SNX29  T Insertion Intronic     35128101 
16 12502034 SNX29 C A SNV Intronic     76748851 
16 12502038 SNX29 A C SNV Intronic     72771556 
19 7709271 STXBP2 A G SNV Intronic     3815754 
13 114477564 TMEM255B C T SNV Intronic     367698554 
13 114477570 TMEM255B AATG CC Substitution Intronic     386775122 
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13 114477577 TMEM255B CAC TAT Substitution Intronic     386775123 
13 114478005 TMEM255B 
TGACACA
CATTGCA
CACACAA
CACACCA
CACACCA
CACA 
 Deletion Intronic     371947737 
13 114478044 TMEM255B  CA Insertion Intronic      
13 114498960 TMEM255B G C SNV Intronic     111173929 
13 114498969 TMEM255B G C SNV Intronic     111173928 
8 140885212 TRAPPC9 TTTGGTGGATAA 
ATAAGT
GGATG
G 
Substitution Intronic      
8 140885238 TRAPPC9 A G SNV Intronic      
8 141125731 TRAPPC9  T Insertion Intronic     397689235 
8 141206857 TRAPPC9 CTCA  Deletion Intronic     373821045 
8 143299632 TSNARE1  
AGCAG
GATCAG
GGTTCA
GTGTGT
G 
Insertion Intronic      
8 143299651 TSNARE1 G T SNV Intronic     78394843 
8 143304426 TSNARE1 T C SNV Intronic     116999715 
8 143304426 TSNARE1 T CGTTCATTC Substitution Intronic      
8 143353920 TSNARE1 
TCCATCC
ACCCACC
CGTCTAC
ACCTTCC
TCC 
CT Substitution Intronic      
8 143353962 TSNARE1 CAC TGT Substitution Intronic      
8 143354002 TSNARE1 CA TG Substitution Intronic      
2 3308451 TSSC1 G A SNV Intronic     71444245 
2 3308616 TSSC1  
GTTCAG
CCCTCC
ACTCCC
GCCCA 
Insertion Intronic      
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2 3323527 TSSC1 GCA ACC Substitution Intronic      
2 3323534 TSSC1 C  Deletion Intronic      
2 3323541 TSSC1 G A SNV Intronic      
2 3340808 TSSC1 
AAAAGAG
AAGGGAA
AAGGGTA
AAAAGAA
G 
 Deletion Intronic      
3 75779680 ZNF717 A G SNV 3'UTR     78431785 
3 75779688 ZNF717 T G SNV 3'UTR     78506989 
3 75780725 ZNF717  A Insertion Intronic      
3 75780783 ZNF717 G A SNV Intronic     78199428 
3 75780806 ZNF717 G A SNV Intronic     62250077 
3 75780813 ZNF717 C T SNV Intronic     62250078 
3 75780841 ZNF717 A T SNV Intronic     111646898 
3 75780853 ZNF717 C T SNV Intronic     113521980 
3 75780874 ZNF717 T G SNV Intronic     112358097 
3 75781049 ZNF717 G T SNV Intronic     77738888 
3 75781404 ZNF717 G T SNV Intronic     73841590 
3 75781536 ZNF717 C G SNV Intronic     74391052 
3 75781564 ZNF717 T C SNV Intronic     368766203 
3 75781579 ZNF717 G C SNV Intronic     79224266 
3 75781583 ZNF717 C A SNV Intronic     76090413 
3 75781665 ZNF717 C T SNV Intronic     79319996 
3 75782062 ZNF717 T C SNV Intronic     149141037 
3 75782087 ZNF717  A Insertion Intronic      
3 75782359 ZNF717 T A SNV Intronic     74744994 
3 75782372 ZNF717 G C SNV Intronic     146049279 
3 75782733 ZNF717 CT TC Substitution Intronic      
3 75782765 ZNF717 GAA AT Substitution Intronic      
3 75784256 ZNF717 T A SNV Intronic     74369226 
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3 75784284 ZNF717 A G SNV Intronic     79188089 
3 75784777 ZNF717 
CTGTCTC
AATAAAA
AAAAAAA
AA 
ATGCTG
TTTCAA
TTTC 
Substitution Intronic      
3 75784991 ZNF717 T C SNV Intronic     78939026 
3 75784998 ZNF717 C T SNV Intronic     77687685 
3 75785130 ZNF717 A G SNV Intronic     78906640 
3 75785133 ZNF717 G T SNV Intronic     78698209 
3 75785149 ZNF717 C G SNV Intronic     79135712 
3 75785318 ZNF717 A G SNV Intronic     80053710 
3 75785333 ZNF717 G A SNV Intronic     79305051 
3 75785338 ZNF717 TG CA Substitution Intronic     386662578 
3 75785351 ZNF717 T C SNV Intronic     77346754 
3 75785355 ZNF717 T C SNV Intronic     75958893 
3 75785752 ZNF717 GAG  Deletion Intronic     145023391 
3 75785757 ZNF717 G C SNV Intronic     80304037 
3 75785773 ZNF717 G T SNV Intronic     75922518 
3 75786892 ZNF717 A C SNV Exonic; Intronic Missense Damaging 0 
Probably 
Damaging 76826286 
3 75786899 ZNF717 T C SNV Exonic; Intronic 
Synonym
-ous    78828372 
3 75786916 ZNF717 C A SNV Exonic; Intronic Stop gain    78906544 
3 75786919 ZNF717 A T SNV Exonic; Intronic Missense Damaging 0 
Probably 
Damaging 77101176 
3 75787222 ZNF717 AGC GGT Substitution Exonic; Intronic In-frame     
3 75787240 ZNF717 A G SNV Exonic; Intronic Missense Damaging 0 
Probably 
Damaging 76111663 
3 75787279 ZNF717 A T SNV Exonic; Intronic Missense Activating 1 Benign 80214832 
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3 75787288 ZNF717 T C SNV Exonic; Intronic Missense Tolerated 0.74 Benign 76815006 
3 75787298 ZNF717 T C SNV Exonic; Intronic 
Synonym
-ous    143229208 
3 75787304 ZNF717 AC TT Substitution Exonic; Intronic In-frame     
3 75787996 ZNF717 C T SNV Exonic; Intronic Missense Damaging 0.01 
Possibly 
Damaging 78640256 
3 75788777 ZNF717 C A SNV Intronic     79935262 
3 75789592 ZNF717 T C SNV Intronic     114166831 
3 75789722 ZNF717 TTT CTA Substitution Intronic      
3 75791120 ZNF717  AT Insertion Intronic      
3 75791136 ZNF717 T C SNV Intronic     62246579 
3 75791370 ZNF717 G T SNV Intronic     137896860 
3 75791393 ZNF717 TG CA Substitution Intronic      
3 75791630 ZNF717 G A SNV Intronic     77369095 
3 75791639 ZNF717 A C SNV Intronic     73843033 
3 75791647 ZNF717 C T SNV Intronic     73843034 
3 75792812 ZNF717  GAGGACAC Insertion Intronic      
3 75792961 ZNF717 T C SNV Intronic     77809421 
3 75792965 ZNF717 G C SNV Intronic     143220375 
3 75793015 ZNF717 G A SNV Intronic     79963736 
3 75793038 ZNF717 A G SNV Intronic     76503683 
3 75793322 ZNF717 G A SNV Intronic     79089350 
3 75793328 ZNF717 CTA  Deletion Intronic     149321743 
3 75793346 ZNF717 A T SNV Intronic     75299410 
3 75793355 ZNF717 G T SNV Intronic     80271408 
3 75793786 ZNF717 A  Deletion Intronic     142452329 
3 75793801 ZNF717 T C SNV Intronic     76017054 
3 75793805 ZNF717 C T SNV Intronic     111761703 
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3 75794043 ZNF717 T  Deletion Intronic     143048594 
3 75794056 ZNF717 C T SNV Intronic     79549753 
3 75794068 ZNF717 A G SNV Intronic     76890775 
3 75794078 ZNF717 G A SNV Intronic     75860137 
3 75794081 ZNF717 C T SNV Intronic     76031595 
3 75794370 ZNF717 T G SNV Intronic     114339799 
3 75797741 ZNF717 TG CA Substitution Intronic      
3 75824236 ZNF717 A C SNV Intronic     372238767 
3 75824259 ZNF717 C T SNV Intronic     367756272 
3 75824378 ZNF717 C G SNV Intronic     62268159 
Structural Variants and CNVs       
Chr Start End Size Type Gene(s) 
1 825765 5726936 4901171 Tandem-Duplication 
ACAP3;ACTRT2;AGRN;AJAP1;ARHGEF16;ATAD3A;ATAD3B;ATAD3C;AURKAIP1;B3G
ALT6;C1orf159;C1orf170;C1orf174;C1orf222;C1orf70;C1orf86;C1orf93;CALML6;CCDC2
7;CCNL2;CDC2L1;CDC2L2;CPSF3L;DFFB;DVL1;FAM132A;FLJ14100;FLJ39609;FLJ42
875;GABRD;GLTPD1;GNB1;HES4;HES5;ISG15;KIAA0495;KIAA0562;KIAA1751;KLHL1
7;LOC100128003;LOC100128838;LOC100129381;LOC100129534;LOC100131742;LOC
100132814;LOC100133612;LOC100287685;LOC100287750;LOC100287848;LOC10028
7898;LOC100288202;LOC100288271;LOC100288313;LOC100288379;LOC100288479;
LOC115110;LOC148413;LOC284661;LOC388588;LOC401934;LOC441869;LOC643988;
LOC728661;LOC728716;LRRC47;MEGF6;MIB2;MMEL1;MMP23A;MMP23B;MORN1;MR
PL20;MXRA8;NADK;NoC2L;PANK4;PEX10;PLCH2;PLEKHN1;PRDM16;PRKCZ;PUSL1;
RER1;SAMD11;SCNN1D;SDF4;SKI;SLC35E2;SSU72;TAS1R3;TMEM52;TMEM88B;TNF
RSF14;TNFRSF18;TNFRSF4;TP73;TPRG1L;TTLL10;UBE2J2;VWA1;WDR8 
2 1801743 1802067 324 Deletion MYT1L 
7 606117 606324 207 Tandem-Duplication PRKAR1B 
15 25468396 25470000 1604 Tandem-Duplication SNORD115-29 
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Appendix I - Observed DNA methylation changes in 58 genes that showed co-localized de novo sequence 
variations in Family 1. (NCBI Build 36/hg18) 
Chr Gene Symbol Start End 
p-value 
(region) 
In 
Mom 
In 
Dad 
Imprinting Database 1 
(geneimprint.com/) 
Imprinting Database 2 
(igc.otago.ac.nz/) 
2 ABCG8 43919524 43919544 0.000606465   Predicted, Maternal Not found 
16 ACSM5 20325935 20325955 0.000667111   No Not found 
10 ADARB2 1732764 1732784 0.000242586   No Not found 
5 AHRR 356365 356385 0.000667111   No Not found 
5 AHRR 356365 356385 0.000667111   No Not found 
12 ANKLE2 131819474 131819494 0.000242586 Yes Yes No Not found 
22 ATP6V1E1 16492493 16492513 0.000909697   No Not found 
22 ATP6V1E1 16492493 16492513 0.000909697   No Not found 
22 ATP6V1E1 16492493 16492513 0.000909697   No Not found 
16 BANP 86591053 86591073 0.000121293   No Not found 
16 BANP 86591053 86591073 0.000121293   No Not found 
16 BANP 86591053 86591073 0.000121293   No Not found 
16 BANP 86591053 86591073 0.000121293   No Not found 
16 BANP 86591053 86591073 0.000121293   No Not found 
16 BANP 86591053 86591073 0.000121293   No Not found 
16 BANP 86591053 86591073 0.000121293   No Not found 
7 C7orf50 1122890 1122910 0.000121293   No Not found 
7 C7orf50 1122890 1122910 0.000121293   No Not found 
7 C7orf50 1122890 1122910 0.000121293   No Not found 
9 CACNA1B 139936085 139936105 0.000849051  Yes No Not found 
9 CACNA1B 139936085 139936105 0.000849051  Yes No Not found 
1 CAMTA1 7687801 7687821 0.000363879   No Not found 
16 CBFA2T3 87489347 87489367 0.000667111   No Not found 
16 CBFA2T3 87489347 87489367 0.000667111   No Not found 
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6 CD2AP 47552558 47552578 0.000667111   No Not found 
15 CLN6 66286407 66286427 0.000667111   No Not found 
7 CNPY1 154995456 154995476 0.000242586   No Not found 
20 COL20A1 61394057 61394077 0.000667111   No Not found 
1 CSMD2 34403910 34403930 0.000788404   No Not found 
1 CSMD2 34403910 34403930 0.000788404   No Not found 
1 DFFB 3763670 3763690 0.000606465   No Not found 
1 DFFB 3763670 3763690 0.000606465   No Not found 
1 DFFB 3763670 3763690 0.000606465   No Not found 
10 DIP2C 620619 620639 0.000545818   No Not found 
10 DIP2C 684962 684982 0.000849051   No Not found 
10 DIP2C 382685 382705 0.000363879  Yes No Not found 
1 DVL1 1275260 1275280 0.000909697   Predicted, Maternal Not found 
6 EXOC2 465198 465218 0.000849051   No Not found 
6 EXOC2 465198 465218 0.000849051   No Not found 
6 FAM120B 170528419 170528439 0.000121293   No Not found 
6 FAM120B 170528419 170528439 0.000121293   No Not found 
6 FAM120B 170528419 170528439 0.000121293   No Not found 
6 FAM120B 170528419 170528439 0.000121293   No Not found 
15 GABRB3 24425395 24425415 0.000788404   Conflicting Data, Paternal Conflicting Data 
15 GABRB3 24425395 24425415 0.000788404   Conflicting Data, Paternal Conflicting Data 
15 GABRB3 24425395 24425415 0.000788404   Conflicting Data, Paternal Conflicting Data 
15 GABRB3 24425395 24425415 0.000788404   Conflicting Data, Paternal Conflicting Data 
15 GABRB3 24425395 24425415 0.000788404   Conflicting Data, Paternal Conflicting Data 
15 GABRB3 24425395 24425415 0.000788404   Conflicting Data, Paternal Conflicting Data 
7 GRID2IP 6510144 6510164 0.000970344   No Not found 
19 HMHA1 1017228 1017248 0.000909697   No Not found 
19 HMHA1 1017228 1017248 0.000909697   No Not found 
19 HMHA1 1017228 1017248 0.000909697   No Not found 
12 HNF1A 119900006 119900026 0.000303232   No Not found 
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1 HNRNPCP5 13107459 13107479 0.000849051   No Not found 
X IL1RAPL2 104352919 104352939 0.000849051   No Not found 
18 KATNAL2 42804957 42804977 0.000242586   No Not found 
18 KATNAL2 42810872 42810892 0.000545818   No Not found 
18 KATNAL2 42798912 42798932 0.000303232   No Not found 
1 KAZN 15122441 15122461 0.000121293   No Not found 
1 KAZN 15122441 15122461 0.000121293   No Not found 
1 KAZN 15122441 15122461 0.000121293   No Not found 
1 KIAA1751 1901884 1901904 0.000849051   No Not found 
7 MAD1L1 1877342 1877362 0.000545818   No Not found 
7 MAD1L1 2056253 2056273 0.000121293   No Not found 
7 MAD1L1 1877342 1877362 0.000545818   No Not found 
7 MAD1L1 2056253 2056273 0.000121293   No Not found 
7 MAD1L1 1877342 1877362 0.000545818   No Not found 
7 MAD1L1 2056253 2056273 0.000121293   No Not found 
2 MYT1L 1920311 1920331 0.000242586   No Not found 
18 NFATC1 75281489 75281509 0.000667111   No Not found 
18 NFATC1 75281489 75281509 0.000667111   No Not found 
18 NFATC1 75281489 75281509 0.000667111   No Not found 
18 NFATC1 75281489 75281509 0.000667111   No Not found 
18 NFATC1 75281489 75281509 0.000667111   No Not found 
18 NFATC1 75281489 75281509 0.000667111   No Not found 
18 NFATC1 75281489 75281509 0.000667111   No Not found 
18 NFATC1 75281489 75281509 0.000667111   No Not found 
18 NFATC1 75281489 75281509 0.000667111   No Not found 
18 NFATC1 75281489 75281509 0.000667111   No Not found 
17 NGFR 44927754 44927774 0.000667111   No Not found 
1 OBSCN 226570772 226570792 0.000909697   Predicted, Paternal Not found 
1 OBSCN 226467367 226467387 0.000788404   Predicted, Paternal Not found 
1 OBSCN 226570772 226570792 0.000909697   Predicted, Paternal Not found 
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1 OBSCN 226467367 226467387 0.000788404   Predicted, Paternal Not found 
1 OBSCN 226570772 226570792 0.000909697   Predicted, Paternal Not found 
1 OBSCN 226467367 226467387 0.000788404   Predicted, Paternal Not found 
15 OCA2 25689155 25689175 0.000363879   No Not found 
1 OPRD1 29062206 29062226 0.000667111   No Not found 
2 OR6B3 240631724 240631744 0.000424525   No Not found 
19 PPP1R13L 50591427 50591447 0.000909697   No Not found 
19 PPP1R13L 50591427 50591447 0.000909697   No Not found 
7 PRKAR1B 717528 717548 0.000667111   No Not found 
7 PRKAR1B 717528 717548 0.000667111   No Not found 
7 PRKAR1B 717528 717548 0.000667111   No Not found 
7 PRKAR1B 717528 717548 0.000667111   No Not found 
7 PRKAR1B 717528 717548 0.000667111   No Not found 
7 PRKAR1B 717528 717548 0.000667111   No Not found 
7 PTPRN2 157352628 157352648 0.000909697   No Not found 
7 PTPRN2 157941351 157941371 0.000181939   No Not found 
7 PTPRN2 157352628 157352648 0.000909697   No Not found 
7 PTPRN2 157941351 157941371 0.000181939   No Not found 
7 PTPRN2 157352628 157352648 0.000909697   No Not found 
7 PTPRN2 157941351 157941371 0.000181939   No Not found 
16 RAB40C 604302 604322 0.000424525   No Not found 
16 RAB40C 604302 604322 0.000424525   No Not found 
16 RAB40C 604302 604322 0.000424525   No Not found 
16 RAB40C 604302 604322 0.000424525   No Not found 
16 RAB40C 604302 604322 0.000424525   No Not found 
13 RASA3 113824201 113824221 0.000485172   No Not found 
13 RASA3 113856967 113856987 0.000242586  Yes No Not found 
17 RPH3AL 206061 206081 0.000545818   No Not found 
17 RPH3AL 206061 206081 0.000545818   No Not found 
17 RPH3AL 206061 206081 0.000545818   No Not found 
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17 RPH3AL 206061 206081 0.000545818   No Not found 
17 RPTOR 76132310 76132330 0.000909697   No Not found 
17 RPTOR 76132310 76132330 0.000909697   No Not found 
9 RXRA 136440826 136440846 0.000667111   No Not found 
3 SCN5A 38667000 38667020 0.000849051   No Not found 
3 SCN5A 38667000 38667020 0.000849051   No Not found 
3 SCN5A 38667000 38667020 0.000849051   No Not found 
3 SCN5A 38667000 38667020 0.000849051   No Not found 
3 SCN5A 38667000 38667020 0.000849051   No Not found 
3 SCN5A 38667000 38667020 0.000849051   No Not found 
X SHOX 523098 523118 0.000909697   No Not found 
X SHOX 523098 523118 0.000909697   No Not found 
2 SLC4A3 220199610 220199630 0.000363879   No Not found 
2 SLC4A3 220199610 220199630 0.000363879   No Not found 
2 SLC4A3 220199610 220199630 0.000363879   No Not found 
5 SLC6A3 1469888 1469908 0.000849051   No Not found 
15 SNoRD115-29 23030052 23030072 0.000545818 Yes Yes No Imprinted 
16 SNX29 12118466 12118486 0.000363879   No Not found 
19 STXBP2 7618186 7618206 0.000121293   No Not found 
19 STXBP2 7618186 7618206 0.000121293   No Not found 
19 STXBP2 7618186 7618206 0.000121293   No Not found 
19 STXBP2 7618186 7618206 0.000121293   No Not found 
13 TMEM255B 113606174 113606194 0.000606465   No Not found 
8 TRAPPC9 141428560 141428580 0.000909697   No Not found 
8 TRAPPC9 141428560 141428580 0.000909697   No Not found 
8 TSNARE1 143405544 143405564 0.000485172 Yes Yes No Not found 
2 TSSC1 3270302 3270322 0.000121293   No Not found 
3 ZNF717 75917850 75917870 0.000363879   No Not found 
3 ZNF717 75917850 75917870 0.000363879   No Not found 
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3 ZNF717 75917850 75917870 0.000363879   No Not found 
3 ZNF717 75917850 75917870 0.000363879   No Not found 
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Appendix J - De novo sequencing variations in the affected twin of Family 2 that show co-localized 
differential methylation and sequence variation. (NCBI Build 37/hg19) 
Chr Position Gene 
Ref 
Allele 
(Build 
37) 
Sample 
Allele 
Variation 
Type 
Gene 
Region Impact 
SIFT 
Function 
Prediction 
SIFT 
Score 
PolyPhen-
2 Function 
Prediction 
dbSNP 
1 33475879 AK2 C T SNV ncRNA; 3'UTR     61800917 
1 33475967 AK2 G A SNV ncRNA; 3'UTR     74066437 
1 33475977 AK2 GGA AGG Substitution ncRNA; 3'UTR     386630167 
1 33475982 AK2 C A SNV ncRNA; 3'UTR     114902220 
1 33476292 AK2 A G SNV ncRNA; 3'UTR     74066439 
X 39986111 BCOR  A Insertion Intronic      
9 138666266 KCNT1 CTGT  Deletion Intronic      
3 195510827 MUC4 C T SNV Intronic; Exonic Missense   Benign 413807 
3 195511780 MUC4 G A SNV Intronic; Exonic Missense   Benign 391928 
8 145039599 PLEC  
CTGGTC
TGCCAT
CATGCC
AGGCC
AC 
Insertion Intronic     371713005 
1 3098038 PRDM16 GC  Deletion Intronic      
1 3098052 PRDM16 A G SNV Intronic     77999053 
1 3247836 PRDM16 A C SNV Intronic     11577229 
1 3326640 PRDM16 A G SNV Intronic     4648494 
7 157413778 PTPRN2 CG TA Substitution Intronic      
7 157413789 PTPRN2 TGT CAC Substitution Intronic      
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7 157413803 PTPRN2 C T SNV Intronic      
7 157564480 PTPRN2  TCAC ACAC Insertion Intronic     55838542 
7 157564526 PTPRN2 GACACA  Deletion Intronic      
7 157679515 PTPRN2 T C SNV Intronic     77012117 
7 157679518 PTPRN2 A G SNV Intronic     76659620 
7 157841832 PTPRN2  CCA Insertion Intronic      
7 157923238 PTPRN2 A T SNV Intronic     4909267 
7 157957688 PTPRN2 GA TG Substitution Intronic     67901051 
7 158055099 PTPRN2 CA  Deletion Intronic      
7 158061226 PTPRN2 A G SNV Intronic     2004588 
7 158082384 PTPRN2 G  Deletion Intronic      
7 158105002 PTPRN2  TA Insertion Intronic     10654725 
7 158105117 PTPRN2 CACA  Deletion Intronic      
7 158112250 PTPRN2 G A SNV Intronic     56188120 
7 158212055 PTPRN2 G A SNV Intronic     62478442 
7 158233753 PTPRN2 
GGGTG
GTAGTG
ATGG 
 Deletion Intronic      
16 6113522 RBFOX1 C  Deletion Intronic     71142671 
16 6423347 RBFOX1 GGC GGA 
AGT 
GGC Substitution Intronic     386788248 
16 6423384 RBFOX1 AG GT Substitution Intronic      
16 7251467 RBFOX1 T  Deletion Intronic      
16 7563288 RBFOX1 TG A Substitution Intronic     386788490 
16 7563293 RBFOX1 G  Deletion Intronic     201299763 
16 7592893 RBFOX1 A G SNV Intronic     8053938 
16 7748187 RBFOX1 T G SNV Intronic     12932981 
10 16831467 RSU1 T A SNV Intronic     10904813 
3 9457871 SETD5 TCT  Deletion Intronic      
4 186509746 SORBS2  
TCCTCC
TCCTCC
T 
Insertion Intronic      
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4 186717589 SORBS2 A G SNV Intronic     13126725 
5 166854854 TENM2  G Insertion Intronic      
5 167398378 TENM2  AAG Insertion Intronic      
5 167398387 TENM2 G A SNV Intronic     71603845 
5 167398403 TENM2 T G SNV Intronic     13173408 
11 89819403 UBTFL1 G T SNV Exonic Missense Damaging 0 Benign  
Structural Variants and CNVs       
Chr Start End Size Type Gene(s)       
7 158029478 158030452 974 Deletion PTPRN2       
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Appendix K - Observed DNA methylation changes in 13 genes that showed co-localized de novo sequence 
variations in Family 2. (NCBI Build 36/hg18) 
 
Chr Gene Symbol Start End 
p-value 
(region) In Mom In Dad 
Imprinting Database 1 
(geneimprint.com/) 
Imprinting Database 2 
(igc.otago.ac.nz/) 
1 AK2 33275973 33275993 0.000485172   No Not found 
1 AK2 33275973 33275993 0.000485172   No Not found 
1 AK2 33275973 33275993 0.000485172   No Not found 
1 AK2 33275973 33275993 0.000485172   No Not found 
1 AK2 33275973 33275993 0.000485172   No Not found 
X BCOR 39846274 39846294 0.000545818 Yes Yes No Not found 
X BCOR 39846274 39846294 0.000545818 Yes Yes No Not found 
X BCOR 39846274 39846294 0.000545818 Yes Yes No Not found 
X BCOR 39846274 39846294 0.000545818 Yes Yes No Not found 
9 KCNT1 137732516 137732536 0.000909697   No Not found 
9 KCNT1 137732516 137732536 0.000909697   No Not found 
3 MUC4 196975464 196975484 0.000909697   No Not found 
3 MUC4 196975464 196975484 0.000909697   No Not found 
3 MUC4 196975464 196975484 0.000909697   No Not found 
8 PLEC 145068180 145068200 0.000727758 Yes Yes No Not found 
8 PLEC 145068180 145068200 0.000727758 Yes Yes No Not found 
8 PLEC 145068180 145068200 0.000727758 Yes Yes No Not found 
8 PLEC 145068180 145068200 0.000727758 Yes Yes No Not found 
8 PLEC 145068180 145068200 0.000727758 Yes Yes No Not found 
8 PLEC 145068180 145068200 0.000727758 Yes Yes No Not found 
8 PLEC 145068180 145068200 0.000727758 Yes Yes No Not found 
8 PLEC 145068180 145068200 0.000727758 Yes Yes No Not found 
1 PRDM16 3061919 3061939 0.000788404   Predicted, Paternal Not found 
1 PRDM16 3061919 3061939 0.000788404   Predicted, Paternal Not found 
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7 PTPRN2 157141154 157141174 0.000667111   No Not found 
7 PTPRN2 157141154 157141174 0.000667111   No Not found 
7 PTPRN2 157141154 157141174 0.000667111   No Not found 
16 RBFOX1 6762885 6762905 0.000909697   No Not found 
16 RBFOX1 6762885 6762905 0.000909697   No Not found 
16 RBFOX1 6762885 6762905 0.000909697   No Not found 
16 RBFOX1 6762885 6762905 0.000909697   No Not found 
16 RBFOX1 6762885 6762905 0.000909697   No Not found 
16 RBFOX1 6762885 6762905 0.000909697   No Not found 
10 RSU1 16900364 16900384 0.000909697   No Not found 
10 RSU1 16900364 16900384 0.000909697   No Not found 
3 SETD5 9414278 9414298 0.000788404   No Not found 
4 SORBS2 187115769 187115789 0.000667111   No Not found 
4 SORBS2 187115769 187115789 0.000667111   No Not found 
5 TENM2 166643495 166643515 0.000909697   No Not found 
11 UBTFL1 89457840 89457860 0.000970344   No Not found 
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Appendix L - Ingenuity Pathway Analysis Legend  
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